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INTRODUCTION AND OUTLINE OF THE THESIS
tuberCulosis
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. It is easier 
to catch M. tuberculosis in places where people are crowding together, such as in prisons, 
schools, mines or marketplaces. However, not everyone who acquires infection develops 
clinical symptoms, because our bodies fight M. tuberculosis. If the body does not win the fight, 
TB causes disease. The commonest form of TB is pulmonary tuberculosis (PTB), which affects 
the lungs [1]. People with lung TB may cough up phlegm that contains the germs, which is how 
TB is mostly spread. TB germs are very tough, and can live in dust for months. TB can also infect 
other parts of the body such as lymph nodes, bones and pleural cavities (commonly known 
as extra-pulmonary TB). Night sweats, fever and weight loss are the common symptoms of 
active TB. Identification of the tubercle bacilli by sputum smear microscopy is the first step in 
diagnosis. Sputum culture is a more sensitive and preferred method, however this method is 
slow and expensive [2].
TB remains a major global health problem. It is ranked as the second most mortality-
causing infectious disease after human immunodeficiency virus (HIV) disease worldwide 
[3]. An estimated 1.4 million (range 1.2-1.5 million) people annually die from TB globally [4]. 
It is the leading cause of death from a curable infectious disease, despite the availability of 
efficacious treatment for decades. One-third of the world population is latently infected with 
M. tuberculosis and has a risk of developing active TB [5]. The World Health Organization (WHO) 
estimates 9 million new cases of TB (range 8.5-9.2 million) each year (Figure 1). TB incidence is 
highest in Africa; the number of incident cases in African countries was estimated at 2.3 million 
in 2010 (range, 2.1 million–2.5 million [4].
TB and HIV infection are overlapping epidemics. HIV infection is the strongest risk factor 
for the development of TB. It increases the progression from TB infection to active disease 
[6,7]. On the other hand, TB increases the risk of progression from HIV infection to AIDS [8,9]. 
Of the 9 million incident cases of TB worldwide, 13% were among people living with HIV and the 
majority of cases were adults aged 15-59 years [4]. Without combined treatment, mortality rates 
are high (up to 2.2 million deaths per year) [10]. The proportion of TB cases co-infected with 
figure 1. Estimated TB incidence rates 2010 (Source: WHO TB report 2011)
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HIV is highest in the African countries (figure 2); overall, African countries accounted for 82% 
of TB cases among people living with HIV [4].
Apart from HIV infection, there is another disease that tends to evolve as an epidemic and 
that overlaps with the TB epidemic, i.e. diabetes mellitus (DM). There is a rapid increase in the 
global prevalence of DM, especially in developing countries, where TB is endemic. Diabetes 
mellitus (DM) is a well-known risk factor for acquiring tuberculosis (TB) [11], with prevalence 
rates among TB patients ranging from 10 to 30% [11,12,13]. In addition, diabetes exerts a negative 
effect on the response to TB treatment. 
Tuberculosis continues to be among the major public health problems in Tanzania as well. 
The number of reported TB cases has steadily increased from 11,753 in 1983 to 64,269 in 2009 
[14]. The WHO 2011 report showed that the majority of cases appear in young adult population 
groups aged 15-45 years [1].
tuberCulosis treatment
The introduction of the sanatorium care provided the first real step in TB management. New 
advances then followed in rapid succession. In 1882, Robert Koch discovered a staining technique 
that enabled him to see M. tuberculosis. The world was excited by the certainty that now the 
fight against humanity’s deadliest enemy could really begin. TB drug development began in 
the 1940s when streptomycin was discovered [15], but after treating some patients, resistant 
mutants began to appear. The discovery of isoniazid in 1952 brought renewed hope. This potent 
agent resulted in rapid sterilization of sputum and, when used in conjunction with streptomycin, 
reduced the rates of drug-induced resistance. In 1954 pyrazinamide was discovered and later 
ethambutol (1962) and rifampicin (1963), which revolutionized TB treatment [16].
figure 2. Estimated HIV prevalence in new TB cases (Source: WHO TB report 2011)
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The current treatment of tuberculosis consists of two phases, which are the so-called initial 
or intensive phase and the continuation phase. In the intensive phase, all actively dividing 
bacteria should be killed as soon as possible. The continuation phase is meant to eradicate 
the persisters, i.e. presumably slower replicating or dormant bacteria. The recommended 
initial phase for the treatment of tuberculosis consists of rifampicin 10mg/kg (maximum 
600mg), isoniazid 5mg/kg (maximum 300mg), pyrazinamide 15–30mg/kg (maximum 2g), and 
ethambutol 15–20mg/kg (maximum 1.6g) given daily for 8 weeks [17]. This is followed by the 
continuation phase of isoniazid 5mg/kg (maximum 300mg) and rifampicin 10mg/kg (maximum 
600mg). Clearly, TB drugs are not used singly except in latent TB or chemoprophylaxis (giving 
medication to people who have no active disease and are currently well). This is because the 
regimens that use only a single drug result in the rapid development of resistance and treatment 
failure [18]. This risk is especially large among large vital bacilli populations such as present at 
the onset of therapy. This is why the intensive phase constitutes even four drugs. 
The different drugs in the regimen have different modes of action. Isoniazid is bactericidal 
against replicating bacteria. Ethambutol is bacteriostatic at low doses, but is used in TB 
treatment at higher, bactericidal doses. Rifampicin is bactericidal and has a sterilizing effect. 
Pyrazinamide is only weakly bactericidal, but is very effective against bacteria located in acidic 
environments, inside macrophages, or in areas of acute inflammation. In order to prevent 
non-adherence to TB drugs and treatment dropouts, the WHO has introduced the Directly 
Observed Therapy (DOT) strategy. One of the crucial components of this strategy is the direct 
observation by trained personnel or relatives of patients when they take their medicines, as a 
means to ensure adherence. There is a definite supply of drugs, and standardized reporting and 
recording of cases and treatment outcomes.
First-line and seCond-line anti-tuberCulosis drugs
isoniazid. Isoniazid is highly bactericidal against replicating M. tuberculosis. It is normally 
taken orally but may be administered intramuscularly or intra venously to critically ill patients. 
It is rapidly absorbed and diffuses readily into all fluids and tissues. The plasma half-life, which 
is genetically determined, varies from less than 1 hour in fast acetylators to more than 3 hours 
in slow acetylators [19]. Isoniazid is largely excreted in the urine within 24 hours, mostly as 
inactive metabolites. Isoniazid is used with caution and clinical monitoring (liver function tests, 
Isoniazid chemical structure
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if possible) should be performed dur ing treatment of patients with pre-existing liver disease. 
Patients at risk of peripheral neuropathy, because of malnutrition, chronic alcohol dependence, 
HIV infection, pregnancy, breastfeeding, renal failure or diabetes, should additionally 
receive pyri doxine, 10  mg daily. It is contraindicated in case of known hypersensitivity and 
jaundice patients. 
rifampicin. Rifampicin is a semisynthetic derivative of rifamycin. It is a complex macrocyclic 
antibi otic that inhibits ribonucleic acid synthesis in a broad range of microbial pathogens. It has 
bactericidal action and a potent sterilizing effect against M. tuberculosis in both cellular and 
extracellular locations [20]. Rifampicin should preferably be given at least 30 minutes before 
meals, since absorp tion is reduced when it is taken with food [21]. Following oral administration, 
it is rapidly absorbed and distributed throughout the cellular tissues and body fluids. A daily dose 
of 600mg administered on an empty stomach produces an average peak serum concentration 
of about 10 mg/L in 2–4 hours, which subsequently decays, with a half-life of 2–3 hours [22]. It is 
extensively recycled in the enterohe patic circulation, and metabolites formed by deacetylation 
in the liver are eventually excreted in the faeces [23,24]. Clinical monitoring (liver function tests, 
if possible) should be performed during treatment of all patients with pre-existing liver disease, 
who are at increased risk of further liver damage. Patients should be warned that treatment may 
cause reddish coloration of all body secretions (urine, tears, saliva, sweat, semen and sputum), 
and that contact lenses and clothing may be irreversibly stained.
Rifampicin chemical structure
Pyrazinamide. Pyrazinamide is a synthetic analogue of nicotinamide that is only weakly 
bactericidal against M. tuberculosis but has potent sterilizing activity, particularly in the 
relatively acidic intracellular environment of macrophages and in areas of acute inflammation. 
It is highly effective during the first 2 months of treatment while acute inflammatory changes 
persist [25]. Its use has enabled treatment regimens to be shortened and the risk of relapse to 
be reduced. Pyrazinamide is administered orally. It is readily absorbed from the gastrointestinal 
tract and is rapidly distributed throughout all tissues and fluids. Peak plasma concentrations 
are attained in 2 hours and the plasma half-life is about 10 hours. It is metabolized mainly in 
17
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the liver and excreted largely in the urine. It is contraindicated for known hypersensitivity and 
active jaundice. A common adverse effect of pyrazinamide is hepatotoxicity.
Pyrazinamide chemical structure
ethambutol. Ethambutol is used in combination with other anti-TB drugs to prevent or delay 
the emergence of resistant strains. It is administered orally and is readily absorbed from the 
gastrointestinal tract. Plasma concentration peaks within 2–4 hours and decays with a half-life 
of 3–4 hours [19]. It is excreted in the urine both unchanged and as inactive hepatic metabolites. 
About 20% is excreted unchanged in the faeces [26]. Dosage must always be carefully 
calculated on a weight basis to avoid toxicity, and the dose or the dosing interval should be 
adjusted in patients with impaired renal function (creatinine clearance <70 ml/min) [27]. If 
creatinine clearance is less than 30 ml/minute, ethambutol should be administered 3 times per 
week. It is contraindicated for known hypersensitivity and pre-existing optic neuritis. Patients 
should be advised to discontinue treatment immediately and to report to a clinician if their 
sight or perception of colour deteriorates. Ocular examination is recommended before and 
during treatment. 
Ethambutol chemical structure
second-line tb drugs. The first-line TB drugs are also designated as TB drugs from group 1. The 
second-line TB drugs, used for multidrug resistant TB (MDR-TB) are then subdivided. Group 2 
which are aminoglycoside injections, e.g. amikacine, kanamycin), group 3 (fluoroquinolones) 
e.g. ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin, group 4 (e.g. cycloserine, 
ethionamide, p-aminosalicylic acid) and group 5 (many agents with unclear efficacy) [28]). 
Second-line drugs are generally less effective, more toxic and more expensive than the first-
line TB drugs. The lower in the group hierarchy, the less evidence is available for their efficacy 
in TB treatment. However, the fluoroquinolones have shown promise to shorten the TB 
18
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treatment duration and are currently being tested as first-line drugs in a phase III clinical trial. 
A concern is that fluoroquinolones are widely used for other infections including respiratory 
tract infections in patients with (undiagnosed) active TB, which could result in fluoroquinolone 
–resistant M. tuberculosis.
PharmaCologiCal studies
Pharmacology (from the Greek pharmakon, meaning “poison” in classic Greek and “drug” 
in modern Greek), is the branch of medicine concerned with the study of drug action while 
clinical pharmacology is the study of drugs in their clinical use. Traditionally there are two 
branches of pharmacology; pharmacokinetics and pharmacodynamics. Pharmacokinetics 
includes the study of the mechanisms of absorption, distribution, metabolism and excretion 
of an administered drug. It looks at the rate at which a drug action begins and the duration 
of the effect, the chemical changes of the substance in the body and the effects and routes 
of excretion of the metabolites of the drug. Important pharmacokinetic parameters are the 
maximum concentration, area under the concentration versus time curve, the time to reach 
the maximum concentration and the minimum concentration (Figure 3). Others are half-life, 
clearance and volume of distribution of the drug. All these pharmacokinetic parameters are 
normally derived from studies in which blood is sampled in patients after administration of TB 
drugs. Sampling and bio-analysis of saliva may be more patient-friendly, as it does not require 
the attendance of medical staff and may be less costly. However, there are limited data of TB 
drugs in saliva.
Pharmacodynamic studies examine the subsequent relationship between drug 
concentrations achieved and eventual desirable and undesirable effects of the drug. 
Stated otherwise, pharmacokinetic studies examine what the body does to the drug, and 
pharmacodynamic studies evaluate how the drug affects the body. Clinical pharmacology 
figure 3. Pharmacokinetic curves after oral administration of different formulations
Chapter 1 
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Figure 3: Pharmacokinetic curves after oral administration of different formulations 
 
Pharmacological concerns about anti-TB drugs 
A. TB/HIV drug interactions 
The treatment of TB in individuals with HIV infection is the same as that for patients with TB who do not 
have HIV disease. Standard first-line therapy for TB is effective in patients with HIV infection–related TB. 
However, management of co-infected patients can be complex because of pharmacokinetic and 
pharmacodynamic interactions between TB drugs and antiretroviral drugs [32]. These interactions may 
cause decreased concentrations of some TB drugs, adverse events due to overlapping adverse effect 
profiles and immune reconstitution disease. More specifically, a rifampicin based TB regimen lowers the 
concentration of non-nucleoside reverse transcriptase inhibitors, protease inhibitors and some new 
antiretroviral drugs such as maraviroc, raltegravir and etravirine [33]. Therefore, continuous original studies 
and reviews on interactions between anti-tuberculosis and antiretroviral drugs are necessary. 
 
B. Pharmacokinetic sampling 
Pharmacokinetic studies are very useful in determining pharmacological activity and toxicity of a drug. 
Therefore, large studies with frequent blood sampling are required. However, these studies necessitate the 
attendance of medical staff. Therefore, the use of saliva samples would facilitate studies to evaluate 
concentrations of drugs. The advantage of this technique is that sample collection is easy and inexpensive 
and can be carried out by the patient him or herself, even at home. Moreover, the risk of HIV transmission 
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currently comprises more than pharmacokinetic and pharmacodynamic studies, e.g. more 
epidemiological-type studies such as surveillance of drug use and adverse effects that are 
performed in order to promote the safety of prescription, maximize drug effects and minimize 
adverse effects. Various types of clinical pharmacological studies are incorporated in this thesis.
An interaction between drugs can be synergistic (when the drugs’ effects are increased) or 
antagonistic (when the drugs’ effect are decreased). The interactions may be alterations in the 
absorption, distribution, metabolism, and excretion of a drug (pharmacokinetic interaction). 
Alternatively, drug interactions may be the result of the alterations of pharmacodynamic 
properties of the drug. Obviously, it is important to find out these pharmacological 
interactions in real practice. Clinically significant interactions occurring during antituberculous 
chemotherapy principally involve rifampicin. Such interactions can be associated with 
consequences even amounting to therapeutic failure or toxicity. The cytochrome P450 iso-
enzymes are responsible for many interactions during drug biotransformation (metabolism) 
in the liver and/or intestine [29]. Generally, rifampicin is known to be a very strong inducer 
of cytochrome P450 iso-enzymes, other metabolic enzymes and transporter proteins. Co-
administration of rifampicin leads to significant reduction in the serum concentrations of many 
drugs [30,31].
PharmaCologiCal ConCerns about anti-tb drugs
a. tb/hiV drug interactions. The treatment of TB in individuals with HIV infection is the same 
as that for patients with TB who do not have HIV disease. Standard first-line therapy for TB 
is effective in patients with HIV infection–related TB. However, management of co-infected 
patients can be complex because of pharmacokinetic and pharmacodynamic interactions 
between TB drugs and antiretroviral drugs [32]. These interactions may cause decreased 
concentrations of some TB drugs, adverse events due to overlapping adverse effect profiles 
and immune reconstitution disease. More specifically, a rifampicin based TB regimen lowers 
the concentration of non-nucleoside reverse transcriptase inhibitors, protease inhibitors and 
some new antiretroviral drugs such as maraviroc, raltegravir and etravirine [33]. Therefore, 
continuous original studies and reviews on interactions between anti-tuberculosis and 
antiretroviral drugs are necessary.
b. Pharmacokinetic sampling. Pharmacokinetic studies are very useful in determining 
pharmacological activity and toxicity of a drug. Therefore, large studies with frequent blood 
sampling are required. However, these studies necessitate the attendance of medical staff. 
Therefore, the use of saliva samples would facilitate studies to evaluate concentrations of 
drugs. The advantage of this technique is that sample collection is easy and inexpensive and 
can be carried out by the patient him or herself, even at home. Moreover, the risk of HIV 
transmission to the medical staff and discomfort for the patients would be minimized and the 
technique may therefore be particularly useful in children. The feasibility of using saliva to 
monitor drug concentrations has been earlier demonstrated for a large variety of drugs, but 
the number of data on TB drugs is very limited [36]. It would be useful if saliva can be used as an 
alternative specimen in monitoring TB drugs concentrations. 
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C. use of tb drugs in diabetic mellitus patients. Diabetes mellitus (DM) is a metabolic 
disorder of energy balance with many contributory causes and forms. As described previously, 
DM exerts a negative effect on TB treatment. One of the possible underlying mechanisms 
could be altered pharmacokinetics of anti-TB drugs. Lower concentrations of anti-TB drugs 
in plasma have been associated with clinical failure and acquired drug resistance [34,35]. It is 
important to study the impact of DM on the pharmacokinetics of TB drugs and on the outcome 
of TB treatment.
d. toxicity of anti-tubercular treatment. Anti-tubercular drugs show a great level of efficacy 
with an acceptable degree of toxicity; however, they may cause derangement of hepatic 
functions. Isoniazid, rifampicin and pyrazinamide are potentially hepatotoxic drugs (Table 1). They 
are metabolized in the liver, making this organ vulnerable for injury. Apart from hepatotoxicity, 
TB drug related adverse reactions such as peripheral neuropathy, gastro-intestinal intolerance 
and skin rashes commonly occur [37]. They can cause significant morbidity and therefore may 
compromise adherence to treatment, eventually contributing to treatment failure, relapse or 
emergence of resistant strains [38]. 
Malnutrition, pre-existing liver disease, genetic factors, use of concomitant drugs and alcohol 
are risk factors specifically related to liver toxicity [39-43]. Hepatotoxicity rates of 13–15% have been 
reported from India and Iran [44]. Other studies reported hepatotoxicity to be <2%, however, liver 
function was not closely monitored in these studies [45-47]. The data on toxicity of anti-tubercular 
drugs in sub Saharan Africa are scarce; the main reason may be absence of biochemistry analysis 
during TB treatment. Valid estimation of the incidence of toxicity due to TB treatment in the African 
or Tanzanian region is important considering the era of TB/HIV co-medication.
e. the use of fluoroquinolones: second-line drugs for tb treatment. As mentioned 
above, there are four classes of second-line drugs (group 2 to group 5) used for treatment of 
(multidrug-resistant) TB. A drug may be classed as second-line instead of first-line for one of 
three possible reasons: it may be less effective than the first-line drugs (e.g., p-aminosalicylic 
acid); or, it may have toxic side-effects (e.g., cycloserine); or it may be unavailable in many 
Table 1. Shared adverse effects of TB and Antiretroviral Therapy
Side Effects ARVs Tuberculous Treatment
Nausea, Vomiting ddl 
AZT
Pyrazinamide
Hepatitis Nevirapine
Efavirenz
Rifampin
INH
PZA
Peripheral Neuropathy d4T
ddl
INH
Rash Nevirapine
Efavirenz
Rifampin
INH
PZA
Source: SA National TB control Programme Practical Guideline
Abbreviations: ddI: didanosine, AZT: zidovudine, d4T: stavudine, INH: isoniazid, PZA: pyrazinamide
21
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developing countries (e.g., fluoroquinolones). Although fluoroquinolones are readily available 
in Tanzania, they are prescribed for a variety of infectious diseases including respiratory 
infection and urinary tract infection. As the extent of use increases, the chance of developing 
resistance to fluoroquinolones, when used to treat TB, increases. Therefore, it is important to 
evaluate the extent of fluoroquinolone use in resource-limited settings like Tanzania and to 
assess the extent of resistance that occurs. 
outline oF the thesis
The aim of the studies presented in this thesis is to address the pharmacological problems in 
the treatment of tuberculosis patients as outlined above. Therefore, this thesis incorporates 
pharmacokinetic studies focusing on TB/HIV co-infection, sampling of saliva in TB patients, 
diabetic TB patients, a survey on toxicity and a study on surveillance of TB drug use. All studies 
presented in this thesis were conducted in Kilimanjaro Region in Tanzania. The Tanzanian 
National Tuberculosis Hospital is located in the Kilimanjaro Region, Siha District. In addition, 
the Mawenzi hospital in Moshi is a large centre for TB treatment. Hence, these two sites 
were used to conduct different studies in this thesis. All studies were coordinated from the 
Kilimanjaro Clinical Research Institute (KCRI) located at Kilimanjaro Christian Medical Centre 
(KCMC Hospital) in Moshi, Kilimanjaro Region. The outline of this thesis is as follows:
Chapter 1: This is the introductory chapter where an epidemiological update, overlapping of 
TB, HIV disease and diabetes mellitus, the history of TB treatment and general information on 
the TB drugs are highlighted. Then follows an exploration of the pharmacological concerns of 
anti-TB drugs.  
Chapter 2: A detailed review of the interaction between first-line TB drugs and antiretroviral 
drugs used in resource-limited setting and the challenges involved are discussed in chapter 2(a). 
Furthermore, the hypothesis that ‘AtriplaR as a fixed dose combination and first-line anti-TB 
drugs are having pharmacokinetic interactions according to the existing literature’ is discussed 
in chapter 2 (b).
Chapter 3: This chapter presents a clinical trial conducted in Tanzania on TB/HIV co-infected 
patients who were given emtricitabine/tenofovir/efavirenz as a fixed dose combination 
concurrently with first-line anti-tuberculosis drugs. The study focused on pharmacokinetics of 
the drugs involved, safety and tolerability. 
Chapter 4: There is complete lack of pharmacokinetic data for TB drugs administered to 
Tanzanian TB patients. We conducted a study to describe pharmacokinetic properties of TB 
drugs in plasma of Tanzanian patients with pulmonary TB.
Chapter 5: The plasma and saliva concentrations of rifampicin were simultaneously measured 
in patients with pulmonary TB, as a means to explore the feasibility of saliva sampling instead 
of blood sampling.
22
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Chapter 6: Changes in lifestyle and diet have contributed to an increased prevalence of diabetes 
in many low-income and middle-income countries where the burden of TB is high. Diabetes 
triples the risk of developing TB consequently; rates of TB are higher in people with diabetes 
than in the general population. In addition, TB patients with DM show a worse response to TB 
treatment compared to non-diabetics. This may result from differences in pharmacokinetics of 
TB drugs between diabetics and non-diabetics. This chapter describes a pharmacokinetic study 
in patients with TB alone and TB with DM as concurrent disease. 
Chapter 7: This chapter describes a survey conducted in Tanzanian TB patients to find out the 
incidence of TB drugs induced hepatotoxicity in Tanzania.
Chapter 8: This is divided in two sections. In chapter 8(a), the rate of fluoroquinolones sale for 
the treatment of other infections, which may cause their effectiveness against TB to be lost, 
is evaluated in an antimicrobial drug surveillance in the Moshi area. Then in chapter 8(b), the 
research question is whether fluoroquinolones resistance in M. tuberculosis is common in 
Tanzanian TB patients, considering the availability of fluoroquinolones in the general population.
Chapter 9: This chapter discusses the findings from the above studies and implications 
of the findings in solving pharmacological concerns about anti-TB drugs. Furthermore, 
recommendations for further research are highlighted.
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abstraCt 
Co-administration of antituberculosis and antiretroviral therapy is often inevitable in high- 
burden countries where tuberculosis is the most common opportunistic infection associated 
with HIV/AIDS. Concurrent use of rifampicin and many antiretroviral drugs is complicated by 
pharmacokinetic drug-drug interactions. Rifampicin is a very potent enzyme inducer, which 
can result in sub-therapeutic antiretroviral drug concentrations. In addition, TB drugs and 
antiretroviral drugs have additive (pharmacodynamic) interactions as reflected in overlapping 
adverse effect profiles. This review provides an overview of the pharmacological interactions 
between rifampicin-based TB treatment and antiretroviral drugs in adults living in resource-
limited settings. 
Major progress has been made to evaluate the interactions between TB drugs and 
antiretroviral therapy, however burning questions remain concerning nevirapine and efavirenz 
effectiveness during rifampicin-based TB treatment, treatment options for TB-HIV co-infected 
patients with NNRTI resistance or intolerance and exact treatment or dosing schedules for 
vulnerable patients including children and pregnant women. The current research priorities can 
be addressed by maximising the use of already existing data, creating new data by conducting 
clinical trials and prospective observational studies and to engage a lobby to make currently 
unavailable drugs available to those most in need. 
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introduCtion 
The tuberculosis (TB) and human immunodeficiency virus (HIV) epidemics show overlapping 
epidemiology globally [1,2]. In 2011, about one million (13%) of the 8.7 million people who 
developed TB worldwide were HIV-positive; 79% of these HIV-positive TB cases were in the 
African Region[3]. 
Since 2010, the World Health Organisation (WHO) has recommended antiretroviral 
treatment (ART) for TB patients regardless of their CD4 cell-count. TB treatment should be 
initiated first and ART should be started as soon as possible within eight weeks of starting 
TB treatment. Those with profound immunosuppression (e.g. less than 50 CD4 cells/mL) are 
recommended to start ART within the first two weeks of TB treatment [3].
This means that about one million people per year are eligible for using concurrent TB and 
HIV medication, and WHO estimated that in 2011 about half of them were started on ART during 
TB treatment [3]. Standard first line TB treatment takes six months and consists of a two-month 
intensive phase with isoniazid, rifampicin, pyrazinamide and ethambutol followed by a four 
months continuation phase with isoniazid and rifampicin[4]. The currently recommended 
antiretroviral drug regimen for TB-HIV coinfected patients is presented in Table 1 [5]. In 
summary, efavirenz should be used as the preferred non-nucleoside reverse transcriptase 
inhibitor in patients starting ART while on TB treatment and the choice of the protease inhibitor 
for second line treatment depends on the availability of rifabutin for TB treatment.
Unfortunately, patients using concomitant TB and antiretroviral treatment face several 
problems. Firstly, multi-drug treatment is prescribed for both TB and HIV, resulting in a high 
daily pill counts, which may cause non-adherence to these therapies. Secondly, both TB 
table 1. Potential overlapping toxicity due to antiretroviral and tuberculosis drugs
Adverse effect from HIV and/or TB treatment 
Antiretroviral drugs 
[5]
first line tuberculosis drugs 
[4]
Drug eruptions (mild to severe, including Stevens-
Johnson syndrome or toxic epidermal necrolysis)
Nevirapine, efavirenz 
(less commonly)
 
Anaemia and neutropaenia Zidovudine Isoniazid (rare)
Peripheral neuropathy  Stavudine Isoniazid (common), 
ethambutol
Gastrointestinal intolerance All All
Hepatotoxicity All ARVs
Particularly nevirapine
Isoniazid, rifampicin, 
pyrazinamide
Central nervous system toxicity Efavirenz Isoniazid
Drug fever All All
Bone marrow suppression and blood dyscrasias Zidovudine, efavirenz Rifampicin
Ocular effect Didanosine Ethambutol, rifabutin
Renal toxicity (renal tubular dysfunction) TDF  
Note: not all potential adverse effects are shown in this table, only toxicity that can be caused by both TB and 
HIV treatment. NRTIs = nucleoside reverse transcriptase inhibitors; PIs = protease inhibitors; AZT = zidovudine, 
FTC = emtricitabine
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and antiretroviral treatment regimens are associated with frequent and potentially severe 
adverse events. This poses a great challenge in managing each of these diseases [2,6]. Due 
to overlapping toxicity profiles of TB and HIV drugs, it is often difficult defining the cause 
of an observed adverse reaction. Thirdly, so called immune reconstitution inflammatory 
syndrome could occur, a phenomenon that may lead to clinical deterioration upon starting 
antiretroviral treatment [7-9]. Finally, relevant pharmacokinetic drug-drug interactions exist, 
especially between rifampicin and two widely used classes of antiretroviral drugs: the non-
nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) [10-12]. Such 
pharmacokinetic interactions can significantly decrease the plasma concentrations of the HIV 
drugs, which can affect treatment outcome of ART. 
This review addresses the pharmacological interactions between TB treatment and the 
antiretroviral drugs that are available to adults living in the resource-limited settings. The main 
focus will be on the effect of rifampicin on the NNRTIs and the PIs. We have described the main 
challenges for concurrent TB and HIV treatment for these settings, identified the most urgent 
research priorities and propose strategies to address these research questions. 
PharmaCokinetiC interaCtions bet ween 
riFamPiCin and antiretroViral drugs
When co-administering TB drugs and antiretroviral drugs, the TB drugs precipitate 
pharmacokinetic interactions, whereas the antiretroviral agents are object drugs. Most 
pharmacokinetic interactions are caused by rifampicin, the cornerstone drug of TB treatment, 
which induces the activity and/or expression of many liver enzymes and transporter proteins.
Rifampicin is a very potent inducer of cytochrome P450 (CYP450) a super family of enzymes 
in the liver and in the intestinal wall [13,14]. It strongly induces the expression of CYP3A4 and 
thereby greatly reduces the plasma concentrations and effects of many CYP3A4 substrates, 
including several antiretroviral drugs. A large number of other CYP450 iso-enzymes, 
including CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19 and CYP3A5 are also induced by 
rifampicin [15]. Therefore, pharmacokinetic properties and treatment effect of antiretroviral 
drugs that are metabolized by one of these enzymes are likely to be effected by rifampicin. 
Pharmacokinetic studies suggest that CYP2D6 activity is only modestly or not increased by 
rifampicin [16,17]. Furthermore, rifampicin induces phase II drug-metabolizing enzymes such 
as UDP-glucuronyltransferases and sulfotransferases. Finally, rifampicin also induces the 
expression of transporter proteins, such as P-glycoprotein, multiple drug resistance protein 2 
(MRP2), and organic anion-transporting polypeptide (OATP [18-20]. 
For the interaction potential of rifampicin, P-glycoprotein appears to be especially 
relevant. CYP3A4 and P-glycoprotein may act synergistically to limit oral drug bioavailability 
and to enhance drug metabolism and elimination, as suggested by their joint presence in 
enterocytes, hepatocytes and renal tubular cells and by the extensive overlap in their substrate 
specificities [21-23]. In fact, the function of P-glycoprotein may allow CYP3A4 to have repeated 
and prolonged access to its substrate molecules [24,25]. The antiretroviral NNRTIs and PIs are 
substrates of CYP450 iso-enzymes and /or P-glycoprotein. In contrast to inhibition of metabolic 
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enzymes and transport proteins, induction takes time to develop and disappear. Full induction 
after starting rifampicin is reached in roughly one week [26] and the activity of enzymes returns 
to baseline in about two weeks after discontinuing rifampicin treatment [27,28]. 
Apart from rifampicin, the TB drug isoniazid affects CYP450 enzymes as well. Isoniazid is 
a relatively potent inhibitor of several CYP450 enzymes (CYP2C9, CYP2C19, CYP2E1) but it has 
less effect on CYP3A4 [29]. However, during TB treatment any inhibitory effect of isoniazid is 
generally outweighed by the strong inductive effect of concomitantly used rifampicin [30,31]. 
Currently, all HIV infected patients without active tuberculosis should be offered isoniazid 
preventive therapy for at least six months as prophylaxis for latent TB infection [5]. This includes 
HIV infected patients who are currently using ART, thus the inhibition of CYP3A and CYP2C19 by 
isoniazid and the consequent effect on plasma levels of antiretroviral drugs becomes relevant 
for a large group of HIV infected patients. The other first-line TB drugs, pyrazinamide and 
ethambutol do not have any inductive or inhibitory effect and are therefore not involved in 
pharmacokinetic interactions with antiretroviral drugs. 
interactions between rifampicin and nnrtis
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are part of WHO recommended first-
line antiretroviral regimens in resource-limited settings [5], hence the interaction between 
rifampicin and NNRTIs is particularly important. Efavirenz is the recommended NNRTI to be used 
in patients starting ART while on TB treatment [5]. It should be taken once daily and is generally 
well tolerated. Efavirenz is mainly metabolized by hepatic CYP2B6. As rifampicin is a potent 
inducer of CYP450 enzymes, concomitant use of rifampicin and efavirenz leads to unavoidable 
drug interactions. However, rifampicin has not been shown to consistently reduce efavirenz 
concentrations. The metabolism of efavirenz is extensively influenced by pharmacogenetic 
factors, particularly the CYP2B6 single nucleotide polymorphism 516G>T, which impairs 
metabolism resulting in high efavirenz concentrations. This polymorphism occurs commonly 
in South Africa [32] West Africa and India [33,34]. Factors influencing efavirenz concentrations 
include body weight and racial or ethnic background [35-37]. Thai and Afro-American patients 
have reduced efavirenz clearance and hence increased efavirenz concentrations [38].
Most pharmacokinetic studies have shown that exposure to efavirenz is decreased upon co-
administration of rifampicin, but whether to increase the dose of efavirenz when concomitantly 
used with rifampicin is still the subject of controversy. A pharmacokinetic study in 12 European 
participants found a decrease in efavirenz area under the concentration curve (AUC) by 
26% [10]. Also, a retrospective analysis of a therapeutic drug monitoring database found that 
efavirenz concentrations were significantly lowered (35%) with rifampicin [36]. The need for 
efavirenz dose increase when rifampicin is co-administered was recommended [39], however 
in recent studies it was concluded that there is no need to increase the dose of efavirenz while 
co administered with rifampicin [40,41].
A prospective pharmacokinetic study conducted in adults from Spain [37]showed a decrease 
in efavirenz concentration but studies in India and South Africa reported a non-significant 
reduction in efavirenz concentrations [34,42]. In these studies, patients showed similar efavirenz 
trough levels and adequate virological outcome in patients who took 600 mg efavirenz during 
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and after co-administration of rifampicin. Previously, no significant difference in efavirenz 
concentrations was observed in a randomized study performed in Thailand where standard 
(600  mg once daily) and increased doses (800 mg once daily) of efavirenz were compared 
[43,44]. Virological outcomes in both arms were similar as well. However, the interpretation of 
this study is limited by the inclusion of just one ethnic group of patients with a low mean body 
weight (<50kg) and by a small number of participants (84 patients). Most of the studies have 
shown that body weight is the important predictor of efavirenz concentration [45-47].
Many of the studies have shown that response to standard-dose efavirenz based ART is 
similar in patients with and without rifampicin -containing treatment [48,49]. Efavirenz, given 
at a standard dosage of 600 mg per day, was found adequate for suppression of HIV, despite 
variation in blood concentrations of the drug [50]. However, ethnicity plays an important role 
because ethnic Black Africans are frequently of the homologous CYP2B6 516-T/T genotype 
in comparison to other ethnic groups [51,52]. This fact is supported by the study conducted 
by Friedland et al [52], where the study results indicated that Black African patients suffered 
more frequently from central nervous system side effects although receiving a dose of 600 mg 
with rifampicin. Also, intersubject variability in pharmacokinetics of efavirenz due to CYP2B6 
polymorphism was observed [53-57].
The suggestion that the effect of CYP2B6 genotype on efavirenz levels is greater 
than that of rifampicin was supported by a recent study from Manosuthi et al who showed 
that particular CYP2B6 genotypes (especially haplotype *6/*6) had the greatest impact on 
efavirenz concentrations in TB-HIV co-infected patients in Thailand [58]. Low body weight 
and concurrent receiving rifampicin were of less influence. Also, in vitro work supports the 
role of pharmacogenetics on efavirenz exposure [59]. Interestingly, CYP2B6 genotype was the 
explanation for an observed increase in efavirenz exposure during TB treatment in a group 
of black African patients [60]. The same was found in Ghana, where patients with CYP2B6 
516TT genotype who were on concomitant TB and HIV treatment had higher efavirenz plasma 
concentrations than volunteers with the same genotype who did not receive TB treatment [55]. 
Because of the effect of CYP2B6 genotype on efavirenz levels when used with rifampicin, some 
argue the use of therapeutic drug monitoring and subsequent efavirenz dose adjustment [61].
In summary, there is still controversy about whether to increase the dose of efavirenz, in 
general or for certain subgroups of patients. Pharmacogenetic factors (CYP2B6) play a major 
role in efavirenz exposure and it is suggested that the effect of pharmacogenetics is larger 
than that of rifampicin. Therapeutic drug monitoring to assess whether a dose increase might 
be justified is an option offered by some researchers. However, more research is needed on 
the association between efavirenz plasma concentrations and virological and immunological 
treatment outcomes. 
Nevirapine, another NNRTI, is widely used in developing countries. It is cheaper than 
efavirenz and is recommended instead of efavirenz in women who might become childbearing 
[62], as efavirenz is teratogenic and therefore contraindicated during the first trimester of 
pregnancy. Nevirapine is mainly metabolized by CYP3A4 and to a lesser extent by CYP2B6 
and is therefore vulnerable for interaction with rifampicin. The mean effect of rifampicin on 
nevirapine concentrations is stronger than its effect on efavirenz concentrations, as reductions 
up to 55% in nevirapine concentrations have been described [63,64]. Likewise, a relatively larger 
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proportion of co-treated patients can be expected to have trough levels of nevirapine below 
the target range [42,63, 65]. This is consistent with the finding that nevirapine associated with 
virological failure and death more frequently than efavirenz [66].
Despite the relatively strong effect of rifampicin on nevirapine concentrations, standard-
dose nevirapine combined with rifampicin was shown not to be associated with worse 
virological outcome compared to HIV patients on ART without TB treatment [67,68]. However, 
in another study virological outcome was worse in patients who received nevirapine based ART 
combined with TB treatment compared to those who had no concurrent TB. Increasing the 
dose of nevirapine upon co-administration of rifampicin can overcome the decreased exposure 
to nevirapine, but this approach raises concerns about hepatotoxicity, which may be dose-
related [69]. This concern is especially relevant because isoniazid, rifampicin and pyrazinamide 
are also hepatotoxic drugs. Monitoring of hepatotoxicity has been recommended when it is 
used with rifampicin [70]. 
There is discussion about the lead-in dose of nevirapine when used with rifampicin-based TB 
treatment. Nevirapine initiation by dose escalation resulted in sub-therapeutic concentrations 
in an Ugandan study [71]. The authors suggest that this strategy should be avoided in rifampicin 
co-treated patients, because nevirapine concentrations were subtherapeutic during initiation 
with dose escalation and nevirapine initiation at the maintenance dose of 200 mg twice daily 
is preferred. Furthermore, the reduction of nevirapine levels by rifampicin is suggested to be 
reversible, as nevirapine exposure significantly increased after 10 weeks of combined TB and 
HIV treatment [72].
Although rifampicin decreases efavirenz and nevirapine concentrations, its effect on ART 
treatment outcome is not clear. Two recent studies showed that the subtherapeutic plasma 
concentrations of nevirapine or efavirenz due to rifampicin were not associated with virological 
failure. Patients had good clinical outcomes, and the combined treatment was tolerated well 
with a low incidence of hepatotoxicity [73]. The viral load and CD4 count of patients using 
nevirapine-based ART with versus without rifampicin were comparable [74]. The association 
between altered NNRTI pharmacokinetics and treatment efficacy warrants more research. 
Furthermore, there is insufficient data to make definitive recommendations about dose 
adjustment of the NNRTIs during rifampicin containing therapy [75]. 
interactions between rifampicin and Pis
Protease inhibitors (PIs) are part of second line antiretroviral treatment. PIs are used in case of 
resistance to NNRTIs and for individuals who cannot tolerate NNRTIs. Of the PIs recommended 
by the WHO saquinavir, lopinavir, indinavir, and atazanavir are all metabolized by CYP3A4 and 
also act as weak inhibitors of CYP3A4 [76]. Therefore, interaction with rifampicin is expected 
(i.e. decreased plasma concentrations). Nelfinavir is the only PI that is metabolized by both 
CYP2C19 and CYP3A4, which means that concomitant use of isoniazid will likely result in 
increased plasma levels due to CYP2C19 inhibition. Ritonavir is metabolized via CYP3A and 
CYP2D6 isoforms [77] and is an exceptionally potent inhibitor of CYP3A4. Less commonly, it can 
serve as an inducer of CYP3A4 and glucuronosyl S-transferase, or act as a mixed competitive/
noncompetitive inhibitor of CYP2D6 [78]. 
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Due to its potent inhibition of CYP3A4 as well as P-glycoprotein, ritonavir is frequently used 
with other PIs to pharmacologically ‘boost’ their concentrations. In such boosted PI regimens, 
ritonavir is used in a low dose (100 mg twice-daily, instead of the approved dose of 600 mg twice-
daily). A recommended option for combined use with rifampicin is so-called superboosting 
with an adjusted dose of ritonavir (200mg or 400 mg) [5]. Considering the metabolic profiles 
of the PIs and their transport by P-glycoprotein, it is not surprising that rifampicin can reduce 
PI plasma concentrations up to 80-95% [79]. The exposure to the therapeutic dose of ritonavir 
(600 mg twice daily) is less affected by rifampicin compared to the other PIs, because ritonavir 
is a potent inhibitor of CYP3A4 and P-glycoprotein, thereby compensating (part of) the 
inducing effect of rifampicin [80]. However, this PI is not well tolerated and its capsules need to 
be refrigerated, which is problematic in developing countries. 
Unfortunately, boosting the exposure to PIs with low dose ritonavir (100 mg BID) is not 
able to overcome the inducing effect of rifampicin. An increased dose of ritonavir (400  mg 
twice daily) to boost saquinavir or lopinavir may be adequate to compensate for the induction 
by rifampicin [8,81-85]. For example in a study with relatively small sample size, high-dose 
saquinavir/ritonavir (400/400 mg) coadministered with rifampicin was well tolerated, produced 
adequate concentrations, and was recommended for use [86]. Similarly adjusted doses of 
lopinavir/ritonavir (800/200 and 400/400 mg) resulted in acceptable mean trough levels, but 
a higher interpatient variability in exposure [82].
Unfortunately, combination of boosted PIs with rifampicin has been associated with 
unacceptable toxicity. In a study of 20 TB-HIV -coinfected patients who started this saquinavir/
ritonavir 400/400 mg after four weeks of rifampicin -containing TB treatment, 15 dropped out 
because of adverse events [8]. 
Likewise, in a study of 14 healthy volunteers who first were given 600 mg of rifampicin daily 
for 14 days and then also were given 1000/100 mg of Saquinavir/ritonavir twice daily, 9  had 
grade 3 or 4 hepatotoxicity; the trial was stopped early [83]. Similar results were obtained 
when adjusted doses of lopinavir/ritonavir were introduced in healthy volunteers on rifampicin 
[87]. Studies from South Africa showed that once patients were established on treatment with 
increased doses of lopinavir/ritonavir co-administered with rifampicin-based tuberculosis, 
treatment was tolerated and lopinavir predose concentrations were adequate [88]. Additionally, 
doubling the dose of the tablet formulation of lopinavir/ritonavir (to 800/200mg) overcomes 
the metabolism induction by rifampicin and was tolerated well in a cohort of HIV-infected 
participants [89]. 
Rifampicin reduces saquinavir concentrations up to 70% in healthy volunteers, however 
the reduction was only 46% in HIV infected patients [90]. These studies show that findings 
from healthy volunteers can be different from findings in HIV-infected patients. The effect of 
doubling the dose of lopinavir/ritonavir and superboosted lopinavir/ritonavir (1:1 ratio) should 
be evaluated further in HIV infected patients, with special emphasis on the virological and 
immunological outcomes as well as development of hepatotoxicity. Recent experience show 
that combined use of lopinavir/ritonavir and rifampicin is a problem as one need to balance 
between sub-optimal efficacy and toxicity [91]. As to actual TB patients, very few data are 
available about pharmacokinetics, efficacy and tolerability of (boosted) PIs and rifampicin-
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based TB treatment. In a current study [92] rifabutin was found to be safe in combination with 
PIs and also cost saving when given with current recommended boosted PIs. 
interactions between rifampicin and nrtis & ntrtis
Nucleoside reverse transcriptase inhibitors (NRTIs) serve as the backbone of antiretroviral 
treatment regimens. Because CYP450 enzymes do not metabolize them, this class of drug is less 
prone to drug-interactions with rifampicin; NRTIs can therefore be combined with rifampicin 
[93]. However, rifampicin is known to reduce the exposure to zidovudine by almost 50% [46,47]. 
The effect of rifampicin on the intracellular concentrations of zidovudine-triphosphate is not 
known. Nevertheless, this interaction is thought to be of minor clinical relevance [94]. Tenofovir 
disoproxil fumarate, the only approved nucleotide reverse transcriptase inhibitor (NtRTI) is 
not a substrate, inhibitor, or inducer of the CYP450 system. A study in healthy volunteers [95] 
showed a clinically insignificant interaction between tenofovir and rifampicin, which reflects 
the possibility of combining this drug with rifampicin.
interactions between rifampicin and other arVs 
Antiretroviral drugs from other classes have been evaluated for interaction with rifampicin. 
Plasma concentrations of the fusion inhibitor enfuvirtide were not shown to be affected by 
ten days of concomitant use with rifampicin, showing that these drugs can be co-administered 
without dose-adjustments [96]. The integrase inhibitor raltegravir is metabolized by 
glucuronidation, an enzyme system that is induced by rifampicin, but raltegravir does not 
inhibit or induce CYP450 enzymes. Recent data show that the dose of raltegravir needs to be 
doubled when combined with rifampicin, but this increased dose (800 mg) tolerated well in a 
small study with two patients [97,98]. Raltegravir trough concentrations were at the lower limit 
of clinical experience when used with rifampicin so caution should be applied [99]. Raltegravir 
was used in increased dose in four Spanish patients to replace the PIs during rifampicin-based 
TB treatment [100]. Raltegravir maintained its virological and immunological efficacy and was 
tolerated well. 
These studies indicate that raltegravir may be a good substitute for the PIs when second line 
ART has to be combined with rifampicin-based TB treatment. A study from Thailand showed 
that using raltegravir at 400 mg once daily was associated with a low C(trough) and with a risk 
for HIV viremia. Raltegravir at 200 or 300mg twice daily should be studied. However, a higher 
dose raltegravir (800mg) might have a better virological response. Another investigational 
second-generation integrase inhibitor, dolutegravir, is a substrate of UGT1A1 and CYP3A. 
Dolutegravir were reduced when combined with rifampicin, however, when dolutegravir was 
given twice-daily mean pharmacokinetic parameters were 20%–33% higher compared to once 
daily use (both in combination with rifampicin) [101].
Maraviroc, a CCR5 antagonist, is a substrate of CYP3A4 and P-glycoproteine. As expected 
maraviroc exposure (Cmax and AUC12) was reduced by approximately 70% by rifampicin [102]. 
Etravirine is the first next-generation NNRTI that is approved for treatment of HIV infection 
in patients who have experienced virological failure while receiving an NNRTI-containing 
regimen. Because the drug is metabolized by CYP450 isoenzymes, it is not recommended for 
use with rifampicin, or high-dose ritonavir and atazanavir [103,104]. 
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The bioavailability of another NNRTI, rilpivirine, is also dramatically reduced during 
combined use with rifampicin and the study investigators concluded that concurrent 
administration of rilpivirine and rifampicin is not recommended [105].
The pharmacokinetic properties of the fusion inhibitor enfuvirtide were not clinically 
affected by coadministration of rifampicin, or the protease inhibitors ritonavir and ritonavir-
boosted saquinavir, indicating the potential for use with TB treatment [106].
Unfortunately, all these newer antiretroviral drugs are not yet available in resource-limited 
settings. However, if proven to be well tolerated and combinable with rifampicin, effort should 
be made to make these drugs available to those who would mostly benefit from these drugs: 
TB-HIV coinfected people who would need to use second line ART.
interactions with isoniazid and antiretroviral drugs
Currently, all HIV infected patients without active tuberculosis should be offered isoniazid 
preventive therapy for at least six months as prophylaxis for latent TB infection [5]. Isoniazid is 
an inhibitor of CYP2C19 and CYP3A [29]. Therefore increased efavirenz and lopinavir/ritonavir 
plasma concentrations are to be expected when isoniazid monotherapy for treatment of latent 
TB infection is given during ART. However, this has not yet been investigated. 
oVerl aPPing toxiCit y ProFiles
Adverse effects to TB drugs appear to occur more commonly among HIV-infected versus 
non-HIV-infected patients, as suggested by most studies [107-109]. In case TB drugs and 
antiretroviral drugs are combined, the antiretroviral drugs as well as the TB drugs may cause 
major treatment-limiting adverse effects. In addition these drugs may have pharmacodynamic 
interactions, which generally involve additive, synergistic or antagonistic effects of drugs 
acting on the same receptors or physiological systems. In this case, TB drugs and antiretroviral 
drugs have an overlapping or additive adverse effect profile, related to (amongst others) 
hepatotoxicity, gastro-intestinal intolerance and peripheral neuropathy. 
Not surprisingly, drug toxicity has been implicated as a major cause of discontinuation 
or interruption of TB and/or antiretroviral therapy during treatment of TB-HIV co-infection. 
Adverse reactions that can occur due to both tuberculosis and antiretroviral treatment are 
summarized in Table 1, which clearly shows the overlap in toxicity profiles between these drugs. 
A recent study from Ethiopia indicated that 30% of TB-HIV co-treated patients developed 
hepatotoxicity during efavirenz based ART and rifampicin based anti-TB therapy. The predictors 
included slow acetylation status and a CYP2B6*6/*6 and ABCB13435TT genotype, which indicates 
that high efavirenz levels (caused by the latter two genotypes) might result in higher risk on 
hepatotoxicity [110]. However, actual data on adverse effects amongst patients who receive 
both TB drugs and antiretroviral drugs coadministered are relatively scarce and most studies 
are retrospective in nature. There is a need for prospective studies that evaluate toxicity to TB 
and antiretroviral drugs in patients with TB-HIV co-infection. Such studies may shed light on 
the effects of ethnicity, pharmacogenetic risk factors, immune suppression and malnutrition 
on adverse effects to TB and HIV drugs. 
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In the mean time, clinicians should be aware of the overlapping adverse effect profiles, 
and it should be attempted to use agents with minimal overlapping or additive toxicities. In 
addition to patient education on signs and symptoms of toxicity, regulatory scheduled clinical 
and laboratory monitoring, and close communication between TB and HIV clinicians are critical 
to minimizing treatment discontinuation due to adverse events.
Challenges For resourCe-limited set tings 
From the above discussion of pharmacokinetic interactions between TB treatment, particularly 
rifampicin, and antiretroviral drugs it is clear that antiretroviral treatment with a backbone 
of NNRTIs and N(t)RTIs can be combined with rifampicin-based TB treatment. Overlapping 
adverse effect profiles may limit the acceptability of such combinations in individual patients. 
In case of such overlapping toxicity, unduly toxicity caused by NNRTIs, or treatment failure 
due to resistance to NNRTIs, a major problem arises: there is no obvious second-line protease 
inhibitor-based antiretroviral regimen that can be administered with rifampicin. 
The currently recommended second line ART schedule with the protease inhibitors 
lopinavir or saquinavir (boosted with ritonavir) has the problem that rifampicin significantly 
reduces the levels of the boosted PIs. The use of increased ritonavir doses (superboosting) can 
overcome this problem; however with increased risk of toxicity. The need for second line ART 
in resource limited settings will likely increase in the near future because ART is being rolled-
out in developing countries. This means that the number of TB patients who will need second 
line ART will also increase: these patients need to overcome a period of (at least) six months of 
combined TB-HIV treatment one way or the other and these are the options: 
the use of boosted Pis
The currently recommended second line ART combined with rifampicin-based TB treatment 
is based on the protease inhibitors lopinavir or saquinavir, with boosting doses of ritonavir 
(lopinavir/ritonavir 400mg/400mg twice daily or lopinavir/ritonavir 800mg/200mg twice 
daily; or saquinavir/ritonavir 400mg/400mg twice daily). These drug combinations have 
resulted in severe toxicity in healthy volunteers. However, two recent studies from South Africa 
indicate that using increased lopinavir/ritonavir doses in HIV-infected TB patients were well 
tolerated [88,89]. This is a promising finding, which also indicates that drug-interactions should 
be studied in the relevant population and not only in healthy volunteers [111]. Data on lopinavir/
ritonavir used in combination with rifampicin is sparse and requires more investigation. Its 
safety and efficacy should be evaluated in larger cohorts of TB-HIV coinfected patients and 
whether the approach to double the lopinavir/ritonavir dose in two steps over a two-week 
period is the best approach to prevent severe hepatotoxicity [88]. 
use of nrti/ntrti-only regimens
Combination triple NRTI/NtRTIs regimens appear to be attractive for concurrent application 
with rifampicin-based TB therapy, as N(t)RTIs do not interact with rifampicin. However, triple 
NRTI/NtRTI combinations have been shown to be less potent than NNRTI or PI-based regimens 
in the treatment of HIV infection, as they have been associated with inferior virological 
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responses in clinical trials [112,113]. Consequently such combinations are not recommended 
with rifampicin-based TB treatment and the role of triple NRTI/NtRI, or possibly quadruple 
NRTI/NtRTI, combined with rifampicin-based TB treatment has not been evaluated in clinical 
trials so far. However, because these regimens would only be needed temporarily (for the 
duration of TB treatment) evaluating its efficacy would be worthwhile. 
use of new antiretroviral drugs
Newer antiretroviral drugs such as the integrase inhibitor raltegravir could be good options 
for second line ART in combination with rifampicin-based TB treatment. Despite the effect 
of rifampicin on raltegravir metabolism, increasing the doses was shown to overcome the 
problem of decreased plasma concentrations and was tolerated well [98,100]. Unfortunately 
these drugs are currently not available in resource-limited settings; a well organized lobby 
should be triggered by the scientific community because of the high potential of these drugs in 
situations where NNRTIs are no longer useful and second line ART is needed. HIV treatment is 
for life. However, as combined HIV-TB treatment is only for a limited period of six months and 
the proportion of TB-HIV patients in need of second line ART is small, there should be options 
for currently unavailable drugs to become available in settings where they are mostly needed.
use of other rifamycins instead of rifampicin
The current guideline for concurrent TB treatment with second line ART suggests replacing 
rifampicin with rifabutin [3,5]. Rifabutin is a less potent inducer of the CYP450 system and is 
therefore preferred over rifampicin in patients on TB treatment that have to use second 
line ART regimens that include a protease inhibitor. However, unlike rifampicin, rifabutin is 
metabolized by CYP3A4. As most PIs are CYP3A4 inhibitors, this means that a reduction in the 
dose of rifabutin is required when co-administered with several PIs. Such two-way interactions 
are complex to manage, especially in developing countries where the high burden of TB and 
TB-HIV infection is preferably managed by standard treatment regimens. 
Apart from this, rifabutin is very expensive, making widespread use in developing countries 
challenging. In addition, even if the price of rifabutin were reduced it would be difficult to 
implement this drug in high-burden countries, because standard TB treatment is often available 
as fixed-dose combination tablets, making it complicated to replace rifampicin by rifabutin. 
Since 79% of patients with TB-HIV coinfections occur in the African Region [114], using rifabutin 
instead of rifampicin is probably only feasible for a minority of coinfected patients.
Another rifamycin, rifapentine, is currently not recommended in HIV-infected patients, as 
it is associated with the emergence of rifamycin-monoresistant TB strains when used in a once-
weekly dosing scheme among patients with TB-HIV co-infection [115,116]. 
use of non rifamycin-based tb regimens
A TB treatment regimen without rifampicin may be considered to circumvent the problem of 
pharmacokinetic interactions with PIs. This is not an attractive option, as use of rifampicin in 
TB-HIV co-infection has been associated with better responses to TB treatment, improved 
survival, and reduced recurrence rates of TB in HIV-co-infected persons [117,118]. In addition, 
TB treatment without rifampicin should be extended to 8 months instead of 6 months. In 
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instances where a rifampicin containing regimen is initially given during the initiation phase 
of TB therapy and then switched to a non-rifampicin regimen, to allow for PI-based ART to 
be initiated, rifampicin should be discontinued at least 2 weeks before the introduction of a 
PI-based regimen. This will allow for the induction effect of rifampicin on CYP3A4 to dissipate to 
avoid sub-therapeutic concentrations of the PI. In summary, no clear second-line antiretroviral 
regimen is available for TB patients. The best option may arguably be the use of a triple-NRTI 
regimen for the duration of rifampicin-based TB treatment. 
ConClusions and researCh Priorities
With about one million TB-HIV coinfected patients eligible for combined TB-HIV treatment 
each year, it is of utmost importance to optimise combined TB-HIV treatment in terms of safety 
and efficacy. Major progress has been made to evaluate the interactions between TB drugs and 
antiretroviral therapy, however burning questions remain concerning nevirapine and efavirenz 
effectiveness during rifampicin-based TB treatment, treatment options for TB-HIV coinfected 
patients with NNRTI resistance or intolerance and exact treatment or dosing schedules for 
vulnerable patients including children and pregnant women. 
The current research priorities can be addressed using different strategies that are equally 
important (table 2): to maximise the use of already existing programme and research data, 
to create new data by conducting clinical trials and prospective observational studies and to 
engage a lobby to make currently unavailable drugs available to those most in need. 
Evaluating program data and conducting meta-analyses or modeling exercises with trial 
data maximizes the use of already existing data. For example, more knowledge is needed on 
the effect of rifampicin on the effectiveness of ART, more specifically on the virological and 
immunological outcomes of HIV infected patients using efavirenz or nevirapine based ART with 
rifampicin. Conducting a meta-analysis or modeling exercise on all currently available clinical 
trial and observational study data could be an approach to solve currently unresolved issues, 
such as finding the optimal efavirenz dose during rifampicin-based TB treatment, elucidating 
the association between subtherapeutic efavirenz plasma concentrations and treatment 
outcome and whether nevirapine-based ART should be recommended. 
An example of modelling was the use of population pharmacokinetic analysis for dose 
optimization, which has been done by Zhang et al whose simulations predicted that almost 
all patients receiving doubled doses of lopinavir/ritonavir achieve satisfying morning trough 
concentrations of lopinavir during rifampicin co-administration [119]. Furthermore, actual data 
on adverse effects during TB-HIV combined treatment are scarce, and in addition to prospective 
studies on this subject, a thorough literature review or meta-analysis of existing data would be 
highly valuable. Retrospective research using already existing data would, however, not replace 
the need for prospective studies. 
Efavirenz is the preferred NNRTI to be used with rifampicin-based TB treatment. Rifampicin 
has an effect on plasma concentrations of the NNRTIs nevirapine and efavirenz. Despite the fact 
that nevirapine is the most widely used NNRTI in developing countries because it is cheaper 
than efavirenz and safe during pregnancy, there is much more clinical and pharmacokinetic 
data on rifampicin with efavirenz than with nevirapine. More research is needed on the 
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effectiveness of nevirapine-based ART when combined with rifampicin and whether the 
lead-in dose could be omitted, as recent research indicated that nevirapine initiation at the 
maintenance dose of 200  mg twice daily is preferred [71]. There is no conclusive evidence 
concerning dose-adjustment of efavirenz during rifampicin-based TB treatment. In summary, 
more adequately powered observational cohort studies and randomized clinical trials should 
be conducted to assess the clinical relevance of the NNRTI-rifampicin interactions for both 
efavirenz and nevirapine.
On the use of PIs and ritonavir-boosted PIs, these drugs only display suboptimal exposure 
when combined with rifampicin. Increasing the dose of protease inhibitors is recommended 
to compensate for the metabolism inducing effect of rifampicin, which can be achieved by 
increasing the ritonavir dose or by doubling the lopinavir/ritonavir dose. More research is 
Table 2. Pharmacological research priorities concerning combined TB and HIV treatment
NNRTIs
Evaluation of 600mg and 800mg efavirenz and/or the need for individual efavirenz dose adjustment when 
combined with rifampicin and the role of pharmacogenetic profile (CYP2B6) 
The effect of rifampicin on the efficacy of nevirapine-based ART (virological and immunological outcomes) 
Evaluate the pharmacokinetic and efficacy effects of omitting the lead-in dose of nevirapine with combined 
with rifampicin.
Protease inhibitors 
Evaluate the efficacy (virological and immunological outcomes) and safety of bPI and sbPI-based regimens 
when combined with rifampicin in relevant populations (HIV-infected TB patients) 
Evaluation of the tolerability (hepatotoxicity) of lopinavir/ritonavir co-administered with rifampicin in 
African and Asian HIV-TB populations.
NRTIs / NtRTIs
Evaluating the efficacy of triple NRTI/NtRTIs regimens for temporal use during combined rifampicin-based 
TB treatment. 
New antiretroviral drugs
Evaluation of the tolerability and efficacy of double-dose raltegravir in HIV-TB patients using concomitant 
rifampicin 
Evaluate the safety and efficacy of twice daily dolutegravir in combined use with rifampicin based TB 
treatment in HIV-TB coinfected patients. 
Other 
Effect of isoniazid monotherapy (treatment LTBI) on PK of efavirenz and lopinavir/ritonavir
Effect of isoniazid monotherapy (treatment LTBI) on treatment outcome of efavirenz or lopinavir-based ART 
General 
Determine the incidence and type of adverse effects during TB-HIV combined treatment
The development of simple and inexpensive analytical tools for TDM, e.g. for efavirenz.
Development of safe and effective ART regimens for children 
Evaluate the efficacy of safe ART regimens (e.g. nevirapine based) in pregnant women 
Legend: TDM, therapeutic drug monitoring; LTBI, latent tuberculosis infection; ART, antiretroviral treatment; 
PK, pharmacokinetic 
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needed on the effect on virological and immunological treatment outcomes of such dose 
increases. Furthermore, toxicity remains an issue with boosted (or superboosted) PIs, although 
the severe adverse effects observed in volunteer subjects using rifampicin and boosted-PIs 
were not observed to the same extent in HIV-infected TB patients [88,89]. This underlines 
the need of pharmacological interaction studies in the relevant populations (i.e. HIV-infected 
TB patients) because data from healthy volunteers cannot be readily translated to patient 
populations [111,120].
There are new antiretroviral drugs, for example raltegravir, that seem promising candidates 
for second line ART when combined with TB treatment in terms of safety and tolerability. 
Plasma concentrations of the integrase inhibitor raltegravir are reduced by rifampicin. However 
increasing the raltegravir dose overcomes this and a recent small study indicated a good 
tolerability of the increased dose [98]. However, more safety, pharmacokinetic and efficacy 
data of an increased raltegravir dose combined with rifampicin is definitely needed. 
Triple/quadruple NRTI/NtRTI treatment in combination with rifampicin-based TB treatment 
has not been evaluated in clinical trials. The efficacy and safety of triple/quadruple NRTI/
NtRTI treatment during rifampicin-based TB treatment for its use as a temporal ART during TB 
treatment should be evaluated. 
There is a need for simple and inexpensive modes of plasma concentration monitoring 
(Therapeutic Drug Monitoring) for antiretroviral drugs, such as a rapid test using a saliva 
sample. 107 This could potentially be useful for efavirenz, where there is a discussion around the 
need for individualized dosing based on pharmacogenetic factors [58]. A pragmatic approach 
with a simple TDM technique would be a way around the need to determine a patient’s CYP2B6 
genotype prior to efavirenz use, which would not be feasible in resource-limited settings. 
The effect of isoniazid monotherapy for treatment of latent TB infections on efavirenz and 
lopinavir pharmacokinetics could be studied in prospective observational studied. However, 
the effect of isoniazid monotherapy on ART treatment outcome might be evaluated using 
already existent program data. 
Pharmacokinetic interaction studies with ARVs should be considered and planned early in 
the course of the TB drug development process, to ensure that HIV-infected TB patients can 
benefit from new treatment regimens for treatment of susceptible or multidrug resistant TB 
[120]. Such interaction studies must be conducted in the relevant populations, as opposed to 
healthy volunteers, to account for environmental and host factors such as HIV infection and 
pharmacogenetic factors.
If pharmacological scientific data shows that new antiretroviral drugs would provide a way 
around the increased toxicity or decreased effectiveness of currently recommended second 
line ART regimens, a lobby to make currently unavailable drugs available to those most in 
need is eventually the ultimate way forward to achieve better treatment for TB-HIV coinfected 
patients. Emphasis should be put on the fact that it is only a relatively small proportion of 
all TB-HIV coinfected patients who would need different (i.e. new) antiretroviral drugs to 
overcome a limited period of time (six months) during which they have to combine second line 
ART with rifampicin-based TB treatment. 
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abstraCt
background: Co-administration of anti-tuberculosis and antiretroviral therapy is often 
inevitable in high-burden countries where tuberculosis is the most common opportunistic 
infection associated with HIV/AIDS. Concurrent use of rifampicin and several antiretroviral 
drugs is complicated by pharmacokinetic drug-drug interaction.
method: Pubmed and Google search following the key words tuberculosis, HIV, emtricitabine, 
tenofovir efavirenz, interaction were used to find relevant information on each drug of the 
fixed dose combination AtriplaR.
results: Information on generic name, trade name, pharmacokinetic parameter, metabolism 
and the pharmacokinetic interaction with Anti-TB drugs of emtricitabine, tenofovir, and 
efavirenz was obtained.
Conclusion: Fixed dose combination of emtricitabine/tenofovir/efavirenz (AtriplaR) which has 
been approved by Food and Drug Administration shows promising results as far as safety and 
efficacy is concerned in TB/HIV coinfection patients, hence can be considered effective and 
safe antiretroviral drug in TB/HIV management for adults and children above 3 years of age.
keywords: Tuberculosis, HIV, Emtricitabine, Tenofovir, Efavirenz, Interaction
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baCkground
Human immunodeficiency virus (HIV) and tuberculosis (TB) are overlapping epidemics that 
cause an immense burden of disease. Sub-Sahara Africa is a region most affected by both 
diseases including Tanzania [1]. Literatures show that more than 75% of TB patients have also 
HIV, and possibly more than half of worldwide patients infected with HIV will also develop TB 
[2,3]. Furthermore TB contributed to 27% of all AIDS diagnoses [4]. For TB the currently used 
combination drug regimens produce cure rates that exceed 95%, given good patient adherence 
during the multiple months’ treatment period [5]. Also for HIV many regimens are available; 
howeveroptimal treatment regimens for TB/HIV co-infection are not yet clearly defined.
As therapy for HIV disease becomes more available, physicians need to know how to treat 
these two diseases effectively while minimizing the risk of drug interactions and maintaining the 
shortest possible duration of treatment for TB. Current treatment of mycobacterium tuberculosis 
in most resource limited settings is comprised of a four-drug initial anti-tuberculosis regimen 
for 2 months (rifampicin, isoniazid, pyrazinamide andethambutol), followed by two-drugs 
continuation phase of anti-tuberculosis regimen for 4 months (rifampicin and isoniazid). For 
TB/HIV co-infected patients the guidelines which exist [6] have shown many challenges. 
Combining drug therapies for dual infection TB and HIV is made complex by alterations 
in the activity of the hepatic Cytochrome P450 (CYP) system, high pill Burdens, shared drug 
toxicities, drug-drug and drug-disease interactions, immune reconstitution inflammatory 
syndrome, co-morbid diseases and drug resistance in both bacillus and virus [7,8]. The CYP 
isoform enzymes are responsible for many interactions [9] (especially those involving rifampicin 
and isoniazid) during drug biotransformation (metabolism) in the liver and/or intestine, due to 
it is enzyme induction effect.
Presentation oF the hyPothesis
Adherence to a complex regimen is often a significant barrier to treatment success. Following 
the current guideline where a patient has to take 4-fixed dose combination for TB and the 
complex triple combination therapy selected for HIV treatment. The consequence of many 
pills reduce compliance and hence adherence to the treatment regimen leading to suboptimal 
TB and HIV treatment, hence increasing the possibility of drug resistance and shared drug 
toxicities [10]. These toxicities may necessitate therapy discontinuation, which exacerbates 
immune suppression and predisposes to other opportunistic infections.
TB/HIV co-infection simultaneous treatment have shown pharmacokinetic interactions 
produced with mainly rifampicin [(a cornerstone in TB treatment) and the non nucleoside 
reverse transcriptase inhibitors (NNRTIs)]. Enzyme inducer decreases elimination halve life 
of nevirapine [11]. When rifampicin and nevirapine are given together there is an observed 
31% to 58% decrease in plasma levels of nevirapine due to rifampicin induction effect [12-15]. 
Available literatures explain that rifampicin combination with efavirenz there is reduction 
of serum levels of 13-33% [16], however no virological failure reported to be significant [17]. 
HIVinfected patients achieve somewhat lower concentrations of the orally administered first-
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line anti-tubercular drugs [18,19]. The effect of rifampicin on the concentrations of Protease 
Inhibitors (PI) is well elaborated in a study of Moreno et al. [20]. Immune reconstitution 
inflammatory syndrome (IRIS), which is due to dysregulated immune recovery [21], occurs in 
severely immune-suppressed HIV patients normally 1 to 4 weeks after ART initiation [22,23]. In 
tuberculosis-related IRIS which is an inflammatory reaction is directed towards mycobacterial 
antigens [24], resulting in worsening pulmonary infiltrates.
Risk factors for TB-IRIS include low baseline CD4 count, high baseline viral load, short 
duration between TB and ART initiation and disseminated tuberculosis [22,25], making difficult 
to determine the optimal time to initiate ART in severely immune-suppressed TB patients 
[26,27]. Immune reconstitution is based on the patient’s ability to respond to treatment. For 
the most part, in patients with CD4 counts of 200-350 cells/mm3 who start treatment, their 
immune systems still have the ability to be activated to produce more CD4 cells [28]. In 
contrast, in patients with low CD4 counts (< 100 cells/mm3), it may be more difficult to activate 
their immune systems to produce many CD4 cells because of existing damage from the virus.
In the management of TB/HIV co-infection directly observed therapy and other adherence 
promoting strategies should be used in all patients with HIV-related TB [29]. Whenever possible, 
the care for HIV-related TB should be provided by or in consultation with experts in management 
of both TB and HIV. The care for persons with HIV-related TB should include close attention to 
the possibility of TB treatment failure, antiretroviral treatment failure, paradoxical reactions, side 
effects for all drugs used, and drug toxicities associated with increased serum concentrations 
of rifampicin. Due to these accompanied complications, selecting an appropriate antiretroviral 
therapeutic regimen is warranted. This involves addressing multiple interdependent issues, 
including patient adherence, pharmacokinetic properties of the drugs (including food effects 
and drugdrug interactions), drug resistance, and overlapping adverse effects. 
On 12 July 2006 Bristol-Myers Squibb and Gilead Sciences announced that the US Food and 
Drug Administration (FDA) had cleared AtriplaR, their fixed-dose combination tablet. AtriplaR is 
a complete regimen in a single, fixed-dose combination tablet that contains: efavirenz 600 mg, 
emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg. It is a novel co formulation 
drugs from two different classes, simplifying administration and increasing adherence too [30]. 
testing the hyPothesis
A new formulation combining fixed doses of the nucleoside reverse transcriptase inhibitors 
emtricitabine (200 mg) and tenofovir disoproxil fumarate (tenofovir DF; 300 mg) with the 
non-nucleoside reverse transcriptase inhibitor efavirenz (600 mg) represents the first once-
daily, one-tablet antiretroviral regimen. Co-formulated efavirenz/emtricitabine/tenofovir DF 
demonstrated excellent potency, tolerability and favorable safety profile [31].
Co administration of co-formulated efavirenz/emtricitabine/tenofovir DF with rifampicin 
based TB regimen clinical trials is going on in TB/HIV patients of Tanzania, therefore is 
important to have knowledge of each individual drug. Also a once-daily regimen of efavirenz, 
emtricitabine and tenofovir DF (administered as individual agents) was superior to once-
daily efavirenz plus twice-daily co-formulated lamivudine/zidovudine in terms of virological 
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suppression, immunological recovery and adverse events [32]. Individually, these agents have 
long half-life that allow for once-daily dosing.
Emtricitabine emtrivaR a cytosine analogue is the newest of the nucleoside reverse 
transcriptase inhibitor (NRTI) drugs. It was well tolerated in clinical trials where most adverse 
events were consistent with the NRTI class. Moreover, emtricitabine based regimens were 
as well tolerated as those with lamivudine [33]. Emtricitabine has no currently known phase I 
(glucuronidation) or phase II (cytochrome P450 and others) interactions [34]. It may be 
taken with or without food [35]. Emtricitabine displays dose-proportional pharmacokinetics. 
Bioavailability is not affected by food intake. Mean steady-state Cmax, Tmax and AUC values were 
1.7 mg/L, 2 h, and 10 mg/L.h respectively in 6 patients with HIV infection. Plasma elimination 
half-life is 8-10 h, but the intracellular half-life of the active compound, emtricitabine-
triphosphate is much longer: 39 h which support the once daily dosing.
Tenofovir disoproxil fumarate VireadR is an analogue of adenosine five monophosphate. 
It is a nucleotide analogue and consequently its mechanism of action differs from that of 
nucleoside analogues. It is a prodrug, therefore after absorption the drug is hydrolyzed and 
the active compound tenofovir-diphosphate is released. It has a longer serum half-life than 
most other NRTIs allowing a once daily dosing. The plasma half-life is 14.4h, but the intracellular 
elimination half-life of the active compound, tenofovir-diphosphate is much longer > 49h. 
This drug has broad tissue distribution, aided by its small molecular size and very low protein 
binding, and is eliminated as unchanged drug in the urine through glomerular filtration and 
active tubular secretion. Because of this latter characteristic, dosage adjustments are required 
in patients with renal insufficiency [36]. 70-80% of a dose is recovered unchanged in the urine, 
suggesting minimal influence of hepatic metabolism. Tenofovir mean steady-state Cmax, 
Tmax and AUC were 0.33mg/L, 2.3 h, and 3.0 mg/L.h respectively in patients infected with HIV. 
Adverse reactions are relatively uncommon, and nausea is the most often reported symptom 
[37]. The bioavailability of tenofovir disoproxil fumarate is increased in the presence of a high 
fat diet (40%-50%), and the drug should be taken with food [38,39].
Tenofovir disoproxil fumarate is not a substrate, inhibitor, or inducer of the P450 system, 
within the class of antiretroviral agents, an increase in the bioavailability of didanosine has been 
described, leading to the recommendation that the dose of didanosine be reduced when used in 
combination with tenofovir. Tenofovir can be used without adjustments with other nucleoside 
and nonnucleoside reverse transcriptase inhibitors. Equally, tenofovir seems to have no effect 
on the pharmacokinetics of protease inhibitors although these latter agents may produce a 
slight increase in the bioavailability of tenofovir, which seems to be of little clinical relevance. 
Efavirenz SustivaR is a NNRTI which is principally metabolized by cytochrome P450, more 
precisely isoenzymes CYP2B6 and CYP3A4. No active metabolites are formed. Efavirenz has 
a long terminal half-life of 40-55h after multiple dosing. Neuropsychiatric symptoms are the 
common side effects observed. Fumaz et al. [40], in a randomized, prospective, two-arm 
controlled study compared quality of life and neuropsychiatric side effects in patients receiving 
an efavirenz-containing regimen versus a group whose treatment did not include efavirenz. 
They found that the group receiving an efavirenz-containing regimen reported a better quality 
of life, particularly because their regimen was easier. They found, however, that 13% of their 
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patients reported “character change”. Meals of normal composition have no appreciable 
effect on the pharmacokinetics of efavirenz. The bioavailability is increased following a high 
fat meal. Time to peak plasma concentration is 3-5 h. Steady state concentrations are achieved 
after 6-7  days. Mean steady state Cmax, Cmin and AUC(0-24 h) were 4.1mg/L, 1.8 mg/L and 
58.1 h*mg/L respectively after multiple dosing of 600 mg efavirenz once daily.
Several pharmacokinetic studies have been conducted showing the interaction of 
rifampicin with efavirenz. Lopez-Cortez et al. [16] in Spain did on 24 patients with concomitant 
infections of HIV and tuberculosis. It was nonblinded study where group A (n = 16) received 
antituberculosis drugs without rifampicin but with added efavirenz 600 mg/day ARV regimen. 
The patients were then switched to a standard antituberculosis regimen containing rifampicin 
with efavirenz 600 mg/day (group A1; n = 8) or efavirenz 800 mg/day (group A2; n = 8). The 
result showed that levels of AUC, Cmax, and Cmin of efavirenz decreased respectively by 24%, 
25%, and 22%, after addition of rifampicin to the efavirenz of 600mg/day group. Significant 
association of body weight, dose of efavirenz and its pharmacokinetic parameters was observed 
and the dose increase to 800 mg/day when efavirenz is used with rifampicin was recommended.
Manosuthi et al. [17,41] conducted a non-blinded randomized clinical trial to Thai patients 
and they were given rifampicin for more than 1 month with regimen containing efavirenz 
600 mg/day (n = 42), or efavirenz 800 mg/day (n = 42). The plasma concentrations of efavirenz 
were determined for both groups 12 h after drug administration and on day 14. Both groups had 
12-h efavirenz concentrations (C12) of same value (median3.0 mg/L vs 3.3 mg/L); but the upper 
C12 levels werehigher in the group receiving efavirenz at the dosage of 800 mg/day (21.3 mg/L) 
in comparison with the group on 600 mg/day (12.2 mg/L). The study concluded that efavirenz 
with a dose of 600 mg/day is adequate for the majority of HIV-infected patients in Thailand 
(as their body weight is around 50 kg) but more studied should be performed to other ethnic 
groups. This is in line with a recent study by Orrell [42] which showed that 600 mg dose of 
efavirenz is adequate. 
Another study was conducted aiming at determining the effects of higher body weights and 
differing ethnicities on exposure to efavirenz. 9 patients with body weights of over 50 kg were 
enrolled in the study [43]. The patients received an antiretroviral regimen containing efavirenz 
800 mg/day and antituberculosis therapy containing rifampicin. Plasma concentrations of 
efavirenz were monitored for 2 years. All patients had sub-therapeutic trough concentrations 
of efavirenz (median 11.7 mg/L; range 5.37-19.6 mg/L). The expected therapeutic range of 
trough concentrations of efavirenz were between 1.2 and 4.0 mg/L. Seven out of the 9 patients 
with HIV/TB co-infection had toxicity (6 of them black and 1 caucasian). Around 20% of ethnic 
Black Africans possess homologous G516T alleles versus 3% of Caucasians [44]. This CYP2B6 
polymorphism is associated with exposure to higher concentrations of efavirenz.
Existence of a wide variability in efavirenz concentrations among black Africans was observed 
in the study of Friedland et al. [45]. This study indicated that inter-subject variability in efavirenz 
concentrations was greater when the drug was administered with rifampicin (coefficient 
of variation [CV] 157%) compared with the intersubject variability after discontinuation of 
rifampicin (58%), with much of consistent intra-subject variation over time (CV 24%). However, 
Cmin was not significantly different during versus post TB therapy.
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Regarding metabolism studies have shown that CYP2B6 genetic polymorphisms influence 
very much efavirenz elimination [46-48]. CYP2B6 polymorphisms have been associated with 
altered PK of efavirenz in HIV-infected adults and children [49-51] resulting in a higher efavirenz 
exposure and an increase in central nervous system side effect [44,46]. CYP2B6 patients are 
poor metabolizer of the drug and dose reduction has been proposed to people with this 
genotype [52,53]. Of note: is the high prevalence of efavirenz related CYP2B6 polymorphisms 
in patients of African region which represent the majority of the HIV-infected population in the 
world [54-58]. This indicates the need for prospective clinical studies to evaluate the utility of 
dose adjustments in these populations.
use oF eFaVirenz in Children
The use of efavirenz as a component of first-line antiretroviral therapy in adult and children 
above 3 years has been accepted worldwide [59], however safety and efficacyof efavirenz in 
children less than 3 years of age has not been performed [60-63] and the data on the efavirenz 
exposure in mothers and their breastfed infants is also limited [64] Despite the report that 
efavirenz is highly effective and well tolerated in the majority of pediatric patients [65], efavirenz 
plasma concentrations have been reported to be suboptimal in a large proportion of children 
and adolescents dosed according to current pediatric guidelines [60,61] Also interindividual 
variability has been observed in paediatric population [66].
Recently data on population pharmacokinetics (PK) of efavirenz in children predicts sub-
therapeutic efavirenz exposure in a significant proportion on children with the currently 
recommended efavirenz dose [61,67]. Authors in ARROW study which was done recently in 
Uganda and Zimbabwe [68] suggested the use of higher paediatric efavirenz doses, as per WHO 
2010 recommendations, however they concluded that children with toxic level of efavirenz 
concentration may be increased.
Also efavirenz pharmacokinetics was shown to demonstrate significant age effects with 
apparent clearance much greater in young infants than older children. High efavirenz dose 
requirements and pharmacokinetic variability in infants will require additional pharmacokinetic 
studies to determine appropriate efavirenz dosing strategies. Therefore priorities should be 
made to access the developmental changes of efavirenz exposure in children and adolescents 
and application of therapeutic drug monitoring to the settings where the facility is available.
imPliCation oF the hyPothesis
HAART regimens have contained very high pill burdens, complex dosing schedules, and 
specific food requirements. The management of HIV-related tuberculosis disease seems to 
be complex although the treatment of TB in persons with HIV is essentially the same as for 
patients without HIV. A major concern in treating TB in HIV-infected persons is the interaction 
of rifampin with certain antiretroviral agents, PIs and NNRTIs [69,70]. Rifabutin, which has fewer 
drug interactions, may be used as an alternative to rifampicin but is expensive and not available 
in resource limited area. Pharmacokinetic data which are present indicate that rifampicin can 
be combined with efavirenz [16,17].or nevirapine,[14] although for TB/HIV co-infected patients 
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who got 600 mg rifampicin, adverse events were reported to be higher in nevirapine based 
regimen compared to efavirenz based regimen [71]. 
Non-boosted PIs cannot be administered with rifampicin because of considerable 
decreases in plasma concentrations of PIs, which may cause sub-therapeutic concentrations 
exceptritonavir [72,73]. Ritonavir is a strong inhibitor of CYP3A4 and P-glycoprotein, and when 
it is low dose is combined with other PIs an important increase in their plasma concentrations 
is achieved, however this is not a solution as substantial decreases in plasma concentrations of 
indinavir,[74] lopinavir [75] and atazanavir [76] have been observed when co-administered with 
rifampicin, even when small doses of ritonavir are given. Another promising PI is saquinavir 
although in a study of Ribera et al. [77] a decrease of 40%, 35% and 49% in the median saquinavir 
AUC0-24, Cmax and Ctrough, respectively, were observed.
In vitro study reveals the benefit from the use of combination therapy achieved with Atripla 
in terms of the emtricitabine and tenofovir intracellular drug concentration [78]. However in 
this study patients were
HIV positive only hence more data are needed from TB/HIV co-infected patient. HIV 
fusion inhibitors represent a novel class of antiretroviral drugs and enfuvirtide is the first drug 
within this class to be approved [79]. When combined with active ARV drugs, different studies 
reported findings of substantial improvements in virological, immunological and clinical 
outcomes [80-83]. It has little potential for drug-drug interactions as far as coadministration 
with TB drugs is concerned [79,84,85]. The major limitation of this drug is the twice daily dosing 
which may interfere with the treatment adherence. Injection-site reactions occurred almost 
universally in its recipients, although did not necessitate stopping treatment. Co-formulated 
atriplaR (emtricitabine/tenofovir/efavirenz) have demonstrated excellent potency, tolerability 
and favorable safety profile. The drug is now available in most of the limited-resources 
countries. The drug is given once per day simplifying administration and increasing adherence 
too, hence may be recommended as a way to jointly treat these two diseases.
reFerenCes
1. Harries AD, Zachariah R, Lawn SD: Providing HIV care for co-infected tuberculosis patients: a perspective 
from sub-Saharan Africa. Int J TubercLung Dis 2009;13:6-16.
2. Bowen EF, Rice PS, Cooke NT, Whitfield RJ, Rayner CF: HIV seroprevalence by anonymous testing in 
patients with Mycobacterium tuberculosis and in tuberculosis contacts. Lancet 2000;356:1488-1489.
3. Msamanga GI, Fawzi WW: The double burden of HIV infection and tuberculosis in sub-Saharan Africa. N 
Engl J Med 1997;337:849-851.
4. Rose AM, Sinka K, Watson JM, Mortimer JY, Charlett A: “An estimate of the contribution of HIV infection 
to the recent rise in tuberculosis in England and Wales: should all tuberculosis patients be routinely HIV 
tested?”. Thorax 2002;57:442-445.
5. Budha R Nageshwar, Lee E Richard, Meibohm Bernd: Biopharmaceutics, pharmacokinetics 
pharmacodynamics of antituberculous drugs. Curr MedChem 2008;15(8).
6. Updated guidelines for the use of ryfamycins for the treatment of tuberculosis among HIV-infected 
patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. [http://www.cdc.
gov/nchstp/tb/tb_hiv_drugs/toc.htm], accessed June 25th 2009.
59
2b
ATRIPLAR AND FIRST-LINE TB DRUGS REVIEW 
7. Rattan A, et al: Multi-drug-resistant Mycobacterium tuberculosis: molecular perspectives. Emerg 
Infect Dis 1998;4:195-209.
8. Turner D, Wainberg MA: HIV transmission and primary drug resistance. AIDS REV 2006;8:17-23.
9. Niemi Mikko, Backman TJanne, Fromm FMartin, et al: Pharmacokinetic interactions with Rifampicin: 
clinical relevance. Clin pharmacokinet 2003;42:819-850.
10. Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, Fisher M, Taylor GP, Miller R, Taylor 
CB, de Ruiter A, Pozniak AL: Treatment oftuberculosis in HIV-infected persons in the era of highly 
activeantiretroviral therapy. AIDS 2002;16:75-83.
11. Pepper DJ, Meintjes GA, McIlleron H, Wilkinson RJ: Combined therapy for tuberculosis and HIV-1: the 
challenge for drug discovery. Drug DiscovToday 2007;12:980-989.
12. Robinson, et al: Pharmacokinetic interactions between nevirapine and rifampin. World AIDs conference 
Geneva Switzerland 1998.
13. Oliva J, Moreno S, Sanz J, et al: Coadministration of rifampin and nevirapine in HIV-infected patients 
with TB. AIDS 2003;17:637-638.
14. Ribera E, Pou L, Lopez RM, et al: Pharmacokinetic interaction between nevirapine and rifampicin in HIV-
infected patients with tuberculosis. JAcqui Immune Defic Syndr 2001;28:450-453.
15. Cohen K, van CG, Boulle A, et al: Effect of rifampicin-based antitubercular Therapy on nevirapine plasma 
concentrations in South African adults with HIV-associatedtuberculosis. J Antimicrob Chemother 
2008;61(2):389-393.
16. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, et al: Pharmacokinetic interactions between efavirenz and 
rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002;41:681-690.
17. Manosuthi W, Sungkanuparph S, Thakkinstian A, et al: Efavirenz levels and 24-week efficacy in HIV-
infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS 
2005;19:1481-1486.
18. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al: Decreased bioavailability of rifampin 
and other antituberculosis drugs in patients with advanced human immunodefficiency virus disease. 
AntimicrobAgents chemother 2004;48:4473-4475.
19. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P: Determinants of rifampicin, isoniazid, 
pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob 
Agents Chemother 2006; 50:1170-7.
20. Moreno, et al: Antiretroviral therapy in AIDS patients with tuberculosis. AIDs Rev 2006;8:115-124.
21. French MA, et al: Immune restoration disease after the treatment of immunodeficient HIV-infected 
patients with highly active antiretroviral therapy. HIV Med 2000;1:107-115.
22. Breton G, et al: Determinants of immune reconstitution inflammatory syndrome in HIV Type 1-Infected 
patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004;39:1709-1712.
23. Narita M, et al: Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with 
AIDS. Am J Respir Crit Care Med1998;158:157-161.
24. Bourgarit A, et al: Explosion of tuberculin-specific Th1-responses induce immune restoration syndrome 
in tuberculosis and HIV co-infected patients. AIDS 2006;F1-F7.
25. Shelburne SA, et al: Incidence and risk factors for immune reconstitution inflammatory syndrome 
during highly active antiretroviral therapy. AIDS 2005;19:399-406.
26. Dean GL, et al: Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral 
therapy. AIDS 2002;16:75-83.
60
2b
CHAPTER 2b
27. Burman WJ, et al: Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. 
Clin Pharmacokinet 2001;40:327-341.
28. Piacenti FJ: An update and review of antiretroviral therapy. Pharmacotherapy 2006;26:111-1133.
29. Friedland G, Abdool KS, Abdool KQ, Lalloo U, Jack C, Gandhi N, El Sadr W: Utility of tuberculosis directly 
observed therapy programs as sites foraccess to and provision of antiretroviral therapy in resource-
limitedcountries. Clin Infect Dis 2004;38(Suppl 5):S421-S428.
30. Long MC, King JR, Acosta EP: Pharmacological aspects of new antiretroviral drugs. Curr HIV/AIDS Rep 
2009;6:43-57.
31. Coicoechea M, Best B: Efavirenz/emtricitabine/tenofovir disoproxil fumaratefixed dose combination, 
first line therapy for all. Expert OpinPharmacotherapy 2007;8:371-382.
32. Frampton JE, Croom KF: Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination 
tablet. Drugs 2006;66:1501-1512.
33. Bang LM, Scott LJ: Emtricitabine: an antiretroviral agent for HIV infection. Drugs 2003;63:241-242.
34. Saag MS: Emtricitabine, a new antiretroviral agent with activity against HIV-1 and hepatitis B virus. Clin 
Infect Dis 2006;42:126-131.
35. Emtriva_ package insert, Gilead Sciences. Foster City 2004.
36. Droste J, Kearney B, Van Horssen P, Burger D: Lack of clinically relevant drug-drug interaction between 
tenofovir DF and rifampin in healthy volunteers. 5th International Workshop on clinical pharmacology 
of HIVtherapy. Rome, Italy. April 1-3, 2004;Abstract 4.11.
37. Viread_package insert, Gilead Sciences. Foster City, Calif; 2001.
38. Grim SA, Romanelli F: Tenofovir disoproxil fumarate. Ann Pharmacother 2003;37:849-859.
39. Kearney BP, Flaherty JF, Shah J: Tenofovir disoproxil fumarate: clinical pharmacology and 
pharmacokinetics. Clin Pharmacokinet 2004;43:595-612.
40. Fumaz CR, Tuldra A, Ferrer MJ, et al: Quality of life, emotional status, and adherence of HIV-1-infected 
patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic 
Syndr 2002;29:244-253.
41. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, Ruxrungtham K, Vibhagool A, Rattanasiri S, et 
al: Efavirenz 600 mg/day versus efavirenz800 mg/day in HIV-infected patients with tuberculosis 
receivingrifampicin: 48 weeks results. AIDS 2006;20:131-2.
42. Orrell C, Cohen K, Conradie F, Zeinecker J, Ive P, Sanne I, Wood R: Efavirenz and rifampicin in the South 
African context: is there a need to doseincrease efavirenz with concurrent rifampicin therapy? Antivir 
Ther 2011;16:527-534.
43. Brennan-Bonson P, Lyus R, Harrison T, Pakianathan M, Macallan D: Pharmacokinetic interactions 
between efavirenz and rifampicin in thetreatment of HIV and tuberculosis: one size does not fit all. AIDS 
2005;19:1541-1543.
44. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, et al: Pharmacogenetics of efavirenz 
and central nervous system side effects:an Adults AIDS Clinical Trial Group Study. AIDS 2004;18:2391-
400.
45. Friedland G, Khoo S, Jack C, Lallo U: Administration of efavirenz (600 mg/day) with rifampicin results 
in highly variable level but excellent clinical outcomes in patients treated for tuberculosis and HIV. 
Antimicrob AgentsChemother 2006;58:1299-302.
46. Desta Z, Saussele T, Ward B, et al: Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in 
vitro. Pharmacogenomics 2007;8(6):547-558.
61
2b
ATRIPLAR AND FIRST-LINE TB DRUGS REVIEW 
47. Ward BA, Gorski JC, Jones DR, et al: The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz 
primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a 
substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003;306:287-300.
48. Bumpus NN, Kent UM, Hollenberg PF: Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 
leads to inactivation by two distinct mechanisms. J Pharmacol Exp Ther 2006;318:345-351.
49. Tsuchiya K, Gatanaga H, Tachikawa N, et al: Homozygous CYP2B6 *6 (Q172H and K262R) correlates 
with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenzcontaining 
regimens. Biochem Biophys Res Commun 2004;319:1322-1326.
50. Klein K, Lang T, Saussele T, et al: Genetic variability of CYP2B6 in populations of African and Asian 
origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy 
withefavirenz. Pharmacogenet Genomics 2005;15(12):861-873.
51. Heine Robter, et al: A pharmacokinetic and pharmacogenetic study of efavirenz in children; dosing 
guidelines can result in sub-therapeutic concentrations. Antivir Therapy 2008;13:779-787.
52. Cabrera SE, Santos D, Valverde MP, et al: Influence of the cytochrome P450 2B6 genotype on population 
pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob Agents 
Chemother 2009;53:2791-2798.
53. Arab-Alameddine M, Di Iulio J, Buclin T, et al: Pharmacogenetics-based population pharmacokinetic 
analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther 2009;85:485-494.
54. Nyakutira C, Roshammar D, Chigutsa E, et al: High prevalence of the CYP2B6 516 G– > T(*6) variant and 
effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. EurJ Clin 
Pharmacol 2008;64:357-365.
55. Wang J, Sonnerborg A, Rane A, et al: Identification of a novel specific CYP2B6 allele in Africans causing 
impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 2006;16:191-198.
56. Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, Bertilsson 
L, Burhenne J, Aklillu E: Effect of rifampicinand CYP2B6 genotype on long-term efavirenz autoinduction 
and plasmaexposure in HIV patients with or without tuberculosis. Clin PharmacolTher 2011;90:406-413.
57. Uttayamakul S, Likanonsakul S, Manosuthi W, Wichukchinda N, Kalambaheti T, Nakayama EE, Shioda T, 
Khusmith S: Effects of CYP2B6G516T polymorphisms on plasma efavirenz and nevirapine levels whenco-
administered with rifampicin in HIV/TB co-infected Thai adults. AIDSRes Ther 2010;7:8.
58. Kwara A, Lartey M, Sagoe KW, Xexemeku F, Kenu E, Oliver-Commey J, Boima V, Sagoe A, Boamah I, 
Greenblatt DJ, Court MH: Pharmacokineticsof efavirenz when co-administered with rifampin in TB/HIV 
co-infectedpatients: pharmacogenetic effect of CYP2B6 variation. J Clin Pharmacol 2008;48:1032-1040.
59. Scherpbier HJ, Bekker V, et al: Once daily highly active antiretroviral therapy for HIV-1 infected children: 
safety and efficacy of an efavirenz containing regimen. Pediatrics 2007;119:705-715.
60. von Hentig N, Koenigs C, Elanjikal S, et al: Need for therapeutic drug monitoring in HIV-1 infected 
children receiving efavirenz doses according to international guidelines. Eur J Med Res 2006;11:377-380.
61. Ren Y, Nuttall JJ, Egbers C, et al: High prevalence of subtherapeutic plasma concentrations of efavirenz 
in children. J Acquir Immune DeficSyndr 2007;45:133-136.
62. Saitoh A, Fletcher CV, Brundage R, et al: Efavirenz pharmacokinetics in HIV-1-infected children are 
associated with CYP2B6-G516T polymorphism. J Acquir Immune Defic Syndr 2007;45:280-285.
63. Fletcher CV, Brundage RC, Fenton T, et al: Pharmacokinetics and pharmacodynamics of efavirenz 
and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial. Clin 
PharmacolTher 2008;83:300-306.
62
2b
CHAPTER 2b
64. Schneider S, Peltier A, Gras A, et al: Efavirenz in human breast milk, mothers’, and newborns’ plasma. J 
Acquir Immune Defic Syndr 2008;48:450-454.
65. Teglas JP, Quartier P, Treluyer JM, et al: Tolerance of efavirenz in children. AIDS 2001;15:241-243.
66. Viljoen M, Gous H, Kruger HS, Riddick A, Meyers TM, Rheeders M: Efavirenz plasma concentrations at 1, 
3, and 6 months post-antiretroviral therapy initiation in HIV type 1-infected South African children. AIDS 
Res HumRetroviruses 2010;26:613-619.
67. Hirt D, Urien S, Olivier M, et al: Are recommended dose of efavirenz optimal in young West African HIV-
infected children? (ANRS 12103). Antimicrob Agents Chemother. 2009 Oct;53(10):4407-13
68. Fillekes Q, et al: Pediatric under-dosing of efavirenz: a pharmacokinetic study in Uganda. J Acquir 
Immune Defic Syndr. 2011 Dec 1;58(4):392-8.
69. De Jong BC, Israelski DM, Corbett EL, et al: Clinical management of tuberculosis in the context of HIV 
infection. Annu Rev Med 2004;55:283-301.
70. Pozniak AL, Miller R, Ormerod LP: The treatment of tuberculosis in HIVinfected persons. AIDS 
1999;13:435-45.
71. Manosuthi W, Mankatitharm W, Lueangnivomkul A, et al: Standard dose efavirenz vs standard dose 
nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who receive 
rifampicin. HIVMed 2008;9:294-299.
72. Pozniak AL, Miller R, Ormerod LP: The treatment of tuberculosis in HIVinfected persons. AIDS 
1999;13:435-45.
73. Moreno S, Podzamczer D, Blazquez R, et al: Treatment of tuberculosis in HIV-infected patients: safety 
and antiretroviral efficacy of the concomitant use of ritonavir and rifampin. AIDS 2001;15:1185-1187.
74. Justesen US, Andersen AB, Klitgaard NA, et al: Pharmacokinetic interaction between rifampin and the 
combination of indinavir and low-dose ritonavir in HIV-infected patients. Clin Infect Dis 2004;38:426-
429.
75. La Porte CJ, Colbers EP, Bertz R, et al: Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined 
with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004;48:1553-60.
76. Burger DM, Agarwala S, Child M, et al: Effect of rifampin on steady-state pharmacokinetics of atazanavir 
with ritonavir in healthy volunteers. Antimicrob Agents Chemother 2006;50:3336-42.
77. Ribera E, Azuaje C, Lopez RM, et al: Pharmacokinetic interaction between rifampicin and the once-
daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. J 
AntimicrobChemother 2007;59:690-697.
78. Bousquet L, Pruvost A, Guvut AC, et al: Combination of tenofovir and emtricitabine plus efavirenz in 
vitro modulation of ABC transporter and intracellular drug accumulation. Antimicrob agent Chemother 
2009;53:896-902.
79. Hardy H, Skolnik PR: Enfuvirtide, a new fusion inhibitor for therapy of humanimmunodeficiency virus 
infection. Pharmacotherapy 2004;24:198-211.
80. Lalezari JP, Henry K, O’Hearn M, Montaner JS, Piliero PJ, Trottier B, et al: Enfuvirtide, an HIV-1 fusion 
inhibitor, for drug resistant HIV infection inNorth and South America. N Engl J Med 2003;348:2175-2185.
81. Lazzarin A, Clotet B, Cooper D, Reyness J, Arasteh K, Nelson M, et al: Efficacy of enfuvirtide in patients 
infected with drug resistance HIV-1 inEurope and Australia. N Engl J Med 2003;348:2175-2185.
82. Nelson M, Arasteh K, Clotet B, Cooper DA, Henry K, Katlama C, et al: Durable efficacy of enfuvirtide 
over 48 weeks in heavily treatmentexperiencedHIV-1 infected patients in the T-20 versus optimized 
background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005;40:404-412.
63
2b
ATRIPLAR AND FIRST-LINE TB DRUGS REVIEW 
83. Youle M, Staszweski S, Clotet B, Arribas JR, Blaxhult A, Carosi G, et al: Concomitant use of an active 
boosted protease inhibitor withenfuvirtide in treatment-experienced HIV-1 infected individuals: 
recentdata and consensus recommendations. HIV lin trials 2006;7:86-96.
84. Ruxrungtham K, Boyd M, Bellibas SE, et al: Lack of interaction between enfuvirtide and ritonavir or 
ritonavir-boosted saquinavir in HIV-1- infected patients. J Clin Pharmacol 2004;44:793-803.
85. Boyd MA, Zhang X, Dorr A, Ruxrungtham K, et al: Lack of enzyme-inducing effect of rifampicin on the 
pharmacokinetics of enfuvirtide. J ClinPharmacol 2003;43:1382-1391.

EfAVIRENz, TENOfOVIR AND 
EMTRICITABINE COMBINED wITH 
fIRST-LINE TUBERCULOSIS TREATMENT 
IN TUBERCULOSIS-HIV-CO-INfECTED 
TANzANIA PATIENTS: A PHARMACOKINETIC 
AND SAfETy STUDy3
Hadija H Semvua, Charles M Mtabho, Quirine Fillekes,
 
Jossy van den Boogaard, Riziki M Kisonga, Liberate Mleoh, 
Arnold Ndaro, Elton R Kisanga, Andre van der Ven, 
Rob E Aarnoutse, Gibson S Kibiki, Martin J Boeree, David M Burger
Antiviral Therapy 2013;18(1):105-13
66
3
CHAPTER 3
abstraCt
background: To evaluate the effect of rifampicin-based tuberculosis (TB) treatment on the 
pharmacokinetics of efavirenz/tenofovir/emtricitabine in a fixed-dose combination tablet, 
and vice versa, in Tanzanian TB-HIV-coinfected patients.
method: This was a Phase II open-label multiple dose pharmacokinetic and safety study. This 
study was conducted in TB-HIV-coinfected Tanzanian patients who started TB treatment 
(rifampicin/isoniazid/pyrazinamide/ethambutol) at week 1 to week 8 and continued with 
rifampicin and isoniazid for another 16 weeks. Antiretroviral treatment (ART) of efavirenz/
tenofovir/emtricitabine in a fixed-dose combination tablet was started at week 4 after initiation 
of TB treatment. A 24-h pharmacokinetic sampling curve was recorded at week 8 (with TB 
treatment) and week 28 (ART alone). For TB drugs, blood samples at 2 and 6 h post-dose were 
taken at week 3 (TB treatment alone) and week 8 (with ART).
results: A total of 25 patients (56% male) completed the study; 21 had evaluable 
pharmacokinetic profiles. The area under the concentration-time curve 0-24 h post-dose 
of efavirenz, tenofovir and emtricitabine were slightly higher when these drugs were 
coadministered with TB drugs; geometric mean ratios (90% CI) were 1.08 (0.90, 1.30), 1.13 
(0.93, 1.38) and 1.05 (0.85, 1.29), respectively. For TB drugs, equivalence was suggested for 
peak plasma concentrations when administered with and without efavirenz/tenofovir/
emtricitabine. Adverse events were mostly mild and no serious adverse events or drug 
discontinuations were reported.
Conclusion: Coadministration of efavirenz, tenofovir and emtricitabine with a standard first-
line TB treatment regimen did not significantly alter the pharmacokinetic parameters of these 
drugs and was tolerated well by Tanzanian TB patients who are coinfected with HIV.
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introduCtion
Co-infection with tuberculosis (TB) and HIV is an important public health problem. Nearly 
40 million people are living with HIV worldwide and one-third is co-infected with TB [1-3]. 
The majority of TB cases in people living with HIV/AIDS occur in Africa, where 39% of people 
who develop TB are HIV-positive. The continent accounts for 82% of new TB cases living with 
HIV worldwide [1]. Management of the dual infection requires combining TB treatment and 
antiretroviral treatment (ART) which markedly decrease the risk of morbidity and mortality to 
those patients [4].
Co-administering TB drugs with ART precipitates pharmacokinetic interactions, mostly 
caused by rifampicin. Rifampicin is a well-known inducer of many iso-enzymes of the hepatic 
cytochrome P450 (CYP) enzyme system, which metabolizes a large number of drugs [5]. In 
addition, it stimulates the expression of the multi-drug resistance transporter, P-glycoprotein 
[6,7]. Current guidelines for ART in patients also using rifampicin recommend the use of 
efavirenz plus two nucleoside reverse transcriptase inhibitors (NRTIs) [8,9]. Although combined 
use of rifampicin and efavirenz leads to an average decrease of about 18 – 26% in efavirenz 
exposure due to induction of the CYP2B6 enzyme [10,11], several studies have demonstrated 
adequate virological response in patients using both drugs [4,12].
A fixed-dose combination (FDC) tablet of efavirenz, tenofovir and emtricitabine has been 
approved by the Food and Drug Administration in the USA in 2006. This combination tablet is 
widely used as it is highly effective and can be administered as a single tablet once-daily [13]. 
There are no data available on the combined use of a rifampicin-based TB regimen and this FDC 
in TB/HIV co-infected patients. The aim of this study was to evaluate the effect of rifampicin-
based TB treatment on the pharmacokinetics (PK) and safety of the FDC of efavirenz, tenofovir 
and emtricitabine. The secondary objective was to evaluate the effect of this FDC on the PK of 
the TB medication.
methods
study design and population. This was a multiple-dose, open-label, three-period, phase II 
PK and safety study. The enrollment started on November 2008 and ended in February 2010. 
Patients included were 18-65 years and TB/HIV co-infected with CD4 counts of 50-350 cells/mm3 
(later amended to 0-350 cells/mm3). Patients were excluded if they were already using ART, 
they were pregnant or breastfeeding, they had liver dysfunction (objectified by biochemistry 
results, and hepatitis B and C antigen tests) and if they were hypersensitive to either of the 
regimens. Another exclusion criterion was a Karnofsky score <40 based on the activities a 
patient could perform. The study protocol was approved by the Institutional Review Board of 
the Kilimanjaro Christian Medical University Centre, Moshi, Tanzania, and the National Institute 
for Medical Research, Dar-es-salaam, Tanzania. Written informed consent was obtained from 
each patient. Eligible patients were admitted at Kibong’oto National Tuberculosis Hospital, 
Kilimanjaro, Tanzania for the first eight weeks of TB treatment (intensive phase). 
Patients <50kg were given TB treatment consisting of rifampicin 450mg, isoniazid 225mg, 
pyrazinamide 1200mg and ethambutol 825mg, all administered once-daily for eight weeks. If 
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patients were >50kg, they received rifampicin 600mg, isoniazid 300mg, pyrazinamide 1600mg 
and ethambutol 1100mg once-daily for eight weeks. After a negative sputum culture at week 8, 
TB treatment was continued with rifampicin and isoniazid for another 16 weeks. TB drugs were 
administered 30 minutes after a light breakfast. TB drugs were provided by the Tanzanian 
National TB program, and they were manufactured by Sandoz, Mumbai India and donated by 
Novartis. The ART regimen of once-daily one FDC tablet of efavirenz 600mg, tenofovir 300mg 
and emtricitabine 200mg (Atripla®, Merck & Co. Inc. USA) was initiated at week 4 after starting 
TB treatment and was administered together with the TB drugs. The study was divided in three 
phases (Figure 1): From week 1 to the end of week 4 patients were exposed to TB drugs alone 
(phase I). From week 5 to the end of week 24 they were exposed to concomitant use of TB drugs 
and a FDC tablet containing efavirenz, tenofovir, and emtricitabine (phase II). After 24 weeks, 
when TB treatment was ended, patients were exposed to ART alone (phase III). Both TB and HIV 
treatment were administered under supervised care including directly observed treatment for 
8 weeks. After 8 weeks, patients were discharged. A one month dose of efavirenz, tenofovir and 
emtricitabine and standard TB treatment was dispensed and patients were asked to come for 
follow-up visits at the clinic every month. 
blood sampling and bio-analysis procedures. Eight weeks after starting TB treatment, 
a 24-hour PK sampling session was done. Samples were taken 5-20 minutes before directly 
observed intake of efavirenz, tenofovir and emtricitabine (t=0) and 1, 2, 3, 4, 6, 8, 10, 12, 16 and 
24 hours later. At 28 weeks, four weeks after cessation of TB treatment, intensive plasma PK 
sampling was repeated. In addition, for the determination of rifampicin, isoniazid, pyrazinamide 
and ethambutol plasma concentrations, blood samples were taken after initiation of TB 
treatment at three weeks (without ART) and eight weeks (with ART). These blood samples were 
drawn at two and six hours after observed medication intake to be able to assess (‘catch’) peak 
plasma concentrations of TB drugs, which was taken as highest of the two. Breakfast (non-
milky tea and/or porridge) was provided 5-20 minutes after pre-dose sampling, together with 
TB and/or HIV medication. Six mL of blood was collected per time point and centrifuged at 
2800rpm for 10min. Within one hour plasma was stored at -20°C for one day and then shifted 
to a -80°C freezer until transportation on dry-ice to Radboud University, The Netherlands, 
Figure 1. Trial study design
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for bio-analysis. Plasma concentrations of all drugs except isoniazid were assayed by validated 
high-performance liquid chromatography methods [14-17]. 
Isoniazid was measured with liquid/liquid extraction followed by UPLC with ultraviolet (UV) 
detection. Accuracy was between 98% and 107%, dependent on the concentration level. The 
intra- and interassay coefficients of variation were less than 13% over the ranges of 0.051  to 
15.1 mg/L. The lower limit of quantitation was 0.051 mg/l. Isoniazid containing samples were 
stable (<5% loss) for at least 12 months at -80oC.
safety and tolerability monitoring. Baseline clinical, hematology and biochemistry parameters 
were taken and, when applicable, a pregnancy test was done. Safety and tolerability of the trial 
treatment were assessed by a medical doctor on the basis of the occurrence of adverse events 
(AEs) about which patients were interviewed every two weeks during the first eight weeks, and 
every one month after hospital discharge. The onset, severity, and potential relationship of 
any AE to the study medication were recorded. Severity was rated according to the Common 
Terminology Criteria for AEs (v4, 2009) and the Division of AIDS table for grading the severity 
of Adult and Paediatrics AEs (DAIDS, 2004). In addition, the use of concomitant medication 
was reported, as were the results of a physical examination including measurement of vital 
signs. Clinical laboratory testing (hematology and biochemistry parameters) was performed at 
baseline, week 2, 4, 6, 8, 12, 16, 24 and 28. Follow-up sputum collection, CD4 lymphocyte count 
and plasma HIV-1 RNA quantification (using Abbott Real Time HIV-1 assay) was done at baseline, 
week 4, 8, 16, and 28. 
Pk and statistical analyses. PK parameters (area under the concentration-time curve 
0-24  hours post-dose [AUC
0-24h
], C
min
, C
max
 of efavirenz, tenofovir and emtricitabine were 
calculated by non-compartmental analysis using WinNonlin (version 5.2; Pharsight, CA). 
AUC
0-24h
 was calculated using the linear-log trapezoidal rule. PK parameters, geometric means 
(GM) with standard deviation (SD), geometric mean ratios (GMRs) for AUC
0-24h
, C
max
 and C
min
 for 
the antiretroviral drugs with and without TB treatment and the corresponding 90% confidence 
intervals (CIs) were calculated. PK parameters of the antiretroviral drugs with vs. without TB drugs 
were considered bioequivalent if the GMR and corresponding 90%CI fell completely within the 
0.80-1.25 range. Equivalence was ‘suggested’ in case the GMR is within the 0.80-1.25  range, 
but with one confidence interval limit outside this range. Inequivalence was to be concluded if 
the GMR and corresponding 90%CI fell completely outside the 0.80-1.25 range. Inequivalence 
was ‘suggested’ if the GMR is outside the 0.80-1.25 range, with one confidence interval inside 
this range [18]. PK analysis included only those patients with two evaluable PK curves (at week 
8 and week 28). All statistical analyses were done in SPSS, version 18.0. To ensure an evaluable 
PK dataset of at least 20 patients, a total of 30 patients were included (based on an expected 
maximum drop-out of 33% during the trial after ART initiation). 
results
study population. We screened 66 HIV-infected, patients with confirmed smear-positive 
pulmonary TB. Thirty-eight (58%) patients were not eligible: 19 had a CD4 count> 350cells/mm3, 
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eight had a CD4 count <50 cells/mm3 (before protocol amendment), five were already on 
ART, two had a positive hepatitis antigen test, three had a Karnofsky score <40 and one had 
relapse TB. Of the 28 patients (42%) enrolled in the trial three withdrew consent; the remaining 
25 patients completed follow-up and were evaluable for analysis. For PK evaluation four patients 
were excluded due to non-adherence or incorrect dosing, as indicated by undetectable plasma 
concentrations for efavirenz, tenofovir and emtricitabine prior to observed intake during 
the intensive PK sampling day. Hence, 21 subjects were qualified for the PK evaluation. In the 
patients who completed follow-up, 14 patients (56%) were male, the median (interquartile 
range, IQR) baseline age and body weight were 32 (27.5-42.5) years and 48.4 (43.5-52.8) kg, 
respectively. In our study population body weight (mean+SD, kg) increased significantly from 
53.4 (8.0) at week 8 to 56.8 (6.5) at week 28. The median (IQR) CD4 count at baseline was 155 
(71-208) cells/mm3, the median (IQR) viral load (VL) was 129,779 (71,214-310,141) copies/mL. 
Baseline characteristics are in Table 1. 
table 1. Enrolment characteristics of the study participants (N=25)
Characteristics Total 
Number of patients followed up 25
Male, n (%) 14 (56%)
Age, years 32 (27.5-42.5)
Weight, kg 48.4 (43.5-52.8)
CD4 count, cells/mm3 155 (71-208)
HIV viral load, copies/ml 129,779 (71,214 -310,141)
Note: Values are N (%) for categorical variables and median ( IQR) for continuous variables.
Pk of art. Figure 2 illustrates the effect of the TB treatment on the geometric mean 
concentration-time profiles of the ART. The average efavirenz AUC
0-24h
, C
max
 and C
min
 were 
slightly higher when efavirenz was co-administered with rifampicin-based TB treatment. The 
GMRs lie within the range of 0.80-1.25 with the upper limit of the 90% CIs for AUC
0-24h
 and C
24h
 
just above 1.25 (Table 2). GMRs (90%CI) were 1.08 (0.90-1.30), 1.02 (0.8-1.23) and 1.11 (0.90-1.37) 
for AUC
0-24h
, C
max
 and C
24h
, respectively, which means that equivalence was suggested (i.e. no 
effect of rifampicin on the efavirenz PK) Three of the 21 (14%) patients had subtherapeutic 
efavirenz plasma concentrations (<1.0 mg/L [19]) after observed intake at one or both PK 
sessions: one patient at week 8 only, one patient at week 28 only and one at both PK days. 
Potentially toxic plasma levels (>4.0 mg/L [19]) after observed intake were found in ten (48%) 
of the patients. Eight of these patients had potentially toxic levels at both PK sessions. Two 
patients had a Cmin and Cmax both >10mg/ml. The time to reach the maximum concentration 
(T
max
) was observed to be higher during co-administration with TB drugs.
Similarly, for tenofovir and emtricitabine the GMRs and 90% CIs of the PK parameters 
suggest a slightly higher exposure in combination with TB drugs. GMRs (90%CIs) of AUC
0-24h
, 
C
max
 and C
24h
 for tenofovir were 1.1 (0.93-1.4), 0.98 (0.78-1.4) and 1.09 (0.86-1.4), respectively, 
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while for emtricitabine they were 1.05 (0.85-1.3), 0.97 (0.75-1.3) and 1.3 (1.04-1.5), respectively. 
The PK parameters (AUC
0-24h
, C
max
, C
24h
, T
max
, elimination half-life (t
1/2
), volume of distribution 
(V/F) and clearance (CL/F)) for efavirenz, tenofovir and emtricitabine are summarized in Table 2.
Pk of tb drugs. The plasma concentrations of all TB drugs tended to be slightly lower during 
co-administration in combination with ART. The bio-equivalence approach applied to the C
max
 
values for TB drugs suggested bioequivalence of the TB drugs when given alone versus in 
combination with ART (Table 3).
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Figure 2:  Curves of mean plasma concentration versus time for efavirenz (2A), emtricitabine (2B) 
  and tenofovir (2C) (order from above downwards) after observed intake of FDC tablet 
  efavirenz/tenofovir/emtricitabine alone (grey curve) and in combination with TB  
  treatment (black curve) 
  
Figure 2. Curves of mean plasma concentration versus time for efavirenz (2A), emtricitabine (2B) 
and tenofovir (2C) (order fro  above downw rds) after observed intake of FDC tablet efavirenz/
tenofovir/emtricitabine alone (grey curve) and in combination with TB treatment (black curve)
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efficacy. Twenty-five patients completed follow-up to the end of week 28. At week 4 of the 
study (prior to ART) they had a median (IQR) VL of 134,204 (71,414-401,004) copies/mL. At 
week 28 (after starting ART), 17 (68%) patients had an undetectable VL (<40 copies/ml). The 
remaining eight patients (32%) had a median (IQR) VL of 51(40-532) copies/mL. From 23 of the 
patients (92%), CD4 counts were available both at baseline and at the end of the study. Their 
median (IQR) CD4 count increased from 119 (69-203) cells/mm3 to 238 (147-424) cells/mm3 
(p<0.01; Signed Rank). 
By the end of eight weeks of TB treatment, 19 of 25 patients (76%) had negative sputum 
smears (confirmed by negative sputum cultures) and continued with rifampicin and isoniazid 
for 16 weeks. Six patients (24%) had positive sputum smear results after 8 weeks of treatment, of 
which two had negative and four had a positive cultures for Mycobacterium tuberculosis (MTB). 
Drug susceptibility testing of the isolates obtained from these four patients showed normal 
susceptibility patterns and therefore, those four patients continued with intensive phase TB 
table 2. Pharmacokinetic parameters of efavirenz, tenofovir and emtricitabine alone and in 
combination with TB treatment
  PK parameter
week 28 (ART alone; 
geometric mean 
(95% CI); mg/L)
week 8 (ART with TB 
treatment; geometric 
mean (95% CI); mg/L) GMR (90% CI)
Efavirenz AUC
0-24h
, h.mg/L 81 (58-114) 88 (60-129) 1.08 (0.90-1.30)
  C
max
, mg/L 5.7 (4.2-7.5) 5.7 (4.3-7.7) 1.02 (0.80-1.23)
  C
min
, mg/L 2.4 (1.6-3.5) 2.6 (1.6-4.2) 1.11 (0.90-1.37)
  T
max
, h 3.1 (1.0-10.1) 4.0 (1.1-8.0) -
  t
1/2
, h 27 (25-35) 29 (20-47) 1.08 (0.77-1.41)
  Cl/F, L/h 7.4 (5.3-10.4) 6.8 (4.6-10.1) 0.92 (0.77-1.11)
  V/F, L 313 (232-421) 301 (236-383) 0.96 (0.72-1.29)
Tenofovir AUC
0-24h
, h.mg/L 2.6 (2.1-3.2) 2.9 (2.4-3.5) 1.13 (0.93-1.38)
  C
max
, mg/L 0.33 (0.26-0.41) 0.32 (0.26-0.40) 0.98 (0.78-1.38)
  C
min
, mg/L 0.05 (0.04-0.06) 0.05 (0.04-0.07) 1.09 (0.86-1.38)
  T
max
, h 1.0 (0.9-8.0) 2.1 (0.0-6.2) -
  t
1/2
, h 14 (12-15) 11 (10-12) 0.81 (0.75-0.86)
  Cl/F, L/h 94 (76-117) 83 (69-100) 0.88 (0.73-1.08)
  V/F, L 1852 (1438-2385) 1319 (1099-1584) 0.71 (0.59-0.86)
Emtricitabine AUC
0-24h
, h.mg/L 14 (12-16) 15 (11-18) 1.05 (0.85-1.29)
  C
max
, mg/L 2.1 (1.8-2.3) 2.0 (1.5-2.7) 0.97 (0.75-1.25)
  C
min
, mg/L 0.10 (0.09-0.12) 0.12 (0.10-0.16) 1.26 (1.04-1.53)
  T
max
, h 2.0 (1.0-8.0) 3.0 (0.0-6.0) -
  t
1/2
, h 6.6 (5.8-7.5) 7.3 (6.1-8.6) 1.10 (0.93-1.31)
  Cl/F, L/h 18 (15-21) 17 (13-22) 0.96 (0.77-1.18)
  V/F, L 171 (139-210) 180 (124-261) 1.05 (0.75-1.48)
Note: T
max 
is presented as median (IQR)
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treatment for another four weeks. At week 12, sputum smear results of all four patients were 
negative. Of the four, two had an undetectable VL at week 16, the remaining two had had 659 
copies/mL and 8,032 copies/mL each. All 25 patients had negative sputum culture results at the 
end of TB treatment.
safety. Twelve patients (48%) developed elevated biochemistry parameters. These included 
elevated alkaline phosphatase in 11 patients (all grade 1 except for two patients who had 
grade 2), elevated creatinine in three patients (two of which were grade 2 and one was grade 3), 
and elevated pancreatic amylase and ALT in one patient each (both grade 1). The patient with 
grade 3 elevation of creatinine recovered spontaneously. Nineteen patients (76%) developed 
decreased hematological parameters. These were mostly leucopenia and neutropenia 
(12 subjects each), and were all grade 1. Four patients had anemia, of which two were grade 1, 
one was grade 2 and the remaining one was grade 3. Two patients had thrombocytopenia (one 
grade 1 and the other grade 2). The laboratory abnormalities had all resolved at completion of 
the study. 
tolerability. Before administration of ART (Phase 1), 24 of 25 (96%) patients had experienced 
one or more clinical AEs; with a total of 99 events (65% grade 1, 34% grade 2, 1% grade 3). After 
starting ART (Phase 2), 23 of the 25 (92%) subjects experienced one or more new or aggravated 
AEs at some time during follow-up. These were in total 95 AEs, mostly mild disturbances (64% 
grade 1, 33% grade 2, 3% grade 3). There were no serious AEs reported and no modifications or 
discontinuations of treatment were done. Thirteen percent of the clinical events were judged 
to have no relationship to the drugs, 83% had either a doubtful or possible relationship and 
4% had a possible relationship. At the end of follow-up, all events were recovered except 
for four patients who still had either loss of appetite, body rash, general body weakness 
or constipation. 
Fifty percent of the 10 patients who had toxic levels of efavirenz experienced a clinical AE 
compared to 40% among patients without toxic levels (p=0.70) and 30% of the events were 
grade 2 for the group with toxic levels versus 38.5% for the sub therapeutic group (p=0.23). Lab 
events were reported in 90% of the patients with toxic levels of efavirenz and 93% of patients 
without toxic levels. Two patients with efavirenz concentration above 10 mg/L throughout 
showed only mild (grade 1) AEs.
table 3. Peak plasma concentrations (Cmax) of rifampicin, isoniazid, pyrazinamide and ethambutol 
alone and in combination with ART, based on sampling at 2 h and 6 h post dose
Drug
GM week 2  
(without HIVdrug; mg/L)
GM week 8  
(with HIV drug; mg/L) GMR (90% CI)
Rifampicin 4.60 3.97 1.16(0.88-1.53)
Isoniazid 1.24 1.18 1.06(0.85-1.31)
Pyrazinamide 31.64 35.95 0.88(0.78-0.99)
Ethambutol 2.09 2.11 0.99(0.78-1.26)
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disCussion
This study is the first to report on the interactions of efavirenz, tenofovir emtricitabine with 
first line rifampicin-based TB treatment. No interactions were observed in the pharmacokinetic 
analysis. The observed slightly higher AUC
0-24h
, C
max
 and C
24h
 of efavirenz when co-administered 
with the rifampicin-based TB treatment in our study is, consistent with a recent study that showed 
the absence of an effect of rifampicin on efavirenz PK when patients are poor metabolizers of 
CYP2B6 [20]. Our data are also in agreement with recent studies in South Africa, Tanzania and 
India showing that efavirenz concentrations do not decrease when it is co-administered with 
a rifampicin-based TB treatment regimen [21-23]. The metabolism of efavirenz is extensively 
influenced by pharmacogenetic factors [21,24-26]. A single nucleotide polymorphism at 
position 516 on the CYP2B6 gene has been widely reported to play an important role in the 
metabolism of efavirenz and nevirapine [27-29]. Genetic polymorphisms with CYP2B6 occur in 
all populations, and this may affect the exposure to efavirenz and its susceptibility to rifampicin-
based enzyme induction [30-32]. The slightly higher efavirenz levels during combined TB and 
HIV treatment in our study could be explained by genetic differences [20,23,25]
A once-daily dose of efavirenz 600mg during TB therapy is reported to be adequate 
[22,33,34]. However, in our study potentially toxic plasma levels (>4.0 mg/L) were observed in 
48% of the patients. Also sub-therapeutic levels of efavirenz (<1.0mg/L) were found in 14% of 
the patients. The observed high intervariability of drug levels suggests inter-patient differences 
in the expression of the drug metabolizing enzymes [11]. For observed potentially toxic levels, 
no further action was taken as the patients were already discharged in a good condition. The 
levels occurred both before and during co-administration with TB treatment. Nevertheless 
the frequent presence of high levels in our African patient population may warrant the use of 
therapeutic drug monitoring of efavirenz plasma concentrations to improve the safe use of ART 
during TB treatment, and the need for individual dose adjustment [10]. 
Comparison of exposure to tenofovir with and without rifampicin-based TB treatment did 
not suggest any effect of rifampicin, although PK equivalence (lack of interaction) could not be 
concluded. Studies elsewhere have also shown no difference in tenofovir concentration while 
observing bioequivalence [15]. However, participants in these studies were healthy volunteer 
subjects who received tenofovir only shortly, which implicate that less potential factor may 
have affected the PK of tenofovir in those subjects. PK parameters may be different in patients 
as compared to healthy volunteers due to changes brought by both HIV and TB infection [35]. 
It is known that tenofovir is eliminated unchanged by glomerular filtration and active tubular 
secretion [36], while rifampicin is extensively metabolized in intestinal and hepatic metabolism 
[7] which minimizes the interactions. Emtricitabine has also been reported to have no PK 
drug-drug interactions with other antiretroviral drugs and rifampicin. 
The time to reach maximum concentrations (T
max
) of emtricitabine, tenofovir and efavirenz 
was longer when co-administered with rifampicin than without rifampicin, although the 
median difference was only one hour for all three drugs. The reason for one of these drugs 
may be delayed absorption upon co-administration of rifampicin. Clearance of efavirenz could 
be affected in patients with genotype CYP2B6. We did not analyze genetic aspects of these 
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patients, hence further studies are warranted. No large differences were found in clearance and 
volume of distribution. 
This study showed a small decrease in levels of TB drugs with versus without co-
administration of efavirenz, tenofovir and emtricitabine. We do not consider this to be clinically 
significant. Studies elsewhere have also found no statistically significant effect of efavirenz on 
rifampicin [5,7,22,37]. In our study, rifampicin and isoniazid peak plasma concentrations were 
lower than the reference peak values (8-24 mg/L rifampicin; 3-5 mg/L isoniazid) [38]. One 
possible explanation could be that the values in this study, obtained from either two or six 
hours after intake, were not the actual peak values. Secondly, our patients took medications 
just after food intake which is known to lower concentrations of rifampicin and isoniazid [39].
All patients had a positive response to treatment in terms of sputum culture and decrease 
of VL. An important finding of our study is that we detected non-adherence in four patients 
included in the trial when pre-dose samples were analyzed. This can be explained by the fact 
that the patients were discharged home after eight weeks, and subjects were asked to come 
for follow-up visits at the clinic every month. We recommend strong coordination between the 
national TB; community DOT system and the AIDS control programs. 
The main shortcoming of this study is that we did not look into genetic factors of the 
patients, which could have provided an explanation of high efavirenz drug levels and for 
the extent of the interaction between efavirenz and rifampicin-based TB treatment. Also, 
the study did not examine the effect of anti-TB treatment on intracellular PK of tenofovir 
and emtricitabine, as intracellular diphosphate or triphosphate levels are associated with 
clinical effects. It is possible that rifampin-containing TB treatment may not influence plasma 
PK but could affect intracellular PK through induction or inhibition of drug transporters. 
In conclusion, our findings suggest that co-administration of the standard first line TB 
treatment regimen with efavirenz, tenofovir, and emtricitabine does not alter pharmacokinetic 
parameters. The combination is tolerated well by Tanzanian TB/HIV co-infected patients. 
Hence, a combination of efavirenz, tenofovir and emtricitabine may be considered in managing 
HIV infection in African patients who are co-infected with TB.
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abstraCt
introduction: East Africa has a high tuberculosis (TB) incidence and mortality, yet there is 
very limited data on exposure to TB drugin patients from this region.We therefore determined 
the pharmacokinetic characteristics of firstline TB drugs in Tanzanian patients using intensive 
pharmacokinetic sampling.
methods: In twenty adult TB patients, plasma concentrations were determined just before 
and at 1, 2, 3, 4, 6, 8, 10 and 24 hours after observed drug intake with food to estimate the 
area under the curve (AUC
0-24h
) and peak plasma concentrations (C
max
) of isoniazid, rifampicin, 
pyrazinamide and ethambutol. Acetylator status for isoniazid was assessed phenotypically 
using the isoniazid elimination half-life and the acetylisoniazid/isoniazid metabolic ratio at 
3 hours post dose.
results: The geometric mean AUC
0-24h
 of isoniazid was 11.0 h*mg/L, rifampicin 39.9h*mg/L, 
pyrazinamide 344 h*mg/L and ethambutol 20.2 h*mg/L.C
max
 was below the reference range for 
isoniazid in 10/19 patients and for rifampicin in 7/20 patients.In none of the patients, the C
max 
values for pyrazinamide and ethambutol were below the reference range. Elimination half-life 
and metabolic ratio of isoniazid gave discordant phenotyping results in only 2/19 patients.
discussion: A substantial proportion of patients had an isoniazid and/or rifampicin C
max
 below 
the reference range. Intake of TB drugs with food may partly explain these low drug levels, 
but such drug intake reflects common practice. The finding of low TB drug concentrations is 
concerning because low concentrations have been associated with worse treatment outcome 
in several other studies. 
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introduCtion
The pharmacokinetic properties of tuberculosis (TB) drugs are well described especially in 
Caucasian populations [1,2]. Pharmacokinetic data from EastAfricaare limited, especially data 
that are based on intensive pharmacokinetic sampling during the full dosing interval. Such 
intensive pharmacokinetic sampling enables an accurate assessment of the total exposure 
to TB drugs (area under the time versus plasma concentration curve; AUC
0-24h
) and the peak 
plasma concentration (C
max
) in individual patients. Large inter-patient variability generally 
exists in thesekey pharmacokinetic parameters of TB drugs [1]. As a result, a proportion of 
patients achieves drug concentrations that are below the reference range for TB drugs. Several 
studies have shown that such lower exposures to TB drugs are associated with suboptimal 
response [3-8]. A recent study showed thatpharmacokinetic variability to just a single drug 
in the multidrug TB drug regimen is associated with treatment failure and acquired drug 
resistance [9,10].
On the other hand, unduly high exposures may cause toxicity and interruption of TB 
treatment.It is therefore important to have more knowledge on pharmacokinetic properties of 
TB treatment in populations from  East Africa, as a high TB incidence and TB mortalityis found in 
this region [11]. HIV infection [12-14] and malnutrition [15] have been associated with decreased 
plasma concentrations ofTBdrugs.Both are highly prevalent amongst  East African TB patients, 
therefore low TB drug levels are to be expected in this population [11].
The objective of this study was to describe the pharmacokinetic parameters of isoniazid, 
rifampicin, pyrazinamide and ethambutol using intensive sampling during the full dosing 
interval in Tanzanian TB patients.
methods
study design. We conducted an observational pharmacokinetic study at the Kilimanjaro Clinical 
Research Institute at the Kilimanjaro Christian Medical Centre (KCMC) in Moshi, Tanzania, 
using the standard two-stage approach. With this approach individual pharmacokinetic 
parameters are estimated in the first stage. In the second stage, population characteristics of 
each parameter are derived by obtaining measures of central tendency and spread of all the 
subjects’ individual parameters.
study participants. Study participants were recruited from an outpatient tuberculosis 
treatment clinic at Mawenzi Hospital in Moshi. Adult TB patients who were in the intensive 
phase of treatment and who were not using medication that could interfere with TB drug 
plasma concentrations were eligible for participation. All participants gave written informed 
consent. The study was approved by the local Institutional Research Board at KCMC and by the 
Tanzanian National Institute of Medical Research.
Tuberculosis was treated with fixed-dose combination tablets (FDC tablets) manufactured 
by Sandoz, Mumbai India and are on the WHO List of Prequalified Medicinal Products. The 
drugs were donated by Novartis through the WHO Global Drug Facility (GDF), which only 
provides high quality drugs that meet stringent WHO standards.Patients with a body weight 
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less than 50 kg usethree FDC tablets per day (i.e. 225 mg isoniazid, 450 mg rifampicin, 1200 mg 
pyrazinamide and 875 mg ethambutol) and patients with a body weight>50 kg use four FDC 
tablets per day (i.e. 300 mg isoniazid, 600 mg rifampicin, 1600 mg pyrazinamide and 1100 mg 
ethambutol) [16].
data collection. Basic demographic and clinical information was collected from all participants, 
including age, sex, body weight and height (to calculate body mass index; BMI), co-morbidities 
(including HIV infection and hepatitis B and C) and concomitant drug use. Malnutrition was 
defined as BMI < 18.5 kg/m2 [17].
sample collection. Pharmacokinetic sampling took place at KCMC hospital. Patients had 
to be on TB treatment for at least ten days because of the expected steady state in the 
pharmacokinetics of the TB drugs at that point. Patients had refrained from food at least 
eight hours before drug intake. On the sampling day, patients took their drugs under our 
supervision at 8am in the morning. Then they had a standardized breakfast within 30 minutes 
after drug intake, which reflected the usual drug intake procedures in this population. The 
standardized breakfast consisted of a cup (125 ml) of tea with whole milk and sugar and either a 
small bowl of porridge or mandaazi, a typical East African fried pasty (analogous to doughnut) 
that is rather fat. 
Serial venous blood samples were collected just before, and at 1, 2, 3, 4, 6, 8, 10 and 24 hours 
after observed TB drug intake. Plasma was separated and stored at -80oC immediately until 
transport on dry ice to The Netherlands for bio-analysis.
bio-analysis. The plasma concentrations of isoniazid, rifampicin, pyrazinamide and 
ethambutol were assessed by validated high-performance liquid chromatography (HPLC) as 
described before [18]. Isoniazid and acetylisoniazid were measured with liquid-liquid extraction 
followed by Ultra Performance Liquid Chromatography (UPLC) with ultraviolet (UV) detection. 
Accuracy was between 97.8% and 106.7% for isoniazid and between 98.0% and 108.9% for 
acetylisoniazid, dependent on the concentration level. The intra- and inter-assay coefficients 
of variation were less than 13.4 % and less than 3.2% (dependent on the concentration) over the 
range of 0.05-15.1 mg/L for isoniazid; and less than 4.2% and less than 5.7% over the range of 
0.16-16.2 mg/L for acetylisoniazid. Lower limits of quantification were 0.05 mg/L for isoniazid 
and 0.16 mg/L for acetylisoniazid. Isoniazid and acetylisoniazid containing samples were stable 
(<5% loss) for at least 12 months at -80oC.
Pharmacokinetic analysis. Pharmacokinetic evaluations were performed using non-
compartmental methods in WinNonLin Version 5.3 (Pharsight Corp., Mountain View, California 
US). The highest observed plasma concentration was defined as C
max
 with the corresponding 
sampling time as T
max
. The log-linear period (log C versus t) was based on the last data points 
(at least three). The absolute value of the slope (β/2.303, in which β is the first order elimination 
rate constant) was calculated using linear regression analysis. The elimination half-life (T½) 
was calculated as 0.693/β. If C
24h
 was below the limit of quantification of the assay (often the 
case for isoniazid and rifampicin), it was estimated based on the last measurable concentration 
(C
last
) and β using the formula C
24h
 = C
last
*e-(β*(24-Tlast). The area under the plasma concentration-
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time curve (AUC
0-24h
) was calculated using the linear/log-trapezoidal rule from zero up to the 
last concentration at 24h. The apparent clearance of the drug (Cl/F; in which F is bioavailability) 
was calculated as dose/AUC
0-24h
 and the apparent volume of distribution (V
d
/F) was calculated 
as (Cl/F)/β. The reference ranges for C
max
 were 3-5 mg/L for isoniazid, 8-24 mg/L for rifampicin, 
20-50 mg/L for pyrazinamide and 2-6 mg/L for ethambutol [19].
These reference ranges represent the normal C
max
 concentrations that can be expected in 
adults after the standard doses of anti-TB drugs. They are based on data that were compiled 
from all available sources (both healthy volunteers and TB patients) by, amongst others, 
Holdiness [1] and Peloquin [2].  Subsequently, the ranges were validated in a range of phase I 
studies in healthy volunteers [20].
determination of acetylator status. We determined the acetylator status phenotypically by 
assessing the T½ of isoniazid. Participants with aT½ greater than 130 minutes were classified 
as slow metabolisers and those with a t½ less than 130 minutes were fast/intermediate 
metabolisers [21-23]. As another means to assess acetylator phenotype, the metabolic ratio of 
acetylisoniazid concentration over isoniazid concentration at 3 hours post dose was calculated.
Patients with a ratio above 1.5 were considered fast/intermediate metabolisers, patients with 
a ratio below 1.5 were slow metabolisers [21]. In addition, we also explored a metabolic ratio of 
0.55 at 3 hours post dose as a cut-off to distinguish fast/intermediate from slow metabolisers, 
as this evolved from a study in African patients [23].
statistical analysis. Most pharmacokinetic parameters were presented as geometric means. 
Sample size was considered too small to test for associations between patient characteristics 
and pharmacokinetic parameters. We only tested the effect of acetylator status on the 
pharmacokinetics of isoniazid. The correlations between C
max
 and AUC
0-24h
of each of the drugs 
were explored using Spearman’s Rhocorrelation. 
To explore the potential of limited sampling for estimating the AUC
0-24h
based on sampling 
earlyin the pharmacokinetic curve, univariate linear regression was used to determine the 
association between the plasma concentration at 2, 3, 4 and 6 hours post dose and the AUC
0-24h
 
for each of the drugs. The R-squared was presented as a measure of variance in the AUC
0-24h
that 
is explained by the variance in the concentration at that time point. Statistical analyses were 
performed in STATA version 10.1 (Stata Corp LP, College Station, Texas, USA). 
results
Twenty tuberculosis patients were enrolled for this study.All were under community-based 
directly observed treatment.Theirmedian age was 38 years (inter-quartile range [IQR] 
30-42), fifteen patients (75%) were male, seven (35%) were HIV positive and seven (35%) were 
considered malnourished based on their BMI, see Table 1.
descriptive pharmacokinetics. Intensive pharmacokinetic sampling took place after a median 
of 19 days after start of TB treatment (range 11-49 days).The pharmacokinetic parameters for 
isoniazid, rifampicin, pyrazinamide and ethambutol are presented in Table 2. In ten patients 
(53%), the isoniazid peak plasma concentration was below the reference range (3-5 mg/L). In 
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seven patients (35%), the rifampicin C
max
 was below the reference range (8-24 mg/L); in five 
of them isoniazid C
max
 was also below the reference range. In none of the patients the C
max 
of 
pyrazinamide or ethambutol was below the reference range.
There was a positive correlation between the AUC
0-24h
 and C
max
 of isoniazid (correlation 
coefficient 0.68; P=0.001), pyrazinamide (correlation coefficient 0.69; P=0.001) and ethambutol 
(correlation coefficient 0.72; P=0.003), but not of rifampicin (correlation coefficient 0.35 
(P=0.14).
table 1. Characteristics of 20 tuberculosis patients in northern Tanzania
Characteristic
Male sex, n (%) 15 (75%)
Age, median years (IQR) 38 (30-42)
Body weight, mean kg (SD) 55.7 (6.4)
BMI, mean (SD) 19.5 (2.4)
Malnutrition, n (%)a 7 (35%)
HIV positive, n (%) 7 (35%)
Type of tuberculosis, n (%)
Pulmonary 19 (95%)
Extra pulmonary 1 (5%)
Concomitant drugs, n (%) 
Amoxycillin 1 (5%)
ARV b 2 (10%)
Co-trimoxazole 3 (15%)
Diclofenac 3 (15%)
Vitamin B complex 2 (10%)
Dose (mg) per kg body weight, mean (SD)
Isoniazid 5.2 (0.46)
Rifampicin 10.4 (0.91)
Pyrazinamide 27.8 (2.4)
Ethambutol 19.1 (1.7)
Acetylator status based on INH t
1/2
, n (%)
Slow 12 (63%)
Fast/ intermediate 7 (37%)
Acetylator status based on ac-INH/INH ratio (cut-off 1.5), n (%)
Slow 10 (53%)
Fast/ intermediate 9 (47%)
Acetylator status based on ac-INH/INH ratio (cut-off 0.55), n (%)
Slow 8 (42%)
Fast/intermediate 11 (58%)
IQR = interquartile range; BMI = body mass index; a Malnutrition defined as BMI < 18.5 kg/m2;b ARV = antiretroviral 
treatment.
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figure 1. The relation between the acetylator status (slow vs. fast/intermediate) based on two 
methods: the t
1/2
 of isoniazid and the acetyl-INH/INH metabolic ratio in the 3h post-dose plasma 
sample. Patients with a t
1/2
 below 130 minutes (=below the horizontal dashed line) were considered 
fast/intermediate metabolisers.[17-19] Patients with anacetyl-INH/INH ratio greater than 0.55 [19] or 
greater than 1.5 17(=right of the first or second vertical dashed line, respectively) were considered fast/
intermediate metabolisers based on metabolic ratio. Note that phenotyping by t
1/2
 and metabolic 
ratio resulted in discordant results (in the upper right quadrant) in 4 patients when a metabolic ratio 
of 0.55 was used as cut-off compared to 2 patients when a metabolic ratio of 1.5 was used as cut-off.
table 2. Pharmacokinetic parameters of tuberculosis drugs in 20 Tanzanian tuberculosis patients
PK parameters,  
geometric mean (min-max) Isoniazid Rifampicin Pyrazinamide Ethambutol
AUC
0-24
, h*mg/L 11 (3.7-22.7) 39.9 (27.4-68.3) 344 (209-610) 20.2 (13.4-32.0)
C
max
, mg/L 2.8 (1.0-4.6) 8.9 (5.9-14.8) 38.2 (29.0-50.8) 3.3 (2.2-5.8)
t
max
, h 1.2 (0.7-2.9) 1.3 (0.9-3.0) 1.2 (0.7-3.0) 1.5 (0.9-2.2)
CL/F, L/h 25.8 (13.0-60.5) 14.4 (8.8-21.9) 4.5 (2.6-6.5) 52 (34.3-71.3)
Vd/F, L 99 (69.6-173.4) 37.3 (22.7-56.5) 40.3 (29.5-98.3) 719 (491-965)
t
1/2
, h 2.9 (1.3-4.2) 1.8 (1.1-3.8) 5.5 (4.1-15.7) 9.5 (6.9-13.5)
Reference range C
max
2 3-5 mg/L 8-24 mg/L 20-50 mg/L 2-6 mg/L
Proportion with C
max
 below reference range 10 (52%) 7 (35%) 0 (0%) 0 (0%)
Isoniazid plasma concentrations were only determined in 19 patients.
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assessment of acetylator status. Based on the elimination half-life of isoniazid, 7 (37%) 
patients were fast or intermediate metabolisers and 12 (63%) were slow metabolisers. Based on 
the 3-houracetyl-INH/INH ratio with a cut-off of 1.5, nine (47%) patients were fast/intermediate 
metabolisers and ten patients (53%) were slow metabolisers (See Figure 1). Two patients had a 
discrepancy in acetylator phenotype determined by the two methods. With a cut-off of 0.55, 
11 (58%) were fast/intermediate metabolisers and eight patients (42%) were slow metabolisers. 
Acetylator status based on the half-life method was associated with the AUC
0-24h
 and C
max
 
of isoniazid. In slow metabolisers geometric mean AUC
0-24h
 was 17.2 h*mg/L (range 9.5-22.7) 
and C
max
 3.4 mg/L (range 2.0-4.6) and in intermediate/fast metabolisers geometric mean 
AUC
0-24h
 was 5.2 h*mg/L (range 3.7-8.1) and C
max
2.0 mg/L (range 1.0-3.3); (P<0.001 and P=0.01, 
respectively). 
association between the 2, 3, 4 and 6h concentration and auC
0-24h
. The isoniazid 
concentrations at 2, 3, 4 and 6 hours post-dose were associated with AUC
0-24h 
and the R-squared 
ranged from 0.91 to 0.96, meaning that 91-96% of the variance in the AUC
0-24h
 is explained by the 
variance in the concentration at a particular sampling time point. For rifampicin the R-squared 
was highest for the concentration 4 hours post-dose (0.82). For pyrazinamide the R-squared 
was highest for the concentrations 4 and 6 hours post dose (0.84 and 0.86, respectively). For 
the different ethambutol concentrations the R-squared was low, varying from 0.40 to 0.71. This 
indicates that limited sampling to estimate the AUC
0-24h
 may be feasible for isoniazid, rifampicin 
and pyrazinamide but less for ethambutol. 
disCussion
This report provides important data on pharmacokinetic characteristics of isoniazid, rifampicin, 
pyrazinamide and ethambutol based on intensive 24-hour pharmacokinetic sampling in East 
African TB patients.
Half of the patients from our study had anisoniazid peak plasma concentration (C
max
) below 
the reference range and a third of patients had a rifampicin C
max 
below the reference range. This 
may partly be explained by the breakfast that patients took within half an hour after the intake 
of TB drugs. This approach was chosen to mimic the real-life situation for TB patients, as most TB 
patients take their pills just before or with their breakfast in order to prevent or alleviate gastro-
intestinal adverse effects. Previous studies have shown that intake of a meal with a high fat or 
carbohydrate content just before drug intake decreases the rate of absorption and significantly 
reduces the isoniazid C
max 
with 20% to 51% [24-27]. Rifampicin C
max 
can be reduced up to −36% 
when it is taken directly after a meal [24,28]. There is no significant effect of food on the C
max
 of 
pyrazinamide and ethambutol [24,29,30]. Of note, in the current study the average T
max
 values 
for the TB drugs were short (about 1 h for isoniazid, rifampicin and pyrazinamide, see table 2), 
indicating that the delay in absorption and a possible related decrease in C
max 
were probably 
limited. Furthermore, it should be noted that pharmacokinetic studies from other African 
countries found even higher proportions of patients with C
max
 below the reference range for 
isoniazid (30% in Botswana [8,31], 89% in Kenya [32]) and rifampicin (69% in South Africa [12], 
78-84% in Botswana [27,28] and 90% in Kenya [32]), despite administration of drugs on an empty 
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stomach in the studies from Botswana and Kenya. The relatively high C
max
 values of the TB drugs 
in our study among African patients may also relate to the average body weight of 55.7 kg 
(table 1), which is just above 50 kg above which 4 FDC tablets (rather than 3) are administered. 
Values for total exposure (AUC
0-24h
) may be even more relevant to the efficacy of first-line TB 
drugs than the C
max
 [33]. AUC
0-24h
 values can best be compared to those recorded in Indonesian 
TB patients [18] and in a racially mixed population of patients in The Netherlands who used 
similar doses on a mg/kg basis (Magis et al, submitted), as the pharmacokinetics in these studies 
were assessed with the same analytical methodology. Average exposures to rifampicin were 
39.9, 48.5 and 41.1 h*mg/L in Tanzanian patients, Indonesian patients and a mixed population, 
pyrazinamide AUC
0-24h
 values were 344, 473 and 380 h*mg/L respectively, and exposures to 
ethambutol were 20.2, 14.4 and 23.5 h*mg/L. Isoniazid was not measured in Indonesian TB 
patients and we used another analytical method in the mixed population (average AUC
0-24h
 was 
15.2 h*mg/L compared to 11,0 in the current study). These comparisons show no drastically 
lower total exposure to TB drugs between Tanzanian patients and the Indonesian patients and 
the mixed population from the Netherlands.
Even though the exposure to TB drugs in Tanzanian patients may be high compared to 
exposurefrom other African studies and similar to those in other populations, a large number 
of patients had low plasma concentrations of isoniazid and rifampicin., Several clinical studies 
have pointed towards a possible association between low TB drug concentrations and poor 
treatment outcome [3-5]. A preclinical model showed that interindividual variability in 
pharmacokinetics is relevant to the emergence of resistance [7] and a recent meta-analysis 
revealed that variability in exposure to isoniazid is associated with failure of therapy and 
acquired drug resistance [10]. On the other hand, other studies have found no association 
between plasma concentrations and effect to first-line TB drugs [34, 35].
We could not readily explain the observed low isoniazid and rifampicin AUC
0-24h
 and C
max 
values by patient characteristics, as the sample size was considered too small for analysis of 
association between patient characteristics and pharmacokinetic parameters.
However, we evaluated the effect of genetic polymorphisms in N-acetyl transferase 2 
(NAT2), a phase II metabolic enzyme, on the pharmacokinetics of isoniazid.Slow acetylation 
of isoniazid into acetylisoniazid is a homozygous recessive trait. Genotypically, homozygous 
fast, heterozygous fast (or intermediate) and slow acetylators are distinguished [22,36]. In our 
study acetylator status was assessed phenotypically using the isoniazid elimination half-life 
and the acetylisoniazid/isoniazid ratio 3 hours post-dose with a cut-off of 1.5. Based on these 
two methods, 63% or 53% of patientsin our study were slow metabolisers. This is consistent 
with available data showing that 50-60% percent of European (Caucasian), African and Indian 
populations are slow metabolisers [37]. Clearly, assessment of the acetylator status by the 
metabolic ratio of acetylisoniazid/isoniazid at a single time point post dose is more convenient.
There was good concordance between the two methods when 1.5 was used as the cut-off for 
the metabolic ratio (2 discordant patients). In the future, limited sampling may allow for an 
assessment of acetylator status as well as estimation of AUC values of TB drugs, considering the 
high correlation between concentrations measured in the early part of the pharmacokinetic 
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curve and exposures to isoniazid, rifampicin and pyrazinamide. AUC
0-24h
 and C
max
 values of 
isoniazid, pyrazinamide and ethambutol were also correlated, but for rifampicin no such 
association was found. We have considered whether this may be explained by the nonlinear, 
saturable pharmacokinetics of rifampicin, but disproportional changes in exposure above 
certain concentrations are expected to affect both C
max 
as well as AUC
0-24h
.  
In summary, this study provides pharmacokinetic data of first-line TB drugs based on 
intensive 24h sampling in East African TB patients.Half of the patients had isoniazid peak plasma 
levels and a third had rifampicin peak plasma concentrations below the reference ranges. 
Although the pharmacodynamics of the currently used first line TB drugs is not entirely clear, 
low isoniazid and rifampicin concentrations have been associated with suboptimal treatment 
response. Exploring the effect, tolerabilityand pharmacokinetics of higher dose of isoniazid 
and rifampicin in African tuberculosis patients is therefore recommended.
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abstraCt
introduction: Plasma is the traditional biological sample for PK studies and Therapeutic 
Drug Monitoring (TDM) of the pivotal anti-tuberculosis (TB) drug rifampicin. Saliva may be 
an attractive alternative matrix, also considering that it may reflect protein-unbound, active 
plasma concentrations. The objectives of this study were (1) to compare the PK of rifampicin in 
saliva and plasma and (2) to assess whether saliva could be an alternative matrix for PK studies 
and TDM with this drug. 
methods: A descriptive PK study was performed among 15 adult Tanzanian TB patients who 
were in the intensive phase of TB treatment. Time-matched samples of stimulated saliva 
(obtained with a Salivette® device containing citric acid) and plasma were collected at predose 
and at 1, 2, 3, 4, 6, 8, 10 and 24 hours after intake of rifampicin. Salivary, total (protein-unbound 
plus bound) and unbound plasma concentrations of rifampicin were measured with validated 
HPLC methods. Salivary and plasma PK parameters were assessed, ratios of salivary to (total 
and unbound) plasma concentrations were calculated and the performance of salivary 
concentrations to predict plasma concentrations was evaluated using the jackknife method. 
results: The geometric mean AUC
0-24h
 of rifampicin in saliva (3.1 h*mg/L) was slightly but 
significantly lower than the protein-unbound AUC
0-24h
 in plasma (5.3 h*mg/L) and these 
were much lower than the plasma AUC
0-24h
 based on total concentrations (32.7 h*mg/L). 
Corresponding geometric mean C
max
 values were 0.64, 1.0 and 6.8 mg/L. Average (geometric 
mean) ratios of loose salivary versus total or unbound plasma concentrations were 0.099 and 
0.614 and these ratios were not dependent on time post dose or associated rifampicin plasma 
concentrations (repeated measures ANOVA). The prediction of total and unbound plasma 
concentrations based on salivary concentrations of rifampicin resulted in median percentage 
prediction errors (MPPE) of 13.4% and 6.0% and median absolute percentage prediction errors 
(MAPE) of 35.7% and 23.0%, respectively, which means that these predictions were sufficiently 
accurate (<15%) yet imprecise (>15%). 
Conclusions: AUC
0-24h
 and C
max
 of rifampicin in saliva were much lower than those in plasma 
based on total plasma concentrations. The AUC
0-24h
 of rifampicin in saliva was significantly 
lower than the protein-unbound plasma AUC
0-24h
. It is not possible to predict total or protein-
unbound plasma concentrations from salivary concentrations, due to inadequate precision 
associated with this prediction. 
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introduCtion
The global burden of tuberculosis (TB) remains immense, with an estimated 8.7 million new cases 
of TB and 1.4 million people dying from this infectious disease in 2011 [1]. Still too many patients 
do not respond adequately to treatment, experience a relapse of TB after treatment completion, 
or are confronted with the emergence of drug resistant strains of M. tuberculosis [1]. 
Inadequate exposure to TB drugs constitutes one of the factors underlying suboptimal 
treatment response and development of resistance, as evidenced by results from the in vitro 
hollow fibre model [2], clinical studies on relationships between drug concentrations and 
response [3-7], and findings of a recent meta-analysis [8]. In view of the relevance of exposure 
to TB drugs, drug dosing may be individualized based on measurement of drug concentrations 
(Therapeutic Drug Monitoring, TDM), a practice applied in a few centres around the 
world [9-13]. Yet in the long term it seems preferable to develop new TB regimens that are 
pharmacokinetically optimized, enabling fixed dosing for all patients. This requires multiple 
pharmacokinetic studies during development of such regimens. 
Plasma is the traditional biological sample for pharmacokinetic studies and TDM, but saliva 
may be an attractive alternative matrix. Advantages of saliva include the easy sample collection, 
which can be standardized with specific saliva collection devices; and the painless collection 
of saliva, which seems particularly advantageous for children [14,15]. Furthermore, salivary 
concentrations may reflect the protein-unbound (free) fraction of drug in plasma, which is 
active and available to be transported to the sites of action, rather than the total (protein-
unbound plus bound) plasma concentration [14]. A clear prerequisite for the use of saliva in 
pharmacokinetic studies and TDM is a strong relationship between the salivary concentrations 
and the (unbound or total) plasma concentrations of a drug. 
The plasma pharmacokinetics of the TB drug rifampicin are well-characterized [16-18]. This 
pivotal TB drug is now being repurposed as a component of future TB drug regimens for adults, 
but at higher doses [19-20]. In addition, higher doses of rifampicin are currently advised for 
treatment of TB in children, requiring pharmacokinetic evaluations as well [21]. Therefore, the 
objectives of this study were (1) to describe the pharmacokinetics of rifampicin in saliva and 
plasma (total and protein-unbound concentrations) and (2) to assess whether saliva could be 
an alternative matrix for pharmacokinetic studies and TDM with this essential TB drug. 
methods
study design and population. We performed a descriptive pharmacokinetic study in Moshi, 
Tanzania. Adult TB patients who were in the intensive phase of TB treatment were eligible for 
participation. They had to be on TB treatment for at least two weeks because of the expected 
steady state of rifampicin at that time. Patients with a body weight less than 50 kg used three 
Fixed Dose Combination (FDC) tablets per day (i.e. 225 mg isoniazid, 450 mg rifampicin, 1200 mg 
pyrazinamide and 825 mg ethambutol) and patients with a body weight ≥50 kg used four FDC 
tablets per day (i.e. 300 mg isoniazid, 600 mg rifampicin, 1600 mg pyrazinamide and 1100 mg 
ethambutol). All participants gave written informed consent. Intensive pharmacokinetic 
sampling for both plasma and saliva took place during 24 h. 
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This was an explorative study and no sample size calculation was performed. The study 
aimed to recruit 15 patients, providing for an expected number of circa 80 time-matched 
detectable salivary, protein-unbound and total (protein-unbound plus bound) concentrations 
of rifampicin.  
Study participants were recruited from the outpatient TB clinic at Mawenzi Hospital in 
Moshi and pharmacokinetic sampling was done at the patient unit of the Kilimanjaro Clinical 
Research Institute. The study was approved by the Research Ethics Committee at the Kilimanjaro 
Christian Medical Centre (KCMC) and by the Tanzanian National Institute for Medical Research. 
Pharmacokinetic sampling. Patients were asked not to eat for at least six hours (i.e. overnight) 
before start of intensive pharmacokinetic sampling. On the sampling day, patients took their 
drugs under supervision of a nurse in the morning, and then had a standardized breakfast 
within 30 minutes after drug intake, which is the usual procedure in this population. The 
standardized breakfast consisted of a cup (250 ml) of tea with milk and sugar and two pancakes. 
Serial venous blood samples were collected just before, and at 1, 2, 3, 4, 6, 8, 10 and 24 hours 
after TB drug intake. Plasma was centrifuged at 2800 rpm for 10 minutes and stored at -80oC 
immediately thereafter. 
Stimulated saliva was collected immediately (i.e within 2 minutes) after every blood sample. 
The patients were asked to rinse their mouth with water. Then a Salivette® was provided, which 
a plastic device is containing a dental cotton roll impregnated with citric acid that stimulates 
the salivary flow (Sarstedt, Etten-Leur, The Netherlands). The patients were asked to chew on 
the cotton roll inside the Salivette®. After one minute, the patient was asked to put the cotton 
roll back in the insert of the Salivette® centrifuge vessel. The centrifuge vessel was centrifuged 
at 3000g for 5 minutes, which allows saliva to be collected in the extended tip of the Salivette® 
tube. The saliva was put in polypropylene tubes and stored at -80°C. The total process until 
storage in the freezer took a maximum of 45 minutes after sampling. 
Both the plasma and saliva samples weretransported on dry ice to The Netherlands, where 
bio-analysis took place. 
bio-analysis. Total (protein-bound plus unbound) plasma concentrations of rifampicin were 
measured with a validated HPLC method as described before [22]. For the analysis of rifampicin 
in saliva, liquid-liquid extraction followed by HPLC was used. Briefly, 250 µL of saliva was mixed 
with 25 µL ascorbic acid (20 g/L), 25 µL 0.2 M acetate buffer pH5, 25 µL of internal standard 
(sulindac) solution and 1 ml of iso-octane / dichloromethane (3:2 %v/v) and the mixture was 
centrifuged at 1910 g for 5 minutes. The water layer was frozen in a cryobath (-40°C), the 
organic layer was decanted and evaporated at 37°C under a N
2 
flow until the tube was dry. 
The residue was reconstituted in 200 µL H
2
O / CH
3
CN (70/30 %v/v) at 4°C by shaking it for 
10 minutes. Immediately after centrifugation at 1910 g for 10 minutes at 4°C, 50 µL was injected 
into the HPLC system.
To measure protein-unbound rifampin, ultrafiltration followed by HPLC was used. Briefly, 
0.5 ml of plasma was added into a Centrifree YM-30 tube (Millipore, Amsterdam, the Netherlands). 
The tube was centrifuged for 15 min at 1650 g at 25oC and 50 µL of the clear ultrafiltrate was 
injected into the HPLC system. One HPLC system was developed for measurement of salivary 
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and protein-unbound rifampicin concentrations. The analytical column was an OmniSpher 5 C18 
column (250 × 4.6 mm ID; particle size 5 µm) protected by a Chromguard RP ss 10 x 3 mm column 
(Varian, Middelburg, The Netherlands). The mobile phase components were 30% acetonitrile 
and 70% 10 mM phosphate buffer with pH 5, run during a HPLC gradient with different flow rates. 
Total run time was 17 min. UV detection was set at 334 nm. The autosampler liquid system was 
set at 4°C.
For measurement of rifampicin in saliva, accuracy and intra-day precision ranged from 98 
to 105% and from 3.7 to 7.3 %, respectively, dependent on the concentration which ranged from 
0.1 (limit of quantitation) to 10.4 mg/L. For measurement of unbound plasma concentrations 
of rifampicin, the average accuracy of ultrafiltrate spiked with rifampin was 107% and intraday 
precision in measurement of rifampicin in ultrafiltrate varied from 1.5 to 1.9% dependent 
on the concentration measured. The range of the method for unbound rifampicin plasma 
concentrations was from 0.06 mg/L (limit of quantitation) to 13 mg/L.
Pharmacokinetic analysis. The area under the plasma concentration-time curve (AUC
0-24h
), 
the highest observed concentration (C
max
) with the corresponding sampling time T
max
, 
apparent clearance (Cl/F; in which F is bioavailability), apparent volume of distribution (V
d
/F) 
and elimination half-life (T
½
) were assessed by noncompartmental pharmacokinetic methods 
using WinNonLin Version 5.3 (Pharsight Corp., Mountain View, California US), as described 
before [22]. C
24h
 was estimated based on the last measurable concentration (C
last
) taken at time 
T
last
 and the elimination rate constant β, using the formula C
24h
 = C
last
*e-β*(24-Tlast). 
statistical analysis. Differences in pharmacokinetic parameters of rifampicin based on 
salivary, protein-unbound and total plasma concentrations were assessed with repeated-
measures (within-subject) analysis of variance (ANOVA) performed on log-transformed 
pharmacokinetic parameters, followed by three separate paired-samples T-tests performed at 
a Bonferroni-corrected significance level of 0.05/3. T
max
 values of rifampicin were tested with the 
related-samples (within-subject) Friedman’s analysis of variance by ranks. Correlation between 
pharmacokinetic parameters was performed on untransformed data using Spearman’s rho 
(rank correlation).
To assess whether saliva could be an alternative matrix for pharmacokinetic studies and TDM, 
the time-matched salivary concentrations, protein-unbound and total plasma concentrations 
of rifampicin were first correlated to eachother using Spearman’s rho. Subsequently ratios of 
salivary concentrations versus total and protein-unbound plasma concentrations of rifampicin 
were calculated for all time-matched samples. The effect of sampling time and the effect of 
the associated rifampicin plasma concentrations on the concentration ratios was assessed 
with repeated-measures (within-subject) ANOVA on log-transformed concentration ratios. 
Geometric means were calculated for the saliva to plasma (total and unbound) concentration 
ratios; the reciprocal average concentration ratios were used as conversion factors to 
estimate total and unbound rifampicin plasma concentrations based on the measured salivary 
concentrations [23]. 
The predictive performance of these estimations was assessed by calculation of conversion 
factors based on datasets in which one out of the 15 patients was omitted, followed by use of these 
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conversion factors to estimate the (total and unbound) plasma concentrations of the 15th patient 
( jackknife method [24]). Such predictions were performed for plasma concentrations of all 15 
patients. Potential bias in the predictions was assessed using the median percentage prediction 
error (MPPE). This is the median of all percentage prediction errors, which were defined as: 
100% * (predicted concentration – measured concentration) / measured concentration. 
Imprecision was assessed using the median absolute percentage prediction error (MAPE). This 
is the median of all absolute percentage prediction errors. The absolute percentage prediction 
error was defined as: 100% * absolute ((predicted concentration – measured concentration) / 
measured concentration). For an acceptable predictive performance, both MPPE and MAPE 
had to be <15% [24,25]. 
As an alternative means to estimate plasma concentrations and assess predictive 
performance, a linear regression analysis was performed on log-transformed salivary 
concentrations versus log-transformed plasma (total or protein-unbound) concentrations of 
rifampicin, yielding a least squares regression line with equation: log (plasma concentration) = 
a + b* log (salivary concentration), in which a is the intercept and b is the slope of the regression 
line [26]. This equation was derived in a randomly selected set of eight patients (index set) 
and was used to estimate plasma concentrations in the remaining seven patients (validation 
set) [24,26]. This procedure was repeated three times. Again, MPPE and MAPE were used as 
measures of bias and imprecision. All statistical analyses were performed with SPSS for Windows 
version 20.0 (SPSS Inc, Chicago, IL). P values of below 0.05 were considered significant. 
results
Patients. Fifteen TB patients were enrolled in the study. Twelve patients were male (80%), their 
median age was 37 years (range 19-50 years), their median body weight was 49.5 kg (range 
41.5-73.6 kg) and they received a median rifampicin dose of 10.2 mg/kg (range 8.2 -11.3 mg/kg). 
Pharmacokinetics of rifampicin based on salivary, protein-unbound and total plasma 
concentrations. The geometric mean AUC
0-24h
 of rifampicin in saliva (3.1 h*mg/L) was lower 
than the geometric mean protein-unbound AUC
0-24h
 in plasma (5.3 h*mg/L) and these were 
much lower than the geometric mean plasma AUC
0-24h
 based on total concentrations 
(32.7 h*mg/L, table 1, figure 1). Repeated-measures ANOVA on log-transformed AUC
0-24h
 values 
showed a significant main effect based on type of concentration measured (<0.001) and paired 
t-tests with Bonferroni correction revealed significant differences between all three AUC
0-24h
 
values (p<0.001). For C
max
 values of rifampicin, the difference in rifampicin C
max
 in saliva and 
C
max
 based on protein-unbound plasma concentrations was not significant, but both these C
max
 
values were significantly lower than the C
max
 based on total plasma concentrations (p<0.001). 
Rifampicin AUC
0-24h
 values based on salivary concentrations, protein-unbound plasma 
concentrations and total plasma concentrations were all strongly (Spearman’s rho at least 0.71) 
and significantly (p≤ 0.003) correlated to eachother. Rifampicin C
max
 values based on protein-
unbound and total concentrations were also correlated (rho = 0.90, p<0.001) but these were 
not correlated with rifampicin C
max
 values in saliva (rho = 0.41, p=0.13 and rho = 0.43, p =0.11). 
5SALIVA STUDY
99
Table 1. Pharmacokinetics of rifampicin in saliva and plasma (n=15)1
PK 
parameter saliva2
Plasma, 
protein-
unbound 
conc. 2
Plasma, total 
conc.2,3
Ratio 
saliva / plasma 
protein-
unbound4
Ratio 
saliva / plasma 
total3,4
Ratio 
plasma protein-
unbound / 
plasma total3,4
AUC
0-24h
 
(h*mg/L)
3.1  
(0.70-8.6)
5.3  
(1.8-10.3)
32.7  
(11.7-73.6)
0.59  
[0.50-0.71]
0.096  
[0.077-0.119]
0.161  
[0.146-0.178]
C
max
 (mg/L) 0.64  
(0.12-1.7)
1.0  
(0.50-2.2)
6.8  
(3.2-17.4)
0.62 
[0.42-0.91]
0.094  
[0.063-0.140]
0.151  
[0.136-0.167]
T
max 
(h) 3.0  
(1.0-6.1)
2.1  
(1.0-6.0)
2.1  
(1.0-6.0)
- - -
Cl/F (L/h) 164.1  
(69.9-646.3)
97.6  
(58.1-256.5)
15.7  
(8.2-38.6)
1.68  
[1.42-2.00]
10.4  
[8.4-12.9]
6.21  
[5.61-6.87]
Vd/F (L) 469.3  
(223.3-1673.6)
318.8  
(167.9-1022.4)
47.7  
(24.4-139.5)
1.47  
[1.26-1.72]
9.8  
[8.1-11.9]
6.69  
[5.69-7.85]
T
1/2
(h) 2.0  
(1.3-2.7)
2.3  
(1.6-4.9)
2.1  
(1.4-3.9)
0.88  
[0.76-1.01]
0.94  
[0.84-1.06]
1.08  
[0.96-1.21]
1. Abbreviations: AUC
0-24h
: area under the concentration versus time curve, C
max
: peak plasma concentration, T
max
: time 
to peak plasma concentration, Cl/F: apparent clearance, Vd/F: apparent volume of distribution, T
1/2
: elimination 
half-life, conc.: concentration
2. Geometric means and ranges, apart from Tmax (median and range)
3. Total plasma concentrations refer to protein-unbound plus bound concentrations
4. Geometric means and 95% confidence intervals
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Figure 1: Geometric mean steady-state concentrations of rifampicin versus time (N=15)1 
1. Concentrations of rifampicin (Y-axis) are displayed in mg/L. Time post dose (X-axis) is in hours.  
figure 1. Geometric mean steady-state concentrations of rifampicin versus time (N=15)1
Concentrations of rifampicin (Y-axis) are displayed in mg/L. Time post dose (X-axis) is in hours.
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T
max
 of rifampicin in saliva appeared to be larger in saliva compared to plasma (3.0 h versus 
2.1  h and 2.1 h, table 1), but this difference did not reach statistical significance (p=0.08). 
Elimination half-lives of rifampicin based on salivary, protein-unbound and total plasma 
concentrations were similar (see table 1, p=0.10).  
evaluation of saliva as alternative sampling matrix: correlation analysis and time and 
concentration dependency of concentration ratios. As expected based on the short 
elimination half-life of rifampicin, loose concentrations of rifampicin were below the limits 
of quantitation at predose (T=0h) and at 24 h post dose for all salivary, protein-unbound and 
total plasma concentration measurements. Salivary and unbound plasma concentrations 
were still below the limit of quantitation at T=1 (6 patients) and T=2h (1 patient) and they 
returned below the limit of quantitation at T=8h (2 patients) and T=10h post dose (T=8 
patients). A total of 88 time-matched salivary and protein-unbound and total plasma 
concentrations were available based on concentrations measured above the limits of 
quantitation of the assays. In 100 time-matched samples, protein-unbound and total plasma 
concentrations were measurable. 
Salivary concentrations were significantly correlated with total plasma concentrations 
(rho = 0.78, p<0.001, n=88) and with protein-unbound plasma concentrations (rho = 0.79, 
p<0.001, n=88, figure 2). Protein-unbound and total plasma concentrations showed a stronger 
correlation (rho = 0.96, p<0.001, n=100). 
The geometric mean concentration ratio for salivary versus total plasma concentrations 
was 0.099 (95% CI: 0.089-0.110, range 0.014-0.539) and that for salivary versus protein-unbound 
plasma concentrations was 0.614 (95% CI: 0.553-0.682, range 0.086-5.51). The concentration 
ratio of salivary versus total plasma concentrations of rifampicin did not seem to be dependent 
of time of sampling (table 2) and this was confirmed by repeated-measures ANOVA performed 
over the sampling times 1h to 10h (p=0.59, n=4), 2h to 10h (p=0.91, n=6) and 2h to 8h (p=0.43, 
Table 2. Effect of sampling time and associated concentrations on concentration ratios
Time 
post 
dose 
(h)1
Total plasma 
concentration 
(mg/L,  
geometric mean)2
Concentration ratio 
of saliva to protein-
unbound plasma 
concentrations 3
Concentration ratio  
of saliva to total 
plasma  
concentrations 2,3
Concentration ratio 
of protein-unbound 
to total plasma 
concentrations2,3
1 2.0 0.773(0.301-5.511) N=9 0.111(0.048-0.539) N=9 0.145(0.098-0.197) N=12
2 4.2 0.575(0.338-1.067) N=14 0.091(0.047-0.142) N=14 0.154(0.106-0.229) N=11
3 5.6 0.528(0.087-1.593) N=15 0.082(0.014-0.214) N=15 0.155(0.110-0.218) N=15
4 4.2 0.658(0.289-1.011) N=15 0.104(0.045-0.168) N=15 0.157(0.113-0.229) N=15
6 3.0 0.656(0.313-1.072) N=15 0.107(0.047-0.171) N=15 0.163(0.105-0.238) N=15
8 1.6 0.581(0.210-1.015) N=13 0.098(0.035-0.210) N=13 0.169(0.100-0.232) N=14
10 0.79 0.593(0.376-1.086) N=7 0.114(0.061-0.182) N=7 0.184(0.116-0.263) N=14
1. Both salivary and protein-unbound plasma concentrations were below the limit of quantitation in all samples at 
T=0 h and T=24 h post dose. 
2. Total plasma concentrations refer to protein-unbound plus bound concentrations 
3. Geometric means and ranges
5SALIVA STUDY
101
n=12) post dose; no trends over the sampling times were shown either. Concentration ratios for 
salivary versus unbound plasma concentrations were not dependent of sampling time either 
(1h to 10h post dose: p=0.23, n=5; 1h to 8 h: p=0.31, n=9). However, concentrations of unbound 
versus total plasma concentrations showed an increase with sampling time according to a 
significant linear trend (sampling times 1h to 10h: p=0.01, n=12, table 2). 
evaluation of saliva as alternative sampling matrix: predictive performance of salivary 
concentrations. The conversion factor to predict total (protein-bound plus unbound) 
rifampicin plasma concentrations from salivary concentrations was 10.14 (n=88, all 15 patients) 
and this factor varied slightly when derived from different sets of 14 patients (range: 9.64 to 
10.53). The jackknife method showed that the median percentage prediction error (MPPE) for 
estimation of total rifampicin plasma concentrations based on salivary concentrations was 
13.4% and the median absolute percentage prediction error (MAPE) was 35.7%.
The conversion factor to predict protein-unbound rifampicin plasma concentrations from 
salivary concentrations was 1.63 (n=88, all 15 patients, varying from 1.56 to 1.70 in the sets 
of 14 patients). The MPPE and MAPE for estimation of protein-unbound rifampicin plasma 
concentrations based on salivary concentrations were 6.0 and 23.0%. 
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Figure 2:  Scatter plot and regression line of log-transformed salivary and total (protein-bound plus  
  unbound) plasma concentrations of rifampicin (R2 =0.608, P<0.001, n=88)  
 
 
figure 2. Scatter plot and reg ssion li e of l g-transformed salivary and total (pr ound plus 
unbound) plasma concentrations of rifampicin (R2 =0.608, P<0. 01, n=88) 
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Use of a linear regression equation to predict total plasma concentrations in three index 
and validation sets resulted in MPPE values of 43.1, 3.8 and -22.4%, and MAPE values were 
43.3, 37.5 and 34.6%. For prediction of protein-unbound plasma concentrations, MPPE and 
MAPE values were 23.5 and 28.1% for one index and validation set, data for the other two sets 
are pending.  
disCussion
The first objective of this study was to describe the pharmacokinetics of rifampicin in saliva 
and compare these to plasma pharmacokinetics based on protein-unbound and total 
concentrations. It appeared that the salivary AUC
0-24h
 and C
max
 of rifampicin were much lower 
than those in plasma as based on total (protein-bound plus unbound) concentrations (table 2). 
This was anticipated, as only the protein-unbound (free) fraction of a drug in plasma can 
pass into the salivary compartment [14,15,27,28]. In fact, saliva concentrations of most drugs 
are thought to reflect unbound drug concentrations in plasma [14,15,27,28]. In this study, we 
actually measured the protein-unbound rifampicin plasma concentrations by using a validated 
analytical method based on ultrafiltration.
 
The AUC
0-24h
 of rifampicin in saliva was of the same order of magnitude as the protein-unbound 
plasma AUC
0-24h
, yet it was significantly lower (table 1). This may be explained by one or several 
other factors that (apart from protein binding) determine the extent of diffusion of drugs into 
saliva, including lipid solubility, the degree of ionisation in blood and in saliva, and salivary 
flow [14,15]. The rifampicin molecule exhibits high lipid solubility [16]; its degree of ionisation 
is dependent on the pH of the solution in which it resides. In solution, rifampin behaves as 
a zwitterion. Its acidic function (pKa = 1.7) is associated mainly to its hydroxyl groups, while 
its basic function (pKa = 7.9) is related to a piperazine-nitrogen functional group. In acidified 
saliva obtained with the Salivette® device (pH=3 [29]), the hydroxylgroup (pKa 1.7) will be 
largely unprotonated and charged negative, whereas the piperazine-nitrogen will be charged 
positive, resulting in neutral molecule. The neutral molecule of rifampicin is not expected to be 
‘trapped’ in saliva (causing higher salivary than plasma concentrations) as is the case for many 
basic drugs that are charged positive in acidified saliva. 
The appearance of rifampicin into saliva was rapid as reflected in a T
max
 of 3.0h (table 1) and 
salivary to plasma concentration ratios were not dependent on sampling time or associated 
rifampicin concentrations. The rapid appearance of rifampicin in saliva and the absence of 
saturation of passage of rifampicin from blood into saliva suggest that this TB drug enters saliva 
by passive diffusion instead of active transport. 
Relatively few comparable studies are available on diffusion of rifampicin into saliva. 
Kenny and Strates have summarized the literature on rifampicin up to 1981 and stated that 
highest rifampicin levels in saliva and sputum are obtained up to 4 hr after peak serum levels 
and that these are only 17-25% of peak serum levels [16]. Gurumuthy et al showed that peak 
concentrations of rifampicin in saliva were 10.6% of those in plasma [30], very similar to data 
from our study. Contrary to the current study, Gurumuthy et al found a clear increase in the 
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saliva to serum concentration ratio with the sampling time post dose. Orisakwe et al found a 
much higher saliva to plasma ratio for AUC
0-24h
 (i.e. a ratio of 0.67) in their study with chewing 
gum stimulated saliva flow and intensive pharmacokinetic sampling in healthy volunteers [31]. 
This is one of very few studies that assessed protein-unbound concentrations of rifampicin 
in all samples of the recorded pharmacokinetic curves. The average protein binding of 84% 
as assessed in this study based on unbound/total plasma AUC
0-24h
 ratios (table 1) is very 
close to the 80% protein binding which is often stated for rifampicin [17,18]. Of note, the 
ratio of protein-unbound versus total concentrations of rifampicin steadily increased with 
higher (total) rifampicin concentrations, which is relevant to rifampicin being repurposed at 
higher doses. 
The second objective of this study was to assess whether saliva could be used as an alternative 
matrix for pharmacokinetic studies and TDM with rifampicin. Based on experience in the past 
[29,32] we deliberately chose to sample ‘stimulated’ saliva using a standardized, reproducible 
and convenient sampling technique with the Salivette® device. It was considered that stimulated 
collection results in less variation of salivary pH and possibly less variation in saliva to plasma 
ratios compared to simple expectoration of saliva [14]. The patients were asked to rinse their 
mouth with water before sampling of saliva to avoid contamination of the oral cavity with drugs 
due to prior drug administration, which could lead to spurious findings [14]. As required for a 
good prediction, saliva to plasma concentration ratios were not dependent of sampling time 
and rifampicin plasma concentrations. 
Prediction of total or unbound rifampicin plasma concentration based on salivary 
concentrations resulted in an acceptable median percentage prediction error (MPPE), which 
means that systematic bias was limited when many individual predictions (each with positive 
or negative bias) were considered. Unfortunately, the average absolute error as measured 
by the median absolute percentage prediction error (MAPE) was above the predefined 
criterium, which means that the overall predictive performance of salivary concentrations 
was insufficient. Use of a regression equation rather than a straightforward conversion factor 
resulted in a similarly imprecise prediction of (total or unbound) plasma concentrations based 
on salivary concentrations. Of note, the current study also showed that monitoring of saliva 
concentrations of rifampicin has limited value in evaluating adherence to this drug, as salivary 
concentrations of rifampicin were below the limits of quantitation at predose (T=0h), at T=1 
and starting from T=10h post dose in many patients who took rifampicin under observation. 
This means that early or late sampling of saliva may incorrectly suggest nonadherence 
to rifampicin. 
In summary, this study showed that total exposure (AUC
0-24h
) and C
max
 of rifampicin in saliva 
were much lower than those in plasma based on total (protein-unbound plus bound) plasma 
concentrations. The AUC
0-24h
 of rifampicin in saliva was of the same order of magnitude as the 
protein-unbound plasma AUC
0-24h
, but was significantly lower. Rifampicin appeared rapidly in 
saliva and probably enters saliva through passive diffusion. It appeared not to be possible to 
predict total or protein-unbound plasma concentrations from salivary concentrations, due to 
inadequate precision associated with this prediction. 
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abstraCt
introduction: Diabetes mellitus (DM) is a well-known risk factor for tuberculosis (TB) and 
is associated with poor TB treatment outcome and an increased risk of TB relapse. With the 
current global increase in cases of type 2 DM, attention needs to be increased on optimum 
treatment of TB in patients with diabetes. Previous studies examining the possible role of altered 
pharmacokinetic (PK) profiles of TB drugs in DM patients have met with different results, and no 
studies have been conducted in Africa. We performed a study to describe the PK of TB drugs in 
Tanzanian TB patients with and without diabetes mellitus. 
methods: We collected blood samples from 20 diabetic TB patients and a control group of 20 
non-diabetic TB patients during the intensive phase of TB treatment at a Tanzanian outpatient 
TB clinic. A full pharmacokinetic profile (0-24 hours) was determined for isoniazid, rifampicin, 
pyrazinamide and ethambutol, and plasma concentrations were measured using validated 
HPLC methods. PK parameters were calculated using non-compartmental methods and were 
compared using the independent samples T-test on log-transformed data. Multiple linear 
regression analysis was performed to assess the effect of other exploratory variables on the PK 
of TB drugs.  
results: The geometric mean exposures (AUC
0-24
) to rifampicin and isoniazid were lower 
in diabetic than non-diabetic TB patients (39.9 versus 29.9 h*mg/L for rifampicin, p=0.052; 
5.4 versus 10.6 h*mg/L for isoniazid, p=0.015). C
max
 of isoniazid was also lower in diabetic TB 
patients (1.7 versus 2.8 mg/L, p=0.010). Forty-seven percent versus 35% of patients had C
max
 of 
rifampicin below the reference range in the diabetic TB group as compared to the non-diabetic 
TB group, and for isoniazid,  the proportions were 74% against 55%. Fast and slow acetylators 
for isoniazid were not statistically different in proportion between diabetic and non-diabetic 
TB patients. In a multiple linear regression analysis with age, sex, dose per kg, HIV status and 
acetylator status as additional explanatory variables, DM remained an independent predictor of 
the PK of isoniazid and rifampicin, next to acetylator status for isoniazid. Fasting blood glucose 
also predicted exposure to isoniazid and rifampicin. No PK parameters for pyrazinamide and 
ethambutol were significantly different between diabetic and non-diabetic TB patients.
Conclusion: Exposure to isoniazid is reduced in Tanzanian diabetic patients with TB and 
a clear trend to a reduction in exposure to rifampicin was observed. These effects are most 
likely explained by the diabetes disease. Increasing the doses of TB drugs in treating diabetic 
TB patientsmay be considered in view of accumulating evidence that exposure to TB drugs is 
related to response. 
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introduCtion
Diabetes mellitus (DM) was a well-known risk factor for tuberculosis (TB) in the past, but this 
was largely forgotten during the second half of the 20th century, with the advent of widely 
available treatment for both diseases [1]. With the current global increase in cases of type 2 
DM, the association between TB and DM is re-emerging [2]. The greatest increase in cases of 
type 2 DM will occur in developing countries, where TB is highly endemic [3]. Patients with DM 
have a higher risk on developing TB [4,5]. This is probably because of impaired immunity [6]. 
On top of that, TB is more difficult to treat in diabetic patients. Recent studies have shown that 
TB patients with DM have a less favourable response to TB treatment as shown by higher failure, 
relapse, and death rates [7]. 
It has been shown that patients with DM have lower plasma concentrations of certain drugs 
[8,9]. Apparently, absorption, distribution, metabolism and/or excretion of drugs are changed 
in patients with DM. If this also applies to anti-TB drugs, this may at least partly explain the 
slower response to TB treatment in patients with DM, as lower plasma concentrations of anti-TB 
drugs have been associated with clinical failure and acquired drug resistance [10-13]. Recently 
simulations also showed that interindividual variability in pharmacokinetics of TB drugs, rather 
than non-adherence, causes multidrug resistant TB [14]. In addition, a meta-analysis showed 
that variability in exposure to a single drug is associated with failure of TB therapy and acquired 
drug resistance [15].
In one study in Indonesia, TB patients with DM had lower rifampicin concentrations than TB 
patients without DM [16]. In that study, TB patients with diabetes and age- and sex-matched TB 
patients without DM were studied during the continuation phase of TB treatment. The exposure 
to rifampicin up to six hours post dose (area under the curve from 0-6 hours; AUC
0–6 h
) was 53% 
lower in patients with TB and DM, compared with patients with TB only; this was attributed to 
DM per se and to the higher weight of patients with DM. In a follow up study, Indonesian TB 
patients with and without DM in the intensive phase of treatment were matched for weight 
and all four TB drugs (isoniazid, rifampicin, pyrazinamide and ethambutol) were analysed; in 
contrast to previous observations, no differences in drug exposure were found between the 
two groups of patients [17]. Another study in Peruvian patients also did not find a difference 
in pharmacokinetic parameters between DM and non DM patients taking TB medication [18].
Clearly, these findings need more research. It needs to be explored whether DM affects TB 
drug concentrations in populations other than Asian and South-American. Pharmacokinetics 
can differ between different races and ethnic groups, because of genetic variation in the 
metabolic and transporter enzymes involved [19]. It is important to study this subject also in 
African TB patients because the African continent has the highest TB incidence and mortality 
rates [3]. Therefore, we designed a pharmacokinetic study in northern Tanzania where we 
studied the effect of type 2 diabetes on the steady state pharmacokinetics of isoniazid, 
rifampicin, pyrazinamide and ethambutol. Tanzania is a high burden country for tuberculosis. 
In 2011, the incidence rate was approximately 169 per 100,000 population per year and there 
were about 82,000 tuberculosis cases [3]. The diabetes prevalence in the Kilimanjaro Region 
is estimated 1-1.5%, and the prevalence is estimated to be higher in urban Tanzania, namely 
around 5.5%, which can at least partly be explained by differences in overweight [20].
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methods 
study design. We conducted a prospective observational pharmacokinetic study in which the 
plasma concentrations of the anti-TB drugs isoniazid, rifampicin, pyrazinamide and ethambutol 
were compared between Tanzanian TB patients with and without diabetes. The plasma 
concentrations were measured during the intensive phase of TB treatment. The patients 
were using TB treatment for drug-sensitive Mycobacterium tuberculosis, as prescribed by the 
Tanzanian National Tuberculosis Guidelines. 
study subjects. Forty adult TB patients were included in this study; 20 TB patients without 
diabetes were recruited at Mawenzi Hospital, an outpatient TB treatment clinic in Moshi in 
northern Tanzania, and 20 TB patients with diabetes were recruited from Mawenzi hospital as 
well as other hospitals around the region that treat TB. TB was diagnosed by these hospitals 
according to the Tanzanian guideline and practice. The diagnosis was based on clinical 
symptoms and signs, chest x-ray examination, and sputum smear microscopy. Diabetic 
patients were included if they had a previously established diagnosis of DM and were attending 
a diabetic clinic. In addition, DM was confirmed at the time of pharmacokinetic sampling 
using WHO criteria [21] where a fasting blood glucose concentration greater than 7 mmol/L 
(126 mg/dL) was considered to indicate diabetes. Only patients above 18 years of age were 
eligible for participation. Participants gave written informed consent and the study was 
approved by the Tanzanian National Institute of Medical Research. 
drug treatment. Tuberculosis was treated with fixed-dose combination tablets (FDC tablets) 
manufactured by Sandoz, Mumbai India and donated by Novartis through the WHO Global 
Drug Facility (GDF) that monitors the quality of TB drugs according to stringent WHO 
standards. Patients with a body weight above 50 kg daily received four FDC tablets daily 
(i.e. 300 mg isoniazid, 600 mg rifampicin, 1600 mg pyrazinamide and 900 mg ethambutol), 
those below 50 kg received three FDC tablets daily (i.e. 225 mg isoniazid, 450 mg rifampicin, 
1200  mg pyrazinamide and 675 mg ethambutol). Patients were all under community-based 
directly observed treatment. Diabetic patients either were on dietary management alone, or 
were treated with oral hypoglycaemic agents and/or injectable insulin.
sample collection. The pharmacokinetic sampling took place when patients were on TB 
treatment for at least two weeks, given the expected steady state of the pharmacokinetic 
parameters at that point. On the sampling day, serial venous blood samples were collected 
just before, and at 1, 2, 3, 4, 6, 8, 10 and 24 hours after observed tuberculosis drug intake. 
Patients fasted at least eight hours (from the preceding dinner to the next morning dose) 
before drug intake and took a standardised breakfast within 30 minutes after drug intake, 
which reflected the usual drug intake procedures in this population. The standardized 
breakfast consisted of a cup (125 ml) of tea with milk and sugar and either a small bowl of 
porridge or maandazi, a typical east African doughnut-like pasty that is rather fat. Plasma was 
separated immediately and kept frozen at -80oC until transport on dry ice to the Netherlands 
for bio-analysis. 
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bio-analysis. The total (protein bound plus unbound) plasma concentrations of isoniazid, 
acetylisoniazid, rifampicin, desacetylrifampicin, pyrazinamide and ethambutol were assessed 
by validated high-performance liquid chromatography (HPLC) as described before [22]. 
Isoniazid and acetylisoniazid were measured with liquid-liquid extraction followed by Ultra 
Performance Liquid Chromatography (UPLC) with ultraviolet (UV) detection. Accuracy was 
between 97.8% and 106.7% for isoniazid and between 98.0% and 108.9% for acetylisoniazid, 
dependent on the concentration level. The intra- and inter-assay coefficients of variation 
were less than 13.4 % and less than 3.2% (dependent on the concentration) over the range 
of 0.05-15.1  mg/L for isoniazid; and less than 4.2% and less than 5.7% over the range of 
0.16-16.2 mg/L for acetylisoniazid. Lower limits of quantification were 0.05 mg/L for isoniazid 
and 0.16 mg/L for acetylisoniazid. Isoniazid and acetylisoniazid containing samples were stable 
(<5% loss) for at least 12 months at -80oC.
Pharmacokinetic analysis. Pharmacokinetic evaluations were performed using non-
compartimental methods in WinNonLin Version 4.1 (Pharsight Corp., Mountain View, California 
US). The highest observed plasma concentration was defined as C
max
 with the corresponding 
sampling time as T
max
. The area under the plasma concentration-time curve (AUC
0-24h
) was 
calculated using the linear/log-trapezoidal rule from zero up to the last concentration at 24h 
(C
last
). The terminal log-linear period (log C versus t) was based on the last data points (at least 
three). The absolute value of the slope (β / 2.303, in which β is the first order elimination rate 
constant) was calculated using linear regression analysis. The elimination half-life (t
1/2
) was 
calculated as 0.693/β. The apparent clearance of the drug (CL/F; in which F is bioavailability) 
was calculated as dose/AUC
0-24h
 and the apparent volume of distribution (V
d
/F) was calculated 
as (CL/F)/β. 
Reference ranges for Cmax values were 3-5 mg/L for isoniazid, 8-24 mg/L for rifampicin, 
20-50 mg/L for pyrazinamide and 2-6 mg/L for ethambutol [23]. 
The acetylator status for isoniazid was determined phenotypically by calculating the 
metabolic ratio of acetylisoniazid concentration over isoniazid concentration at 3 hours post 
dose. Patients with a ratio above 1.5 were considered fast or intermediate metabolisers; patients 
with a ratio below 1.5 were slow metabolisers [24].
statistical analysis. Demographic data were presented as mean plus standard deviation when 
normally distributed and as median plus interquartile range when data were not normally 
distributed. Continuous variables were compared between diabetic and non-diabetic TB 
patients using a two-sample t-test or Mann-Whitney U test. Associations between numerical 
variables were determined using parametric correlation (Pearson’s correlation) when data 
were normally distributed, and non-parametric correlation (Spearman’s Rho correlation) when 
not normally distributed. 
For pharmacokinetic parameters AUC
0-24
, C
max
, volume of distribution, clearance, and 
elimination half-life, analysis was performed on logarithm transformed data and geometric 
means were presented. The differences in these parameters between diabetic and non-
diabetic TB patients were calculated with an independent sample T-test on the transformed 
data. Tmax values were not transformed and were compared with the Mann-Whitney U test. 
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Pearson Chi-square test was used to determine the difference in proportions of patients who 
reached reference peak plasma concentrations of the TB drugs.
Univariate analyses were performed in the whole group to assess the effects of age, sex, 
body weight, dose in mg/kg, HIV status, acetylator status, fasting plasma glucose and HbA1con 
the AUC
0-24h
 and C
max
 of the four first-line TB drugs.
A multivariate analysis with multiple linear regression was used to assess the effects of the 
explanatory variables DM, age, sex, body weight, dose in mg/kg, HIV status and acetylator status 
on the log-transformed AUC
0-24h
 and C
max
 of the TB drugs by using the stepwise method with 
Probability-of-F-to-enter ≤ 0.05 and Probability-of-F-to-remove ≥ 0.10. In addition, a second 
regression analysis was performed in which fasting blood glucose was assessed as independent 
variable for the log-transformed AUC
0-24h
 and C
max
 values. The presence of DM and fasting blood 
glucose cannot be assessed in one model simultaneously as these variables are highly correlated. 
All statistical analyses were performed using SPSS version 20 (SPSS Inc, Chicago II). 
results
demographics/ baseline characteristics. We enrolled 40 subjects, 20 diabetic and 20 non-
diabetic TB patients. For pharmacokinetic (PK) analysis, the data of one subject (with DM) were 
excluded because the patient had high concentrations for all TB drugs at time zero hours, 
indicating that the patient had incorrectly taken the drugs at home prior to pharmacokinetic 
sampling. Patient characteristics of the remaining 39 patients are summarized in table 1. Of 
these, 78.5% were male, 35% were HIV infected and the median age was 41 yrs. One patient had 
extrapulmonary TB (TB of the spine), all others had pulmonary TB. 
There was no difference in body weight, body mass index (BMI), sex, and dose per kg of 
the TB drugs between diabetic and non-diabetic TB patients. Diabetic TB patients were older 
than non-diabetic TB patients (median age 49 versus 38 years). As expected, the median 
fasting blood glucose (FBG) was higher for diabetic TB patients than non-diabetic TB patients 
(15.9 versus 6.95 mmol/L). Common presenting symptoms are also shown in table. All diabetic 
patients had glycosylated haemoglobin (HbA
1c
; range, 65 to 147 mmol/mol) above the target 
limit of 53 mmol/mol for good control.
All but one of the diabetic patients knew they had DM, and were enrolled to a diabetic 
clinic. Three of the diabetic patients were not currently on antidiabetic medications; two 
were on insulin, 11 on metformin, 10 on chlorpropamide, and six on glibenclamide. Other co-
administered drugs were not known to interact with anti-TB drugs (data not shown). 
Pharmacokinetic parameters. Table 2 shows the average of PK parameters in diabetic and 
non-diabetic TB patients and figure 1 compares the plasma concentration-time curves of TB 
drugs between diabetic and non-diabetic TB patients.
The average AUC
0-24h
 for rifampicin was 25% (p=0.052) lower in diabetic TB patients. 
Rifampicin clearance showed a trend for an increase (p=0.06) and its elimination half-life was 
significantly shorter in diabetic versus non-diabetic TB patients. In addition, time to maximum 
concentration (T
max
) of rifampicin was longer in diabetic (2.1h; IQR 1-3) than non-diabetic TB 
patients (1.08h; IQR 0.98-2.05, p=0.027, table 2). 
115
6
DIATUB STUDY
The average AUC
0-24h
 for isoniazid was 49% (p=0.015) lower in diabetic TB patients. 
Compared to non-diabetics, diabetic TB patients also had significantly lower values of the 
isoniazid maximum concentration (C
max, 
p = 0.01). Both clearance and volume of distribution 
were increased in diabetics compared to non-diabetics (table 2). 
table 1. Characteristics of 20 tuberculosis (TB) and 20 TB-diabetes (TB-DM) patients in northern 
Tanzania
Parameter
Measure
TBDM TB p value
Sex (female, n[%]) 5[25%] 4[20%] 0.705**
Age (years; median[IQR]) 49(40-56) 38(30-42) 0.001*
Body weight (kg; mean[SD]) 58.7(12.3) 55.7(6.4) 0.346
BMI(kg/m2 mean[SD]) 20.6(4.0) 19.5(2.4) 0.293
TB drugs
Number of FDC tablets, n[%]
3FDCs 3[15%] 5[25%]
4FDCs 17[85%] 15[75%] 0.695**
Dose per kg (mg/kg, mean[SD])
Rifampicin 9.8(1.4) 10.4(0.9) 0.118
Isoniazid 4.9(0.7) 5.2(0.5) 0.118
Pyrazinamide 25.5(3.8) 27.8(2.4) 0.029
Ethambutol 18(2.5) 19.1(1.7) 0.118
FBG(mmol/L, median(IQR)) 15.9(13.1-18) 6.95(5.7-7.4) <0.001*
HIV positive, n(%) 7(35%) 7(35%) -
HBA1c(mmol/mol; mean[SD]) 106.4[22.7] - -
Diabetes treatment
Dietary only 3(15%)
Metformin 11(55%)
Chlorpropamide 10(50%)
Glibenclamide 6(30%)
Presenting symptoms, n(%)
Cough 14(70%) 15(75%)
Night sweats 14(70%) 17(85%)
Weight loss 17(85%) 20(100%)
Chest pain 2(10%) 2(10%)
Anorexia 2(10%) 4(20%)
Shortness of breath 2(10%) -
Fever 7(35%) 4(20%)
Hemoptysis 3(15%) 1(5%)  
*test performed is Mann-Whitney U
**test performed is chi square
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table 2. Pharmacokinetic parameters of tuberculosis drugs in Tanzanian diabetic and non-diabetic 
TB patients in northern Tanzania (continued)
Drug/PK parameter
Value for group    
TB-DM TB
Ratio of TB-DM to 
TB value[95%CI] P
Rifampicina
AUC
0-24
, h*mg/L 29.91[1.77] 39.91[1.26] 0.75[0.56-1.03] 0.052
Cmax, mg/L 7.92[1.71] 8.92[1.28] 0.89[0.67-1.17] 0.384
Proportion with Cmax below reference 
range, n[%]c
9[47.4] 7[35.0] - 0.433
Tmax, h[IQR]b 2.12[1.03-3.30] 1.08[0.98-2.05] - 0.027
T1/2, h 1.44[1.30] 1.80[1.38] 0.80[0.66-0.97] 0.026
Vz, L 38.74[1.79] 37.30[1.31] 1.04[0.77-1.40] 0.798
CL, L/h 18.60[1.74] 14.40[1.24] 1.29[0.98-1.71] 0.072
Desacetylrifampina
AUC
0-24
, h*mg/L 3.97[1.81] 4.90[1.45] 0.81[0.57-1.16] 0.240
Cmax, mg/L 0.73[1.97] 0.91[1.32] 0.80[0.56-1.14] 0.206
T1/2, h 1.61[1.44] 2.00[1.30] 0.81[0.64-1.01] 0.066
Desacetylrifampin/rifampin ratiod
AUC 0.125[0.057] 0.133[0.035] - 0.672
Cmax 0.100 [0.039] 0.107[0.029] - 0.576
Isoniazida
AUC
0-24
, h*mg/L 5.41[2.61] 10.61[1.94] 0.51[0.30-0.87] 0.015
Cmax, mg/L 1.65[2.15] 2.77[1.45] 0.60[0.40-0.89] 0.013
Proportion with Cmax below reference 
range, n[%]c
14 [73.7] 11  [55.0] - 0.224
Tmax, h[IQR] b 1.03[0.97-2.08] 1.07[0.98-1.19] - 0.855
T1/2, h 2.55[1.51] 2.54[1.61] 1.00[0.75-1.34] 0.985
Vz, L 188.78[2.26] 99.19[1.26] 1.90[1.27-2.85] 0.003
CL, L/h 51.31[2.78] 26.89[1.84] 1.91[1.09-3.32] 0.024
Acetylisoniazida
AUC
0-24
, h*mg/L 21.70[2.00] 22.56[1.50] 0.96[0.67-1.39] 0.831
Cmax, mg/L 2.29[2.29] 2.18[1.80] 1.05[0.66-1.67] 0.831
T1/2, h 5.50 [1.76] 5.03[1.49] 1.10[0.80-1.50] 0.562
Acetylisoniazid/isoniazid ratio
AUC 4.01 [3.6] 2.125[2.75] 0.53 [0.25-1.12] 0.095
Cmax 1.40[3.36] 0.788[2.3] 0.57 [0.29-1.11] 0.095
AUC
0-24h
 and C
max
 of pyrazinamide showed a trend to lower exposure in diabetic versus non-
diabetic TB patients, yet all PK parameters for pyrazinamide as well as for ethambutol were not 
significantly different between diabetic and non-diabetic TB patients. 
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With respect to metabolite desacetylrifampicin, there appeared to be no statistically 
significant difference in average AUC
0-24h
 and C
max
 values or corresponding desacetylrifampicin / 
rifampicin ratios between diabetics and nondiabetics. Despite the lower exposure to isoniazid 
in diabetics, the AUC
0-24h
 and C
max 
values for metabolite acetylisoniazid were similar in diabetics 
and nondiabetics, resulting in nonsignificantly higher acetylisoniazid/isoniazid ratios in 
diabetics versus nondiabetics. The proportion of patients with maximum concentrations (C
max
) 
of rifampicin and isoniazid below reference ranges was higher in diabetic than in non-diabetic 
TB patients (table 2), yet the distribution of these proportions was not statistically different 
between diabetic and non-diabetic TB patients. For pyrazinamide and ethambutol all patients 
had C
max 
within reference ranges. Based on the metabolic ratio of acetylisoniazid concentration 
over isoniazid concentration at 3 hours post dose, acetylator status of 37 patients was 
determined. Nineteen (51.4%) patients were found to be fast acetylators. Breaking them down 
by diabetes group, 55.6% of the diabetic versus 47.4% of the non-diabetic TB patients were fast 
acetylators. The difference was not statistically significant (chi square = 0.248, p value 0.618).
table 2. Pharmacokinetic parameters of tuberculosis drugs in Tanzanian diabetic and non-diabetic 
TB patients in northern Tanzania (continued)
Drug/PK parameter
Value for group    
TB-DM TB
Ratio of TB-DM to 
TB value[95%CI] P
Pyrazinamidea
AUC
0-24
, h*mg/L 289.63[1.41] 344.16[1.29] 0.84[0.69-1.02] 0.083
Cmax, mg/L 34.47[1.23] 38.19[1.17] 0.90[0.80-1.02] 0.090
Proportion with Cmax below reference 
range, n[%]c
0 0 -
Tmax, h[IQR] b 1.12[1.00-3.00] 1.07[0.97-1.76] - 0.252
T1/2, h 5.35[1.36] 6.28[1.45] 0.85[0.68-1.07] 0.154
Vz, L 39.54[1.37] 40.35[1.33] 0.98[0.81-1.19] 0.832
CL, L/h 5.12[1.45] 4.45[1.27] 1.15[.094-1.41] 0.170
Ethambutola
AUC
0-24
, h*mg/L 19.64[1.57] 20.24[1.22] 0.97[0.77-1.22] 0.789
Cmax, mg/L 3.15[1.56] 3.31[1.31] 0.95[0.75-1.21] 0.672
Proportion with Cmax below reference 
range, n[%]c
0 0 -
Tmax, h[IQR] b 2.00[1.00-3.00] 1.98[0.99-2.09] - 0.317
T1/2, h 8.59[1.65] 9.58[1.20] 0.90[0.70-1.16] 0.384
Vz, L 643.74[1.67] 719.03[1.24] 0.90[0.69-1.16] 0.394
CL, L/h 51.92[1.62] 52.04[1.17] 1.00[0.78-1.27] 0.985
aData are presented as geometric mean(standard deviation) unless stated otherwise
bBy Mann-Whitney U test
cBy Pearson’s chi-square test
dData are presented as mean(standard deviation). An independent-samples T-test was used for testing.
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figure 1. Geometric mean steady-state plasma concentration-time profiles of rifampicin (A), 
isoniazid (B), pyrazinamide (C), and ethambutol (D) in TB-DM patients (solid line graph, n=19) and TB 
only patients (dotted graph,  n=20)
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univariate analysis. Analysis of the association between PK parameters AUC
0-24 
and C
max
 of the 
TB drugs and other possible explanatory variables (age, sex, body weight, dose per kilogram, 
HIV status, acetylator status, fasting blood glucose, HbA1c) showed that age significantly 
correlated only with C
max
 of isoniazid (Spearman’s rho = -0.392, p = 0.014). Between men and 
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Figure 1: Geometric mean steady-state plasma concentration-time profiles of rifampicin 
  (A), isoniazid (B), pyrazinamide (C), and ethambutol (D) in TB-DM patients 
  (solid line graph, n=19) and TB only patients (dotted graph,  n=20
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Figure 1: Geometric mean steady-state plasma concentration-time profiles of rifampicin 
  (A), isoniazid (B), pyrazinamide (C), and ethambutol (D) in TB-DM patients 
  (solid line graph, n=19) and TB only patients (dotted graph,  n=20
figure 1. (Continued)
women, rifampicin C
max
 (geometric means 7.8 versus 10.7 mg/L, p = 0.048) and pyrazinamide C
max
 
(35.1 versus 40.7 mg/L, p =0.036) were different. Body weight and dose per kilogram showed no 
correlations with AUC
0-24 
and C
max
 of the TB drugs. HIV positive and negative patients only differed 
with respect to the C
max 
of pyrazinamide (geometric means 39.7 versus 34.7 mg/L, p = 0.033). Fast 
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acetylators had significantly lower AUC
0-24 
(geometric means 4.1 versus 16.2 h*mg/L, p = <0.001) 
and C
max
 (1.6 versus 3.1 mg/L, p = 0.001) valuesof isoniazid than slow acetylators.
Fasting blood glucose showed a significant correlation with AUC
0-24 
of rifampicin 
(Spearman’s rho = -0.406, p =0.013) and with AUC
0-24
 (Spearman’s rho = -0.376, p =0.022) and 
C
max
 (Spearman’s rho = -0.421, p =0.009) of isoniazid. For the diabetic group, HbA
1c 
did not show 
a significant correlation with any of the PK parameters of rifampicin, isoniazid, pyrazinamide, 
and ethambutol. 
multivariate analysis. Multiple regression with the stepwise method and diabetes mellitus, 
age, sex, dose in mg/kg, HIV status and acetylator status as explanatory variables yielded 
significant models with regression equations that only contained diabetes mellitus as 
explanatory variable for log AUC
0-24
 and log C
max
 of rifampicin, as well as for log AUC
0-24
 and 
log C
max 
of pyrazinamide. Diabetes mellitus and acetylator status were the only variables that 
remained in regression equations for log AUC
0-24
 and log C
max
 of isoniazid. 
Similarly, multiple regression analyses with fasting blood glucose instead of DM yielded 
fasting blood glucose as a significant predictor for log AUC
0-24
 and log C
max
 of rifampicin, 
pyrazinamide and isoniazid as well as acetylator status as a predictor for log AUC
0-24
 and log 
C
max
 of isoniazid. 
These results show that the effect of diabetes mellitus and the effect of fasting blood 
glucose on the pharmacokinetic parameters of TB drugs remained (or even became) significant 
when other explanatory variables were taken into consideration.
disCussion
This is the first report describing the pharmacokinetic (PK) parameters of tuberculosis (TB) drugs 
in diabetic and non-diabetic TB patients using intensive PK sampling in an African population. 
We have found a clear, nearly significant trend for a decrease in AUC
0-24 
of rifampicin in diabetic 
versus nondiabetic TB patients. Similarly, AUC
0-24 
and C
max
 of isoniazid were significantly 
decreased in diabetic TB patients. The effect of DM correlated with a similar effect of fasting 
blood glucose on the exposure to these TB drugs. In multivariate analyses, the effects of DM 
and fasting blood glucose remained significant and acetylator status was another predictor of 
the AUC
0-24 
and C
max 
of isoniazid 
Similar studies in Indonesia and Peru have shown contradicting results [16-18]. The first 
Indonesian study [16] concluded that DM was associated with a strong decrease in plasma 
concentrations of rifampicin whereas a follow up study in the same population [17], and a 
Peruvian study [18] revealed no significant difference in exposure to TB drugs between diabetic 
and non-diabetic TB patients. 
Our study was carried out in a distinctively different ethnic population (Africans) and 
involved intensive (9 sampling points over 24 hour interval) PK sampling. We analysed all four 
standard TB drugs in 40 patients with validated methods. In the second Indonesian study, 
the authors implicate the low levels of TB drugs seen in their first study to weight differences 
between diabetic and non-diabetic TB patients [17]. Although this is still a clinically relevant 
finding, they matched their patients for body weight in their follow-up study to disentangle 
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the effects of weight and DM per se. Although we did not match our patients for body weight, 
the distribution of body weight (and therefore drug dose per kilogram weight) were the same 
between diabetic and non-diabetic TB patients (table 1); and besides that body weight was 
no predictor of exposure to TB drugs in our multiple linear regression analyses. There is no 
evidence that antidiabetic drugs lower the concentration of TB drugs [25]. Therefore, we 
believe the observed differences in PK parameters are due to diabetes mellitus. This is further 
substantiated by similar associations that we found between fasting blood glucose levels and 
exposure to rifampicin and isoniazid in our population of diabetic and non-diabetic patients.
Unlike previous studies, for the first time, we have performed the analysis of isoniazid in 
diabetic and non-diabetic TB patients and it is actually isoniazid that was found to be most 
adversely affected in its values for AUC
0-24
 and C
max
. Next to diabetes mellitus, acetylator status of 
isoniazid appeared to be a predictor of the AUC
0-24
 and C
max
 of isoniazid. It should be noted that 
we realize that we evaluated the effect of DM on the pharmacokinetics of isoniazid and at the 
same time used a phenotyping method (which is based on relative exposure to acetylisoniazid 
and isoniazid) to assess the acetylator status. Theoretically, an incidental overrepresentation of 
(genotypic) fast acetylators among the diabetic TB patients might explain the lower exposure 
to isoniazid in this group, and this might by concealed by an effect of DM on the phenotypic 
assessment of acetylator status. Therefore, a genotypic assessment of the acetylator status of 
isoniazid is currently planned.
Although we cannot readily translate suggested diabetes-mediated changes in 
pharmacokinetics of particular drugs to TB drugs, documented mechanisms suggest that 
diabetes influences the pharmacokinetics of various drugs by affecting (i) absorption, due to 
changes in subcutaneous and muscle blood flow and delayed gastric emptying; (ii) distribution, 
due to non-enzymatic glycation of albumin; (iii) biotransformation, due to differential regulation 
of enzymes involved in drug biotransformation and drug transporters; and (iv) excretion, due 
to nephropathy [8,9,26,27]. As to rifampicin, the current study suggests that the clearance of 
rifampicin may be increased by DM, yet this appears not to be mediated by an effect on the 
metabolism of rifampicin into desacetylrifampicin (table 2). For isoniazid, both clearance and 
volume of distribution were increased in diabetic TB-patients, ultimately resulting in a relative 
increase in the formation of metabolite acetylisoniazd.  
Evidence has shown that diabetic patients who get TB have poor treatment response to TB 
treatment and poor treatment outcome [28,29]. Moreover accumulating evidence suggests 
that total exposure (AUC) and maximum concentration (C
max
) of TB drugs are very important for 
efficacy of the drugs [30]. Since increasing the dose of TB drugs may result in increased plasma 
concentrations of the drugs and improved treatment outcome [31], individualization of the 
dosages and therapeutic drug monitoring in diabetic TB patients are necessary. However because 
therapeutic drug monitoring is not feasible in developing countries, increasing the doses of TB 
drugs (especially rifampicin and isoniazid) in the whole population of diabetic patients seems to 
be a better strategy so as attain average plasma concentrations that are associated with good 
treatment outcome in the majority of patients. To this end, higher doses of TB drugs have been 
shown to be safe and tolerable [22,31-33]. Besides our findings and conclusions, further studies 
in African and other ethnic groups are required to confirm our hypothesis.
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Our study findings may be limited by unequal age distribution between the groups, the 
diabetic TB group having on average older patients than the TB group. Age has been found not 
to be associated with pharmacokinetics of TB drugs in many studies [34,35]. Similarly we did not 
match the groups for sex and weight; however the distribution of these parameters was the 
same in the two groups. In addition, age, gender and dose/kg were no significant predictors 
in multiple regression analyses. The number of patients (n=39) may be high for a PK study with 
intensive PK sampling, yet this number is relatively low to perform regression analyses with 
several possible explanatory variables. 
In summary, we have shown a reduction in isoniazid plasma concentrations and a clear 
trend towards a reduction in exposure to rifampicin in Tanzanian diabetic patients with TB. We 
conclude that diabetes disease is likely to be responsible for the observed effects. More African 
and other studies are needed to confirm our findings, and higher doses of the drugs need to 
be considered.
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summary
Data on antituberculosis drug-induced hepatotoxicity in sub Saharan Africa are limited, probably 
because liver function tests are not carried out routinely during tuberculosis treatment in most 
African countries. 
We monitored the liver function of 112 Tanzanian hospitalized pulmonary tuberculosis 
patients during the first two months (i.e. the intensive phase) of tuberculosis treatment. The 
rate of hepatotoxicity in our study was 0.9% (95% CI 0.04 - 4.3%). It is encouraging to find a 
lower rate of antituberculosis drug-induced hepatotoxicity than one would expect based on 
the high prevalence of risk factors such as HIV and hepatitis B.
keywords: antitubercular treatment, adverse reactions, liver toxicity, Africa
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introduCtion
With nine million new cases and almost two million deaths in 2007, tuberculosis (TB) remains a 
major cause of illness and death worldwide. The highest incidence rate is found in Africa, due to 
the HIV epidemic. TB is the leading cause of death among HIV patients [1].
Standard TB treatment consists of a six-month course with isoniazid, rifampicin, pyrazinamide 
and ethambutol. In a clinical setting, this regimen is able to cure more than 95% of the patients 
with active TB caused by normally sensitive Mycobacterium tuberculosis. However, in practice 
cure rates are lower. Adverse effects have a negative impact on therapy adherence, which may 
decrease treatment success rates and could eventually enhance treatment failure, relapse or 
the emergence of drug-resistance [2-4].
Isoniazid, rifampicin and pyrazinamide are potentially hepatotoxic drugs. They are 
metabolised in the liver, making this organ vulnerable for injury. Antituberculosis drug-induced 
hepatotoxicity (ATDH) is a serious adverse effect that can be fatal if therapy is not interrupted 
in time [5,6]. ATDH occurs in 2 to 28% of the tuberculosis patients; the variation is large due to 
different definitions of hepatotoxicity and differences between the populations studied [6].
Data on ATDH in sub Saharan Africa are limited, probably because liver function tests are 
not carried out during tuberculosis treatment in most African countries. ATDH is reported to 
be less than 2%, but liver function was not closely monitored in these studies [7-9].
It is important to have a valid estimation of the incidence of ATDH in this region. It may help 
to explain low cure rates and is particularly relevant considering the continued introduction 
of antiretroviral treatment, which enhances hepatotoxicity when combined with tuberculosis 
drugs [10]. In addition, new tuberculosis treatment regimens containing moxifloxacin and a 
high dose of rifampicin are currently being tested in sub-Saharan Africa. 
To estimate the rate of ATDH in an African population, we closely monitored the liver 
function in Tanzanian hospitalized patients during the intensive phase of TB treatment.
methods
This study was conducted between April 2007 and July 2008 at the Kibong’oto National 
Tuberculosis Hospital in SanyaJuu, Northern Tanzania. All adults who were not on antiretroviral 
therapy before starting tuberculosis treatment, were eligible for participation. The study was 
approved by the Tanzanian National Institute for Medical Research and all patients gave written 
informed consent. 
Tuberculosis was treated according to guidelines of the Tanzanian National Tuberculosis 
and Leprosy Programme. During the intensive phase of treatment, patients with a body weight 
<50 kg received 225 mg isoniazid, 450 mg rifampicin, 1200 mg pyrazinamide and 675 mg 
ethambutol daily (three fixed-dose combination [FDC] tablets, Novartis®) and patients >50 kg 
received 300 mg isoniazid, 600 mg rifampicin, 1600 mg pyrazinamide and 900 mg ethambutol 
daily (four FDC tablets). All patients received full facility-based directly observed therapy 
(DOT), as they were admitted in the hospital during the intensive phase of treatment.
Demographic data was collected prior to treatment. Patients were tested for HIV (SD 
BioLineTM [HIV rapid test]; if positive then confirmed by DetermineTM; Abbott). Hepatitis B 
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surface antigen (HbsAg) and hepatitis C virus antibodies were detected with a qualitative rapid 
chromatographic immunoassay (ACON Laboratories Inc, San Diego, USA). 
Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin 
were determined at baseline and after 2, 4, 6 and 8 weeks of TB treatment, using the Roche 
Reflotron® (Kerkhof Medical Service, the Netherlands). Hepatotoxicity was defined as serum 
ALT > three times the upper limit of normal (ULN) in the presence of hepatotoxicity symptoms 
or ALT > 5x ULN without symptoms of hepatotoxicity.6 The reference values were 41 U/l for ALT, 
40 U/l for AST and 17 µmol/L for bilirubin. Every two weeks, a research nurse screened the 
patients for symptoms of hepatotoxicity ( jaundice, abdominal pain, nausea and vomiting). 
Parameters that were presented as mean (standard deviation; SD) when normally 
distributed or median (inter-quartile range; IQR) if not normally distributed. Statistical analysis 
were performed using SPSS for Windows (version 14.0; SPSS). 
results
We included 117 patients in this study. Five patients were excluded from analysis: three 
patients died in the first week of treatment, for reasons other than possible drug-induced 
hepatotoxicity and two patients withdrew from the study immediately after baseline. Of the 
112 patients included in the analysis, 98 (87.5%) completed the two month study period. Eleven 
patients (9.8%) were HIV positive and six of them were started antiretroviral treatment during 
the intensive phase of TB treatment. Table 1 shows the patients’ characteristics. 
None of the patients developed hepatotoxicity during the first two months of TB treatment. 
Seven patients (6.3%) developed slight ALT increases, all less than 3 times the ULN. The highest 
ALT observed was 87 U/L; the median of peak ALT values during the study period was 12 U/L 
(IQR 9-21 U/L). The highest AST was 64 U/L, with a median peak value of 17 U/l (IQR 12-22 U/L). 
Table 2 shows the liver biochemistry at baseline and during the intensive phase of treatment. 
One patient developed hepatotoxicity symptoms in the sixth week of treatment: she 
experienced serious abdominal pain, nausea and vomiting and after intake of the TB drugs 
and got discoloration of the conjunctives after drug-intake which disappeared again after a 
few hours. Because serum ALT and bilirubin were completely normal, this patient did not have 
hepatotoxicity according to our definition. She had lost a lot of weight during treatment (from 
54 kg to 34 kg) and was using 4 FDC tablets a day (for > 50 kg). Treatment was interrupted and 
relieved the symptoms, after which she continued with 3 FDC tablets. 
Three patients developed hyperbilirubinemia (bilirubin levels > 2.5 times ULN). ALT and AST 
levels were within the normal range and jaundice was not reported in these patients. Fourteen 
patients (12.5%) dropped out during the study. Nine patients withdrew because they refused to 
give any more blood samples, due to cultural believes concerning blood; three after week 2, 
four after week 4 and two after week 6 of treatment. 
disCussion
This is the first study to date where the liver function is closely monitored during TB treatment in 
a sub-Saharan African population. None of our 112 Tanzanian pulmonary TB patients developed 
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hepatotoxicity during the intensive phase of TB treatment. One patient developed serious 
symptoms of hepatotoxicity. Although her liver biochemistry remained normal, the symptoms 
could have been caused by the TB drugs. Therefore, the rate of hepatotoxicity in our study was 
0.9% (95% CI 0.04 - 4.3%) at the most. 
Clinical trials with moxifloxacin and a high dose of rifampicin are in preparation in the 
sub Saharan African region. Rifampicin-induced hepatotoxicity may be dose-related [11]. 
It is encouraging to observe that the rate of TB drug-induced hepatotoxicity is lower than 
expected in an area with HIV and hepatitis B. Although case reports of moxifloxacin-induced 
hepatotoxicity have been published, moxifloxacin is considered safe and is not expected to 
increase the risk of hepatotoxicity [12,13].
Our findings are in line with previous reports that indicate a low rate of ATDH in sub Saharan 
African TB patients. Recently, a study from South Africa reported that only two out of 400 TB 
patients (0.5%) developed hepatotoxicity during treatment [14]. In a trial on cotrimoxazole 
Table 1. Patient characteristics
N = 112
Age, median years (IQR) 32 (27-40)
Male sex, n (%) 88 (78.6%)
weight, mean kg (SD) 52.4 (7.6)
HIV, n (%)
Positive 11 (9.8%)
Negative 90 (80.4%)
Unknown 11 (9.8%)
Hepatitis B, n (%)
Positive 8 (7.1%)
Negative 88 (78.6%)
Unknown 16 (14.3%)
Hepatitis C, n (%)
Positive 3 (2.7%)
Negative 93 (83.0%)
Unknown 16 (14.3%)
Study outcome, n (%) 
Study completed 98 (87.5%)
LTF between week 2 and 4 3 (2.7%)
LTF between week 4 and 6 5 (4.5%)
LTF between week 6 and 8 6 (5.4%)
Concomitant drugs, n (%)
Antiretroviral drugs * 6 (5.4%)
Cotrimoxazole 8 (7.1%)
Legend. LTF = Lost to follow-up; IQR = inter quartile range; SD = standard deviation; * Antiretroviral treatment in 
Tanzania: Combivir® (zidovudine + lamivudine) + efavirenz. 
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prophylaxis in Malawian HIV-positive pulmonary TB patients, about 2% of the patients 
developed hepatotoxicity during TB treatment [7]. Since cotrimoxazole can be hepatotoxic in 
patients with AIDS, the ATDH rate may even be slightly overestimated [15]. Two studies from 
Congo and Uganda reported no hepatotoxicity and 1% hepatotoxicity, respectively, during 
standard TB treatment [8,9]. Even though liver function was not routinely monitored and 
treatment was not directly observed, this indicates that hepatotoxicity during TB treatment is 
not a big problem. 
It is difficult to explain why the hepatotoxicity rate is low in sub-Saharan Africa despite the 
prevalence of risk factors such as HIV and hepatitis B. Hepatotoxicity rates of 13-15% have been 
reported from such as India and Iran [16]. Our study population was characterised by a low 
proportion of women, a relatively young age, 10% HIV and 7% hepatitis B carriers. Old age, 
female sex, malnutrition, HIV, alcohol usage, underlying liver disease such as hepatitis and 
several genetic polymorphisms are risk factors for ATDH [5,6]. 
Several genetic polymorphisms in drug metabolising enzymes have been associated 
with TB drug-induced hepatotoxicity, such as slow acetylator status (N-acetyltransferase 2), 
cytochrome P450 2E1 c1/c1 genotype and a glutathione S-transferaseM1 homozygote null 
genotype [17]. Slow and intermediate acetylators are highly prevalent in African populations 
[18,19]. Almost 95% of the black South Africans had a CYP2E1 c1/c1 genotype[20] and 33% of the 
Tanzanians have a GSTM1 null genotype [21]. These studies suggest that ‘high risk genotypes’ 
are prevalent amongst Africans, which would contradict the low rate of hepatotoxicity found 
in our study.
We monitored the liver function for two months only. Even though ATDH most often 
occurs in the first two months of treatment [6], this may have slightly underestimated the 
hepatotoxicity rate. Our study was limited to hospitalised patients only, which could have 
overestimated the rate of hepatotoxicity, since generally higher rates of hepatotoxicity are 
seen in hospitalised patients. To estimate the rate of hepatotoxicity in sub Saharan African 
patients more accurately, a similar study could be performed in a larger group of TB patients 
that are not hospitalised. 
Ten percent of the patients from our study were HIV positive; six of them had started 
antiretroviral therapy during TB treatment (zidovudine, lamivudine and efavirenz). None of 
Table 2. Liver biochemistry during the intensive phase of treatment
Liver function parameter ALT AST Bilirubin
Baseline 
Median (IQR) 10 U/l (7-15) 13 U/l (10-18) 11 µmol/l (9-16)
Maximum 53 U/l 91 U/l 43 µmol/l
Intensive phase *
Median (IQR) 12 U/l (9-21) 17 U/l (12-22) 13 µmol/l (10-19)
Maximum 87 U/l 64 U/l 47 µmol/l
Legend: ALT = alanine aminotransferase; AST = aspartate aminotransferase; Bilirubin = total bilirubin; 
* based on highest value measured during the intensive phase of TB treatment; IQR = inter quartile range
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them developed any increase in ALT or AST. Concurrent TB-HIV therapy is often complicated 
by overlapping toxicities and drug-drug interactions.10 Drug toxicity, including hepatotoxicity, 
is a major cause of TB or HIV treatment interruption during combined TB-HIV treatment [22]. 
Nevirapine is the most hepatotoxic non-nucleoside reverse transcriptase inhibitor [23]. The 
majority of the nucleoside reverse transcriptase inhibitors (e.g. didanosine and stavudine) are 
potentially hepatotoxic as and hepatotoxicity has been described for some protease inhibitors 
(e.g. ritonavir, indinavir and saquinavir). 
The worldwide incidence of hepatotoxicity during antiretroviral treatment ranges from 
2 to 18% [24]. In sub Saharan Africa, data are conflicting. In the study of Marks et al (that 
wasmentioned before) the rate of hepatotoxicity during TB treatment in HIV positive (n=141) 
and HIV negative (n=240) TB patients was low (0.5%), while 16.3% of the HIV positive patients 
received antiretroviral treatment [14]. These findings are in contrast with another South 
African study by Hoffmann et al, where 4.6% of the 868 patients that used antiretroviral drugs 
(zidovudine, lamivudine and efavirenz) developed hepatotoxicity (grade 3 or 4; i.e. ALT > 5 times 
the ULN) and where the use of TB therapy increased the risk of hepatotoxicity eightfold [25]. 
More knowledge on hepatotoxicity during combined HIV-TB treatment is warranted, since a 
significant proportion of the TB patient population in sub-Saharan Africa is HIV positive and 
would need to use combined TB-HIV treatment [26]. A suggestion for future research would 
be to get more insight in country specific rates of hepatotoxicity during TB treatment and the 
effect of HIV and antiretroviral therapy by using data of the national TB programs. 
International guidelines recommend alanine aminotransferase (with or without bilirubin) 
for the monitoring of hepatotoxicity [5,6]. Regarding the low rate of TB drug-induced 
hepatotoxicity found in our study as well as other studies, routine liver function monitoring 
will not be necessary in sub-Saharan Africa. Nevertheless, it remains important that TB patients 
receive clear instructions on possible signs and symptoms of hepatotoxicity and they should be 
instructed to visit their doctor in case such symptoms occur. 
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abstraCt
objectives: Fluoroquinolones have a potential role in shortening tuberculosis (TB) treatment 
duration. They are currently used in the treatment of other infections. This has raised concerns 
about mycobacterial resistance development. The current study evaluates the sale of 
fluoroquinolones (among other antibacterials) in Moshi, Tanzania, one of the world’s countries 
with the highest burden of TB.
methods: Trained pharmacy assistants registered the sale of fluoroquinolones during 
February and March 2009 to outpatients in Moshi in all 14 pharmacies that are authorized to 
sell antibacterials for systemic use. The sale of all antibacterials of the Anatomic Therapeutic 
Chemical (ATC) J01 class was expressed in Defined Daily Doses (DDD) per 1000 inhabitants per 
day (DID). The availability of fluoroquinolones in drug outlets that are not authorized to sell 
antibacterials for systemic use, was assessed in 15 randomly selected outlets in Moshi.
results: The sale of antibacterials to outpatients in Moshi by authorized pharmacies was 
4.99 DID. The sale of fluoroquinolones was 0.63 DID (12% of total antibacterial sale). Ciprofloxacin 
was available in all 15 unauthorized drug outlets. 
Conclusions: The substantial sale of the fluoroquinolones by authorized pharmacies and 
the wide availability of fluoroquinolones in unauthorized drug outlets in Moshi constitute a 
challenge to the use of fluoroquinolones in TB treatment in Tanzania. Control of antibacterial 
use in Tanzania requires the implementation of surveillance systems for antibacterial use and 
resistance, and adequate restriction of antibacterial sale by authorized pharmacies only.
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introduCtion
Fluoroquinolones are used to treat a variety of conditions, including genitourinary, respiratory 
tract and gastrointestinal infections, sexually transmitted diseases and a number of skin, bone 
and soft tissue infections [1]. In addition, the fluoroquinolones form a promising class of drugs 
in the treatment of tuberculosis (TB) [2]. Second and third generation fluoroquinolones are 
used in the treatment of multi-drug resistant (MDR) and extensively drug resistant (XDR) TB, 
and in case of intolerance to first-line TB drugs [3]. Moreover, moxifloxacin and gatifloxacin 
are being evaluated for their potential to shorten TB treatment duration, one of the major 
strategies for TB control [2].
The use of fluoroquinolones against various infections has raised concerns about the risk of 
mycobacterial resistance development in patients who are co-infected with actively replicating 
Mycobacterium tuberculosis.[1]Importantly, reduced mycobacterial susceptibility to one 
fluoroquinolone results in reduced susceptibility to all fluoroquinolones [4].
Whereas the European Surveillance of Antimicrobial Consumption (ESAC) project [5] 
provides data on fluoroquinolone consumption in Europe and the IMS Health has collected 
similar data for the United States [6], to our knowledge no systematic data regarding 
fluoroquinolone consumption is available for sub-Saharan Africa. Evaluating the extent of 
fluoroquinolone use in this part of the world with the highest burden of TB [7] is highly relevant 
given the role of the fluoroquinolones in current and future TB treatment regimens. The 
aim of this study therefore was to systematically evaluate fluoroquinolone sale among other 
antibacterials by pharmacies in northern Tanzania. 
methods
Data were collected from February 1st 2009 until March 31st 2009 (the dry, hot season) in Moshi, 
the capital of the Kilimanjaro Region in northern Tanzania. Drug sale in Moshi is covered 
by fourteen part I pharmacies, i.e. run by a registered pharmacist and allowed to sell both 
prescription-only and over-the-counter drugs, and 105 part II pharmacies, i.e. authorized 
to sell drugs for minor conditions, but no prescription-only drugs such as antibacterials for 
systemic use [8]. All fourteen part I pharmacies, serving a total population of 170500 (Moshi 
Urban Municipality, 2009), participated in data collection. Pharmacy assistants were trained 
to register the generic name, amount and strength per unit dose of each antibacterial sold 
to outpatients, on pre-designed forms that had been tested during a one-week pilot phase. 
Antibacterials were classified in accordance with the international Anatomic Therapeutic 
Chemical (ATC) system. Only antibacterials of the ATC J01 class (antibacterials for systemic use, 
excluding antifungals, antibacterials for tuberculosis and topical antibiotics) [9] were included. 
Data collection was closely monitored by the investigators who visited the pharmacies on a 
daily basis in the first week and at least once weekly throughout the remaining period of data 
collection, and who were fulltime available by phone in case of queries. 
Data were expressed in Defined Daily Dose (DDD) per 1000 inhabitants per day (DID) [9]. To 
calculate the DID per antibacterial, the total amount (in grams) of the antibacterials sold during 
the study period was calculated first. This amount was divided by the DDD conversion factor 
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(ATC/DDD index 2009) [9]. The DID for each antibacterial was calculated by dividing the DDDs 
by 59 days (the study period) and dividing it by 170,5 (1000-inhabitants). 
To verify whether antibacterials for systemic use were indeed not available from part II 
pharmacies, fifteen randomly selected part II pharmacies (15% of all part II pharmacies) were 
visited by the investigators who requested a dose of ciprofloxacin, without referring to the 
study, but also without showing a prescription, in each pharmacy.
The study was approved by the Institutional Review Board (IRB) of the Kilimanjaro Christian 
Medical Centre (KCMC) in Moshi. 
results
In Table 1, the sale of antibacterials for systemic use (ATC J01 class) is summarized. The total 
sale of antibacterials to outpatients in Moshi was 4.99 DID. The penicillins accounted for the 
majority (2.18 DID; 44%) of antibacterials sold, followed by the quinolones (0.63 DID; 13%). A 
wide spectrum of fluoroquinolones was available, but ciprofloxacin was sold most frequently 
(74% of fluoroquinolones). Contrary to drug sale regulations, ciprofloxacin was available 
without prescription in all fifteen part II pharmacies visited. 
disCussion
To our knowledge, this is the first study in sub-Saharan Africa in which the sale of antibacterials 
(in particular of the fluoroquinolones) was evaluated thoroughly. The total sale of antibacterials 
to outpatients by authorized drug outlets was 4.99 DID in Moshi. In comparison, outpatient 
antibacterial consumption in Europe ranged from 9.8 DID in the Netherlands to 31.4 DID in 
Greece [10], and was 24.92 DID in the Unites States [6].
The dominant class of antibacterials sold to outpatients in Moshi was the penicillins (44%). 
In Europe and the United States, the penicillins also represent the most frequently used 
antibacterials (46% and 39%, respectively) [6]. The total sale of quinolones to outpatients in 
Moshi by part I pharmacies was 0.63 DID (fluoroquinolones: 0.62 DID). Outpatient quinolone 
consumption ranged from 0.25 DID in Denmark to 3.10 DID in Portugal5 and was 2.47 DID in the 
United States [6].
Given the high burden of infectious diseases in Tanzania and the limited diagnostic facilities 
resulting in empirical use of antibacterials, higher DIDs had been expected from our study. 
However, we also revealed the unregulated availability of antibacterials in part II pharmacies. 
This finding suggests that the sale of antibacterials in northern Tanzania by part I pharmacies 
is an incomplete representation of the availability of antibacterials in reality, and the actual 
antibacterial consumption in Moshi is likely to be higher than found in the current study. 
Considering the high incidence of active TB infection in Tanzania [7], the widespread 
availability of the fluoroquinolones raises concerns about mycobacterial resistance 
development. Resistance to the fluoroquinolones reduces second-line treatment options for 
drug resistant TB and will limit future use of moxifloxacin and gatifloxacin in shorter, first-line 
treatment regimens. 
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This study has some limitations. It is unknown whether the antibacterials that were sold 
were actually used by patients. The data represent a single measurement period of two months 
in a limited area only, whereas antibacterial consumption generally shows seasonal and regional 
variation [5,10]. No differentiation was made between antibacterial sale with and without 
prescription. Alarmingly, antibacterials are available in either way according to pharmacy 
assistants (personal communication).
In conclusion, the substantial and inadequately controlled sales of the fluoroquinolones in 
northern Tanzania constitute a challenge to the incorporation of the fluoroquinolones in TB 
table 1. Antibacterials sold in Moshi, presented in accordance with the ATC* classification 
(includingsubstance specification for fluoroquinolones) and expressed in Defined Daily Doses per 
1000 inhabitants per day (DID)
ATC* code Corresponding antibacterial (sub)class or substance name DID# (% of total)
J01C Penicillins 2.18 (44)
J01CA Penicillins with extended spectrum 1.39
J01CE Beta-lactamase sensitive penicillins 0.14
J01CF Beta-lactamase resistant penicillins 0.29
J01CR Combinations of penicillins 0.36
J01M Quinolones 0.63 (13)
J01MA Fluoroquinolones 0.62
J01MA02 Ciprofloxacin 0.46
J01MA06 Norfloxacin 0.04
J01MA07 Lomefloxacin 0.04
J01MA12 Levofloxacin 0.04
J01MA01 Ofloxacin 0.03
J01MA09 Sparfloxacin <0.01
J01MA03 Pefloxacin <0.01
J01MB Other quinolones 0.01
J01F Macrolides, lincosamides and streptogramins 0.61 (12)
J01A Tetracyclines 0.57 (11)
J01E Sulphonamides and trimethoprim 0.33 (7)
J01X Other antibacterials 0.31 (6)
J01XD Imidazole derivatives 0.30
J01XE Nitrofuran derivatives 0.01
J01D Cephalosporins 0.20 (4)
J01B Amphenicols 0.11 (2)
J01G Aminoglycoside antibacterials 0.05 (1)
Total 4.99 (100)
Note: *ATC, Anatomic Therapeutic Chemical classification; #DID, Defined Daily Dose (DDD) per 1
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treatment. Restricting their use to TB treatment only will pose a major practical challenge. To 
improve control on antibacterial use in Tanzania, the implementation of surveillance systems 
for antibacterial consumption and resistance is warranted, and the sale of antibacterials should 
be restricted to part I pharmacies only. 
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abstraCt
objectives: Fluoroquinolones are used in second-line treatment of tuberculosis (TB) and 
have a potential role in shortening TB treatment duration. The wide use of fluoroquinolones 
in the treatment of other infections including respiratory tract infections in patients with 
(undiagnosed) active TB, could result in fluoroquinolone resistant Mycobacterium tuberculosis 
(M. tuberculosis). We determined the rate of fluoroquinolone resistance in M. tuberculosis 
isolates obtained from Tanzanian patients and linked this to previous fluoroquinolone exposure 
and mycobacterial resistance to rifampicin and isoniazid.
methods: A total of 291 M. tuberculosis isolates were obtained between April 2009 and 
June 2010 from patients with smear-positive pulmonary TB and tested for susceptibility to 
ciprofloxacin, moxifloxacin, rifampicin and isoniazid. Information on previous fluoroquinolone 
use was obtained by interviewing patients and checking their medical files.
results: Only two (0.7%) of the 291 M. tuberculosis isolates were resistant to ciprofloxacin; 
one of which was intermediately resistant to moxifloxacin as well. These two isolates were 
susceptible to rifampicin and isoniazid. Twenty-two (8%) of the 291 patients had a history of 
fluoroquinolone use (median: 7 days, interquartile range: 5-10). The patients from whom the 
fluoroquinolone resistant M. tuberculosis isolates were obtained had no known history of 
previous fluoroquinolone use.
Conclusions: Our findings indicate that the rate of fluoroquinolone resistant M. tuberculosis 
in Tanzanian patients with TB is low and not related to previous, brief episodes of exposure to 
fluoroquinolones. The findings favour future application of fluoroquinolones in TB treatment 
regimens of shorter duration.
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introduCtion
Fluoroquinolones, a class of broad spectrum antibacterial drugs, are pivotal second-line drugs 
in the treatment of multidrug-resistant (MDR) tuberculosis (TB) and they are used as substitute 
agents in patients who are intolerant to the first-line TB drugs [1,2]. Moreover, in vitro and in 
vivo experiments have shown that the newer fluoroquinolones moxifloxacin and gatifloxacin 
have the potential to shorten TB treatment duration; an important strategy in the fight against 
TB [3-6]. The agents are currently being tested in phase III clinical trials for their role in TB 
treatment regimens of shorter duration [7].
A potential problem of using fluoroquinolones in first-line TB treatment is that they are 
prescribed for treatment of a wide variety of bacterial infections, including empirical treatment 
of community-acquired pneumonia [8,9]. Exposure to fluoroquinolone monotherapy in 
patients with yet undiagnosed active TB can result in the emergence of fluoroquinolone 
resistant Mycobacterium tuberculosis (M. tuberculosis) and this could jeopardize the 
application of the fluoroquinolones in TB treatment regimens, particularly in regimens of 
shorter duration [10,11]. Fluoroquinolone resistance in M. tuberculosis has been observed 
in a number of studies around the world and the resistance rates ranged from <1% to >35% 
[12-15]. In several studies, M. tuberculosis resistance to fluoroquinolones was associated with 
MDR TB (resistance to at least rifampicin and isoniazid) [16-20], probably as a consequence 
of adding a fluoroquinolone to a failing multidrug TB treatment regimen [11]. In a number of 
studies, the association between previous fluoroquinolone use for any kind of infection and 
the development of fluoroquinolone resistance in patients with active TB was assessed. While 
the association was confirmed in some studies [14,21], other studies yielded more ambiguous 
results with respect to the existence of such a correlation [16,19,22] or showed a risk increment 
of fluoroquinolone resistance development only after substantial (i.e. >10 days) exposure to 
these drugs [23]. 
The occurrence of fluoroquinolone resistance in M. tuberculosis and its possible association 
with previous fluoroquinolone exposure has not yet been studied in Tanzania, one of the 22 
countries with the highest burden of TB [24]. In a previous study, we assessed the extent of 
fluoroquinolone use for all kinds of infections in outpatients from the Kilimanjaro Region in 
northern Tanzania. We confirmed that the fluoroquinolones are widely used in Tanzania; they 
account for 12% of the total sale of antibacterial drugs in authorized pharmacies and they are 
readily available in unauthorized drug outlets as well [25]. In the present study, we determined 
the occurrence of fluoroquinolone resistance in M. tuberculosis isolates from TB patients in the 
Kilimanjaro Region and we linked this to previous fluoroquinolone exposure and resistance to 
isoniazid and rifampicin.
material s & methods
setting. The study was conducted in the Tanzanian Kilimanjaro Region where the annual TB 
case notification rate (new and retreatment cases) is around 178 per 100,000 population [25]. 
Forty-one percent of TB patients in the region are diagnosed with smear-positive pulmonary 
TB and 59% with smear-negative pulmonary or extrapulmonary TB. Thirty-one percent of TB 
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patients are co-infected with HIV [26,27]. TB diagnosis is primarily based on clinical symptoms 
and Ziehl-Neelsen (ZN) smear microscopy for the detection of acid-fast bacilli (AFB), 
complemented by radiology in case of AFB-negative smears. At the time of the conduct of this 
study, no TB culture facilities were available for routine practice in the Kilimanjaro Region, and 
there was no second-line treatment for drug resistant TB [28].
study population and procedures. We conducted a cross-sectional study between April 
2009 and June 2010 in patients who were diagnosed with smear-positive pulmonary TB and 
had not yet started TB treatment. Smear-positivity was defined as at least one AFB-positive 
smear out of two sputum samples: one spot and one morning sample [28]. District TB and 
Leprosy Coordinators from all seven districts of the Kilimanjaro Region were responsible for 
enrolling patients from their district’s clinics. Because of logistical constraints (in particular, 
long travelling time from the most distant districts to the culture laboratory), convenience 
sampling was applied, meaning that as many patients as logistically possible were enrolled.
Demographic and clinical data such as TB classification (new or retreatment case) and 
HIV-status were collected from medical files. A new TB case was defined as a patient who 
had not received more than 1 month of TB treatment in the past. Retreatment cases included 
patients classified as treatment failures, returning after default and relapse cases. Trained 
clinicians interviewed patients on the use of antibacterial drugs with or without prescription 
in the previous 6 months (a longer period was expected to result in substantial recall bias) and 
explicitly asked about ciprofloxacin use (the fluoroquinolone that is most frequently used in 
Tanzania) [25]. Furthermore, medical files were checked for fluoroquinolone prescription in 
the previous 6 months. 
One spot sputum sample for culture and drug susceptibility testing to isoniazid, rifampicin, 
ciprofloxacin and moxifloxacin was collected from every patient. Ciprofloxacin was selected 
because this fluoroquinolone is sold most extensively in Tanzania [25], and moxifloxacin was 
chosen because this is one of the newer fluoroquinolones with the potential to shorten TB 
treatment duration [6]. 
The study protocol was approved by the Institutional Review Board of the Kilimanjaro 
Christian Medical Centre (Moshi, Tanzania) and the National Institute for Medical Research 
(Dar es Salaam, Tanzania). Written informed consent was obtained from all participants.
laboratory analysis. After collection, sputum samples were refrigerated for a maximum 
of 1 week and transported to the TB culture laboratory of the Kilimanjaro Christian Medical 
Centre (KCMC; Moshi, Tanzania). After decontamination, sputum samples were incubated 
in an automated liquid culture system (BACTEC MGIT960, BD Biosciences, Erembodegem, 
Belgium). The content of positive MGIT tubes was inoculated on blood agar plates for 24 h 
to assess possible contamination, and ZN microscopy was done to confirm the presence of 
AFB. In case of AFB positivity and growth on the blood agar plates, MGIT tube sediments 
underwent renewed decontamination and incubation. In case of AFB positivity and no 
growth on the blood agar plates, concentrated MGIT tube sediments were subcultured on 
Löwenstein-Jensen (LJ) slopes. Growth on LJ slopes was assessed after 8 weeks of incubation 
and the isolates obtained in this way were stored in glycerol at -80°C until transport to the 
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National Tuberculosis Reference Laboratory of the National Institute for Public Health and the 
Environment (RIVM) in The Netherlands. 
At the RIVM, the isolates were first identified as M. tuberculosis complex by spoligotyping 
[29]. Drug susceptibility testing was performed using BACTEC MGIT960; the drugs included 
in the panel and their critical concentrations were isoniazid 0.1 mg/L, rifampicin 1 mg/L, 
ciprofloxacin 1 mg/L and moxifloxacin 0.5 mg/L [30]. The process was controlled using EpiCenter 
software; standard MGIT960 conditions applied. Cultures were incubated an additional 3 days 
after full appearance of the growth control. If growth was detected in a fluoroquinolone-
containing tube after the additional 3 days incubation but not before, the isolate was labelled 
‘intermediately resistant [31]’.
All fluoroquinolone-resistant isolates were subjected to gyrA gene mutation analysis using 
the GenoType MTBDRsl reverse line blot assay (Hain Lifescience, Nehren, Germany) [30].
The results were discussed with the regional TB coordinators and laboratory technicians, to 
provide them with feedback on the quality of ZN microscopy in the region.
results
Patient characteristics. A total of 379 sputum samples were collected. M. tuberculosis isolates 
were obtained from 291 of these 379 sputum samples. Thirty samples were culture-negative, 35 
showed growth but no M. tuberculosis, and 23 were contaminated. 
The characteristics of the 291 patients with culture-confirmed TB are shown in Table 1. 
Twenty-two (8%) of the 291 patients had a history of fluoroquinolone use in the previous 6 
months: 11 (50%) had used the drug for respiratory symptoms and the others for gastrointestinal 
problems. Seven patients had used fluoroquinolones in the past month and 15 patients between 
Table 1. Patient characteristics of the total study population (n=291) and by drug resistance pattern
Characteristic
Total group 
(n=291)
Patients 
with pan-
susceptible 
MTB (n=262)
Patients 
with INH 
resistant 
MTB (n=23)
Patients  
with RIf 
resistant 
MTB (n=1)
Patients  
with INH +  
RIf resistant  
MTB (n=3)
Patients 
with fq 
resistant 
MTB (n=2)
Age, median (IQR) 35 (27-44) 35 (27-45) 36 (27-42) 25 39 (34-50) 30 (20-40)
Male sex, n (%) 208 (72) 183 (70) 20 (87) 1 (100) 3 (100) 1 (50)
Retreatment cases, 
n (%)*
29 (10) 27 (10) 0 (0) 0 (0) 1 (33) 0 (0)
HIV-positive, n (%) 63 (22) 55 (21) 6 (26) 0 (0) 1 (33) 1 (50)
Positive history of 
FQ use, n (%)
22 (8) 21 (8) 1 (4) 0 (0) 0 (0) 0 (0)
* Of the 29 retreatment cases, two were defaulters who returned and 27 were classified as relapse cases. The two 
patients who returned after default both had pan-susceptible Mycobacterium tuberculosis isolates.
MTB = Mycobacterium tuberculosis
IQR = interquartile range
INH = isoniazid
RIF = rifampicin
FQ = fluoroquinolone
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1 and 3 months ago. The median duration of fluoroquinolone use was 7 days (interquartile 
range (IQR): 5-10), the maximum duration was 10 days. None of the patients had used the 
fluoroquinolones more than once in the previous 6 months.
drug susceptibility test results. Isoniazid resistance was found in 26 M. tuberculosis isolates 
(8.9%), three of which were resistant to rifampicin as well, giving an MDR rate of 1.0%. Mono-
resistance to rifampicin occurred in one isolate (0.4%). Ciprofloxacin resistance was found 
in two isolates (0.7%): one was intermediately resistant to ciprofloxacin and susceptible 
to moxifloxacin, the other was resistant to ciprofloxacin and intermediately resistant to 
moxifloxacin. Both were susceptible to isoniazid and rifampicin. The isolate resistant to 
ciprofloxacin and intermediately resistant to moxifloxacin harboured an A90V mutation 
in the gyrA gene, but wild type sequences were detected simultaneously. In the isolate 
intermediately resistant to ciprofloxacin and susceptible to moxifloxacin no gyrA mutations 
were found. 
The characteristics of the patients from whom resistant M. tuberculosis isolates were 
obtained are shown in Table 1. The two patients with ciprofloxacin resistant M. tuberculosis 
had no history of previous fluoroquinolone use and had not been treated for TB before. The 
patient from whom the M. tuberculosis isolate with intermediate resistance to ciprofloxacin 
was obtained, was a 40-year-old HIV-positive woman with a CD4 count of 3 cells/mm3. The 
other patient was a 20-year-old HIV-negative man with a CD4 count of 478 cells/mm3. There 
was no known link between these two patients.
disCussion
Fluoroquinolone resistance in M. tuberculosis is uncommon in Tanzania, despite the 
widespread use of these antibacterial drugs in the treatment of bacterial infections. The 
proportion of M. tuberculosis isolates with fluoroquinolone resistance was less than 1% in our 
study population and there was no association with previous fluoroquinolone exposure in the 
two isolates with fluoroquinolone resistance. Both fluoroquinolone resistant isolates were 
susceptible to rifampicin and isoniazid. 
Fluoroquinolone resistance in M. tuberculosis is associated with mutations in the gyrA and, 
to a lesser extent, gyrB genes of the mycobacterial genome but these mutations are not always 
present in resistant isolates [11,32]. Cross-resistance between the different fluoroquinolones 
is common in M. Tuberculosis [33]. It is hypothesized that resistance to fluoroquinolones with 
strong bactericidal activity against M. tuberculosis (such as moxifloxacin) is generated through 
a stepwise process of additive mutations, whereas resistance to ciprofloxacin and ofloxacin 
requires a single mutation only [11]. This could explain that the M. tuberculosis isolate with 
intermediate resistance to ciprofloxacin in our study was susceptible to moxifloxacin (and 
did not have mutations in gyrA), and that the isolate with resistance to ciprofloxacin was 
intermediately resistant to moxifloxacin. We found a A90V gyrA mutation in the latter isolate 
but wild type sequences were also detected, suggesting a single strain with both wild type 
and mutant bacterial populations, as previously observed [30], or a mixed infection with two 
strains [30]. Considering that our aim was to determine the rate of fluoroquinolone resistance 
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in northern Tanzania and relate this to previous fluoroquinolone use, we decided to categorize 
the M. tuberculosis isolate with intermediate resistance to ciprofloxacin as fluoroquinolone 
resistant. However, the clinical relevance of intermediate fluoroquinolone resistance in 
M. tuberculosis remains controversial [31]. 
Low fluoroquinolone resistance rates were also found in two other studies from the 
African continent [12,14]. In Tunisia, 0.8% fluoroquinolone resistance was found in a hospital-
based study but the association of fluoroquinolone resistance in M. tuberculosis with 
previous fluoroquinolone exposure was not investigated [12]. In Rwanda, the fluoroquinolone 
resistance rate was 0.6% in a nationwide study. The four patients with fluoroquinolone resistant 
M. tuberculosis in this study all had a history of previous fluoroquinolone use (three as part of a 
second-line TB treatment regimen) [14].
There are a few possible explanations for the low fluoroquinolone resistance rate and the 
absence of an obvious association with previous fluoroquinolone exposure in our study. As 
Devasia et al. (2009) showed, the risk of fluoroquinolone resistance in M. tuberculosis isolates 
increases particularly after fluoroquinolone exposure of more than 10 days [23]. In our patient 
population, fluoroquinolone use was restricted to brief treatment episodes (5-10 days) only. 
Moreover, at the time this study was conducted, there was no second-line treatment for 
MDR TB available and thus there was no risk of long-term fluoroquinolone exposure as part 
of a failing second-line TB treatment regimen in M. tuberculosis. In most regions where high 
(i.e. >15%) fluoroquinolone resistance rates in M. tuberculosis were observed, its occurrence was 
associated with resistance to rifampicin and isoniazid [15,20,22,34,35]. In our study, the rates of 
isoniazid, rifampicin, and isoniazid plus rifampicin (MDR) resistance were low: 8.9%, 0.3% and 
1.0%, respectively, and similar low rates of MDR TB were found in other studies from Tanzania.
This study has some limitations. Since the prescription and sale of antibacterial drugs 
to patients in Tanzania is not automatically registered, it was difficult to obtain reliable 
information about previous fluoroquinolone use. Furthermore, it is unknown how long it takes 
for M.  tuberculosis to develop fluoroquinolone resistance after fluoroquinolone exposure. 
Devasia et al. (2009) assessed fluoroquinolone exposure over a period of 12 months prior to TB 
diagnosis and found that exposure that had occurred more than 60 days before TB diagnosis was 
associated with the highest risk of fluoroquinolone resistance [23]. We assessed fluoroquinolone 
use over a period of 6 months (180 days) prior to TB diagnosis only, because we expected that 
fluoroquinolone use longer than 6 months ago would be difficult for patients to recall.
In conclusion, our findings indicate that the occurrence of fluoroquinolone resistance in 
M. tuberculosis isolates obtained from Tanzanian patients is limited and not related to previous, 
brief episodes of fluoroquinolone exposure. This is an encouraging finding in light of the 
possible incorporation of the fluoroquinolones in first-line TB treatment regimens. 
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introduCtion
The overall objective of this thesis was to address pharmacological aspects in the treatment of 
tuberculosis patients in Tanzania. Pharmacokinetic and pharmacodynamic problems affecting 
tuberculosis therapy were therefore investigated. The combined treatment of TB and HIV, 
pharmacokinetics of TB drugs in plasma and saliva, the effect of type II diabetes mellitus on the 
pharmacokinetics of TB drugs, TB drug induced hepatotoxicity and fluoroquinolones use and 
resistance were described in the respective articles. All studies presented in this thesis were 
conducted in Kilimanjaro Region, Tanzania.
PharmaCokinetiCs and PharmaCodynamiCs in 
tb treatment
TB therapy must be given with multiple drugs for a prolonged period, making it necessary 
to monitor drug toxicity, drug interactions, and patients’ adherence. The currently used 
combination drug regimens produce cure rates that exceed 95% in carefully monitored clinical 
trials. When there is insufficient patient adherence during the multiple months of the treatment 
period, failure is common. In addition, the TB drugs exhibit inter-individual differences in 
their activity and these differences are largely determined by their pharmacokinetic and 
pharmacodynamic properties. An understanding of the relationships among these properties 
is considered key for a good response and rational use of anti-tuberculosis drugs. 
The success of antimicrobial therapy is determined by complex interactions between 
an administered drug, a host, and an infecting agent. We advocate that combination 
antimicrobial regimens, dosages and dosing intervals of individual antimicrobial agents should 
be designed while considering the pharmacokinetic and pharmacodynamic properties of the 
individual drugs. This means that it should be realized that the dose of drugs results in drug 
concentrations in various biological matrices; subsequently, these concentrations result in 
desirable or undesirable (eg. concentration-dependent adverse effects) responses. Thus, the 
concentration achieved is an important intermediary link between the dose administered and 
the eventual response to the drug.
Several pharmacokinetic and pharmacodynamic parameters have been defined to 
describe the antibacterial activity of various classes of antimicrobial agents [1,2]. Evolving data 
suggest that the total exposure to TB drugs or the ‘area under the concentration versus time 
curve (AUC
0-24
) is most relevant to the efficacy of the first-line TB drug [3-8]. Ideally, AUC
0-24
 
is combined with the minimum inhibitory concentration (MIC) of the mycobacteria to yield 
AUC
0-24
/MIC, a pharmcodynamic parameter or index that is supposed to best predict response. 
drug interaCtions bet ween anti-tb and 
antiretroViral drugs
There are four main concerns in combining TB treatment with antiretroviral drugs. One is 
when to start the drugs. Second, TB treatment involves taking many tablets, as do most 
ARV regimens. Higher pill burden often results in lower adherence. Third is the immune 
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reconstitution inflammatory syndrome (IRIS). There can be a transient worsening of clinical 
status of TB patients 2-3 weeks after initiation of ARVs. Fourth is the interaction with TB drugs 
(especially rifampicin) and antiretroviral drugs as well as their  overlapping drug toxicities, 
which are described in this thesis book.
The rifamycins (rifampicin, rifabutin and rifapentine) induce the hepatic cytochrome P450 
and uridine diphosphate glucuronosyltransferase (UGT) enzymes and thus can potentially 
lower blood levels of other drugs that utilize this pathway of metabolism, including many ARVs 
[9]. Rifampicin is a potent enzyme inducer whereas rifabutin acts as a more moderate enzyme 
inducer. Other commonly used drugs to treat tuberculosis, such as isoniazid, ethambutol, and 
pyrazinamide, generally do not have significant interactions with antiretroviral drugs when 
they are co-administered with rifampicin. Isoniazid inhibits some metabolic enzymes, but the 
effects of this drug are outweighed by the (inductive) effects of rifampicin when the two drugs 
are combined. The reviews in chapter 2a and 2b describe details of drug interactions between 
first-line TB drugs and antiretrovirals used in resource-limited settings. In this discussion, the 
important findings of these two articles are highlighted. Furthermore, additional information 
for special groups like pregnant women, children and MDR-TB patients is given.
The nucleoside reverse transcriptase inhibitors (NRTIs) are not metabolized by the liver 
and therefore, their levels are not significantly impacted by medications that induce or inhibit 
hepatic cytochrome P450 enzymes. One exception occurs with concomitant use of zidovudine 
and rifampicin, since both zidovudine and rifampicin are cleared by glucuronidation. The 
interaction between zidovudine and rifampicin resulted in a 47% decrease in the AUC 
concentration of zidovudine [10]. Nevertheless, no dose adjustment was recommended [11].
For Non Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) efavirenz can be used 
with rifampicin. Rifampicin lowers nevirapine levels by 20 to 58% and most experts do not 
recommend using this combination [11] unless the patient is pregnant when efavirenz cannot 
be given. Although limited data exist with the combinations of rifampicin and etravirine or 
rifampicin and rilpivirine, the coadministration of these drugs should be avoided because of the 
potential significant decrease in plasma etravirine and rilpivirine concentrations. 
Standard doses of protease inhibitors cannot be given with rifampicin as > 90% decreases in 
trough concentrations of the protease inhibitors occur which makes them ineffective [9,12,13]. 
Most protease inhibitors are given with low-dose ritonavir (100-200mg per dose of the other 
protease inhibitor). However, low-dose ritonavir does not overcome the effects of rifampicin, 
as even after boosting the doses, low serum protease inhibitor concentrations were observed. 
Therefore, standard protease inhibitor regimens, whether boosted or not, cannot be given 
with rifampicin. In chapter 2b, the hypothesis is evaluated that a fixed dose combination of 
emtricitabine, tenofovir and efavirenz (AtriplaR) can be considered as an effective and safe 
antiretroviral drug in TB-HIV management for adult and children above 3 years of age. 
In pregnancy, treatment for HIV and TB is challenging as pregnancy alters the distribution 
and metabolism of a number of drugs, including antiretroviral drugs [14]. Efavirenz is 
contraindicated in pregnancy and in women of childbearing potential who are not on adequate 
contraception. The only NNRTI drug that can be administered with rifampicin in pregnancy 
is nevirapine. However, nevirapine is associated with an increased risk of hepatotoxicity in 
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women. In such women who are pregnant, HAART regimens will be difficult to administer 
during TB treatment in areas where rifabutin is not available. Therefore, if nevirapine is used 
with rifampicin, close clinical, hepatic and virologic monitoring should be performed [15-17]. Of 
note, the serum concentrations of protease-inhibitors are decreased during the latter stages 
of pregnancy [18,19]. There are no published data on drug-drug interactions between anti-
tuberculosis and antiretroviral drugs among pregnant women.
HIV-infected patients with multidrug-resistant tuberculosis, needs fast initiation of 
antiretroviral therapy to decrease the alarmingly high death rate among them. However, 
most of the drugs used to treat multidrug-resistant tuberculosis (the “second-line drugs”: 
e.g. kanamycin, amikacin, capreomycin fluoroquinolones, ethionamide, cycloserine, para-amino 
salicylate) were developed nearly 40 years ago. These second-line TB drugs are characterized 
by very diverse metabolic pathways. Unfortunately, there are only limited published studies of 
possible drug-drug interactions between second-line anti-tuberculosis drugs and antiretroviral 
drugs [20]. Studies of second line TB drugs are a major priority in this era.
management oF tb/hiV Co -inFeCted Patients
Due to recent advances in antiretroviral therapy, anti-TB therapy has become more complicated. 
Many doctors recommend either delaying HIV treatment until the TB has been controlled, or 
even stopping or changing anti-HIV medication if a person develops TB whilst taking HIV drugs. 
In our study (Chapter 3) the antiretroviral regimen of once-daily efavirenz 600mg, tenofovir 
300mg and emtricitabine 200mg (Atripla® Merck & Co. Inc. USA) was initiated at week 4 after 
starting TB treatment. The four weeks meant that if you have a low CD4 cell count, and start 
anti-HIV drugs immediately after starting your TB treatment, you may be at risk of developing 
what is called immune reconstitution syndrome. This is when your strengthening immune 
system is stimulated to attack TB again. In this study, IRIS was not observed.
HIV infected patients achieve somewhat lower concentrations of the orally administered 
first line anti-TB drugs [21-23]. This was also observed in our study (chapter 3). The plasma 
concentrations of all TB drugs tended to be slightly lower during co-administration with 
efavirenz, tenofovir and emtricitabine (table 3, chapter 3). Considering the drug-drug 
interactions in TB-HIV co-infection, these are most likely to be caused by rifampicin [24]. 
Our study is the first to report on the interactions of efavirenz/ tenofovir/ emtricitabine 
with first line rifampicin-based TB treatment, however, no interactions were observed in 
the pharmacokinetic analysis. The pharmacokinetic parameters (AUC, Cmax, and Cmin) of 
efavirenz, tenofovir and emtricitabine were not significantly altered based on geometric mean 
ratios (table 2, chapter 3).
Pharmacokinetic drug-drug interactions between rifampicin and antiretroviral drugs, may 
lead to loss of antiretroviral efficacy [25-27]. This was not the case in our study as by the end of 
eight weeks of TB treatment, 19 of 25 patients (76%) had negative sputum smears (confirmed 
by negative sputum cultures). In addition, their median (IQR) CD4 count increased from 119 
(69-203) cells/mm3 to 238 (147-424) cells/mm3 (p<0.01; Wilcox Signed Rank). There are existing 
overlapping adverse effects profiles between antituberculosis and antiretroviral drugs [28]. In 
our study, the combination of first-line TB drugs with efavirenz, tenofovir and emtricitabine was 
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well tolerated. There was a 96% percent of patients who experienced adverse effects mostly 
grade 2 before the start of ART and the rate was 92% after the start of ART. Generally, there were 
no serious AEs reported and no modifications or discontinuations of treatment done. 
Rifampicin modestly decreases the efavirenz exposure [29,30]. AUC
0-24h
, C
max
 and C
24h
 
of efavirenz in our study were slightly higher, which is explained by the presence of genetic 
differences in most of African population [31-33]. Our findings suggest that co-administration 
of the standard first line TB treatment regimen with efavirenz, tenofovir, and emtricitabine 
does not alter pharmacokinetic parameters of either of these drugs to a clinically relevant 
extent, however future studies should look into genetic factors of the patients because the 
metabolism of efavirenz is extensively influenced by pharmacogenetic factors [33-35]. 
PharmaCokinetiCs oF tuberCulosis drugs
Therapeutic drug monitoring using pharmacokinetic parameters may be useful in tuberculosis 
management. However, pharmacokinetic data from sub-Saharan Africa are limited, especially 
data based on intensive pharmacokinetic sampling. In chapter 4, the pharmacokinetic parameters 
of isoniazid, rifampicin, pyrazinamide and ethambutol using intensive sampling during the full 
dosing interval were described. It is well known that certain patients, such as those infected with 
HIV and thus prone to malabsorption, are at higher risk for low drug levels [36-38]. In our study, 
35% of patients had Cmax of rifampicin below the reference range (8-24mg/L). It was noted that 
none of the determinants (age, body weight, sex, HIV, malnutrition, dose per kg body weight) 
were significantly associated with the AUC
0-24h
 or C
max
 of isoniazid, rifampicin, pyrazinamide 
or ethambutol. However, numbers were small for determinant assessment. Although the 
pharmacodynamics of the first-line TB drugs is not completely established yet, suboptimal 
treatment responses have been associated with low rifampicin concentrations. This is a reason 
for considering higher doses of rifampicin in African tuberculosis patients. Apart from this, even 
higher doses of rifampicin may enable treatment shortening in patients from all races [39]
saliVa samPling as alternatiVe For Plasma samPling
Ideally, the concentration of drug should be measured at the site of action of the drug; that is, 
at the receptor. However, owing to inaccessibility, drug concentrations are normally measured 
in whole blood from which serum or plasma is generated. Other body fluids such as saliva 
[40,41] and cerebrospinal fluid are sometimes used. It is assumed that drug concentrations in 
these fluids are in equilibrium with the drug concentration at the receptor. Saliva specimen has 
several advantages, such as easy and inexpensive sample collection and reduction of infection 
risk and discomfort especially in individuals infected with HIV, in children, and in compliance 
measurement. In addition, it should be noted that the measured drug concentrations in plasma 
or serum refer to the total drug concentration, i.e. a combination of bound and free drug that 
are in equilibrium with each other. Only the free or unbound fraction of the drug in plasma is 
active and precisely this fraction is available for diffusion to saliva. Therefore, another advantage 
of measuring drugs in saliva is that these salivary concentrations may reflect the active, free 
fraction of drug in plasma. 
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We conducted a study (chapter 5) to explore the possibilities of using saliva instead of 
plasma for therapeutic drug monitoring and pharmacokinetic studies with rifampicin in TB 
patients. As expected, measurable rifampicin concentrations were not detected in all plasma 
and saliva samples, as rifampicin is having a short elimination half-life. Pharmacokinetic 
parameters of rifampicin both in plasma and saliva and their ratios are shown in (chapter 5). 
The table also shows the unbound rifampicin PK parameters that reflect how much rifampicin 
could diffuse to the saliva; however, the exposure to salivary rifampicin was significantly lower 
than the protein-unbound exposure in plasma. Furthermore, it was evident from the study that 
the salivary rifampicin was not able to predict total or protein-unbound plasma concentrations, 
due to inadequate precision associated with this prediction. This means, unfortunately, that 
salivary concentrations cannot be used as a substitute for plasma or serum concentrations in 
therapeutic drug monitoring or pharmacokinetic studies. 
diabetes mellitus and tuberCulosis
TB is a major public health problem in many low- and middle-income countries, where 
the number of people with diabetes is also rising rapidly. The growing prevalence of 
diabetes poses a challenge for TB control as uncontrolled diabetes leads to a greater risk of 
developing TB [4]. Figure 1 shows percentages of TB cases attributable to diabetes mellitus. 
The link between tuberculosis and diabetes has been mentioned previously [43]: not only 
does diabetes contribute to a person’s risk of developing tuberculosis, but it also makes it 
more difficult to treat those who have both diseases. Lower plasma concentrations of anti-TB 
drugs have been associated with clinical failure and acquired drug resistance [44-47]. In 
an unmatched weight study in Indonesia performed during the continuation phase of TB 
treatment [48], the AUC
0–6 h
) of rifampicin was 53% lower in TB and DM patients compared 
with TB only patients. However, when the researchers matched the weights of the patients in 
a study performed during the intensive phase of treatment, no differences in drug exposure 
were found between the two groups for rifampicin, pyrazinamide and ethambutol [49]. Thus, 
TB patients with diabetes mellitus may need a higher dose of TB drugs in view of their higher 
body weight, but diabetes per se may not affect the pharmacokinetics of TB drugs, at least 
in Indonesian patients. 
In our study described in chapter 6, we screened Tanzanian tuberculosis patients with 
diabetes mellitus to find out the effect of diabetic disease on the concentrations of TB drugs in 
the intensive phase of TB treatment. We found that exposure to both isoniazid and rifampicin 
was reduced in diabetic patients with TB compared to TB patients without diabetic. Much 
effect was seen in isoniazid as C
max, 
clearance and volume of distribution were also reduced. 
The diabetes disease itself most likely explains these effects as it may reduce the absorption 
of TB drugs. It is known that low serum levels can also be a consequence of malabsorption, 
inaccurate dosing, altered metabolism, or drug–drug interactions in TB and diabetic patients 
[50]. On efficacy and safety, one prospective study examined sputum cultures at the completion 
of 6 months of TB treatment, and the result was that positive cultures were found in 22.2% of 
patients with diabetes and 6.9% of those without diabetes [51]. A relative risk of death of 1.89 
among TB patients with diabetes was observed in a systematic review of treatment outcomes 
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when compared to non-diabetic patients [52]. Our study (chapter 6) did not measure sputum 
cultures for the patients, as we performed a purely pharmacokinetic study. 
hePatotoxiCit y in tb treatment
Drug-induced hepatotoxicity has been a long-standing concern in the treatment of 
tuberculosis infection. The liver has a central role in drug metabolism and detoxification, and is 
consequently vulnerable to injury. TB drugs induced hepatotoxicity is a serious adverse effect 
[53,54]. Treatment should be interrupted and, generally, a modified or alternative regimen 
must be used for those with alanine aminotransferase (ALT) elevation more than three times 
the upper limit of normal (ULN) in the presence of hepatitis symptoms and/or jaundice, or five 
times the ULN in the absence of symptoms [55]. 
The observational study we conducted (chapter 7) showed a low rate (0.9%) of 
hepatotoxicity. This was the first study of this kind in Tanzanian hospitalized TB patients. Due 
to different definitions of hepatotoxicity and differences between studied populations, the 
incidence of anti-TB drug induced hepatotoxicity varies across studies. A study done in South 
Africa observed 0.5%, hepatotoxicity [56], Malawi reported 2% [57] while Uganda and Congo 
reported 1% and zero respectively [58,59]. Higher incidences to be reported were 13-15 percent 
from India and Iran [60].
Several genetic polymorphisms in drug metabolizing enzymes have been associated 
with anti-TB induced hepatotoxicity [61]. The three key anti-tuberculosis drugs, isoniazid, 
pyrazinamide and rifampicin, are all potentially hepatotoxic [62]. A meta-analysis has shown 
figure 1. Percentage of TB cases attributable to diabetes mellitus. Source: http//www.idf.org/site 
map 4.3
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an incidence rate of liver toxicity of 2.6% with isoniazid and rifampicin coadministration, but 
only 1.1% with rifampicin alone, and 1.6% with isoniazid alone [63]. The influence of acetylation 
rate on isoniazid hepatotoxicity has raised a lot of attention in past years. In fast acetylators, 
more than 90% of the drug is excreted as acetyl-isoniazid, whereas in slow acetylators, 67% 
of the drug is excreted as acetyl-isoniazid and a greater percentage of isoniazid is excreted as 
unchanged drug into the urine [64]. Early studies suggested that fast acetylators were at higher 
risk for hepatic injury because they generated more acetyl-isoniazid, which could be further 
metabolized to other toxic intermediaries [64-66]. Most of the follow-up phenotyping studies 
have shown that there is either a higher risk of hepatotoxicity for slow acetylators or that no 
such difference exists. The majority of genotyping studies, performed more recently, suggest 
that slow acetylators are at an increased risk for isoniazid-induced hepatotoxicity [67].
Slow and intermediate acetylators are highly prevalent in an Africa population [60], which 
would contradict the low rate of hepatotoxicity found in our study (chapter 7). To minimize the 
risk of hepatotoxicity, all patients should be thoroughly educated about the symptoms of hepatitis, 
and advised to report them promptly for early evaluation. Close clinical monitoring is essential. 
Contrarily, our study suggests that this may be not large problem. This gives more possibilities 
for increasing the dosages of the several TB drugs, especially rifampicin and pyrazinamide, to 
increase the sterilizing effect and the prevention of the emergence of drug resistance.
Fluoroquinolone use
Fluoroquinolones are fluorine-containing nalidixic acid derivatives characterized by broad-
spectrum antimicrobial activity. They are currently used as second-line TB drugs, but the 
fluoroquinolone moxifloxacin is currently being evaluated as a first-line agent as well. 
Furthermore, the effectiveness and broad-spectrum activity of fluoroquinolones have 
made this antibacterial class one of the most widely used in other infections, both in human 
medicine and veterinary practice. This use of fluoroquinolones against various infections has 
raised concerns about the risk of mycobacterial resistance development in patients who are 
co-infected with actively replicating Mycobacterium tuberculosis [68]. This is why we have 
studied the quantification of the fluoroquinolone sale extent (Chapter 8a). It appeared that 
fluoroquinolones accounted for 12% of the total sale of antibacterials. It was also observed that 
fluoroquinolones were widely available in unauthorized drug outlets, which make the 12% result 
an underestimation since these outlets were not included in the evaluation.
It is known that reduced mycobacterial susceptibility to one fluoroquinolone results in 
reduced susceptibility to all fluoroquinolones [68,69]. In addition, resistance to quinolones can 
evolve rapidly, even during a course of treatment and after as little as 13 days of fluoroquinolone 
therapy [70]. In Chapter 8b, the risk of development of resistance was evaluated. We assumed 
that the risk is higher in patients with previous exposure to fluoroquinolones (chapter 8a), 
but only 0.7% (2/291) of the isolates were resistant to ciprofloxacin, the most widely used 
fluoroquinolone as reflected in Chapter 8a. 
Although fluoroquinolone resistance in M. tuberculosis is not routinely assessed, the 
proportion of fluoroquinolone resistance among newly diagnosed (i.e., previously un-treated) 
patients with tuberculosis has ranged from 0.15 to 3.6% in previous reports [71-75]. However, the 
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risk factors for fluoroquinolone resistance in M. tuberculosis have not been fully elucidated. It 
is important to characterize the extent of fluoroquinolone resistance in M. tuberculosis, as well 
as the risk factors for resistance, so that this potent class of antimicrobial agents can be used 
rationally to treat both routine bacterial infections and tuberculosis.
ConClusion
Tuberculosis remains an important public health problem in Tanzania and worldwide. 
Medications are the cornerstone of tuberculosis treatment. However, today’s TB drug regimen 
takes too long to cure, is too complicated to administer and can be toxic. Tuberculosis and HIV/
AIDS are fatally synergistic. In high-burden countries, people with HIV/AIDS are 20 times more 
likely to contract TB than those not suffering from HIV/AIDS. The deadly synergy of these two 
diseases demands first-line treatments that can be fully harmonized to avoid ARV interactions, 
and can be utilized to treat the growing number of people dually infected with TB and HIV.
Other immunosuppressive conditions and MDR-TB have changed the face of TB and posed 
challenges for its management. Despite the flaws with and growing resistance to current TB 
treatments, no new TB drugs have been developed in nearly 50 years. In conclusion, improved 
tuberculosis management plan is urgently required. Strategies that improve the quality of drug 
use and efficacy are crucial to fight TB successfully
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SUMMARY
TB remains a major global health problem, although efficacious treatment has been available 
for decades now. It is ranked as the second most mortality-causing infectious disease after 
human immunodeficiency virus (HIV) disease worldwide. Worldwide data show 9 million new 
cases and 1.4 million deaths annually. TB and HIV are overlapping epidemics. Both have been 
declared global emergencies demanding global attention, as HIV is the strongest risk factor for 
the development of TB. Apart from HIV, diabetic mellitus is another disease that also evolves as 
epidemic and overlaps with TB, especially on the treatment responses. 
Clinical pharmacological research has always been translational in the sense that the 
discipline aims to translate new scientific data on drugs into rational patient care. Research 
in clinical pharmacology therefore includes studies on drug interactions, drug toxicity, 
pharmacokinetic data and drug utilization. Since TB treatment involves fixed dose combinations, 
an understanding of their pharmacokinetic properties and the interactions during co-
medication for co-infection cases is key for a rational use of antituberculosis drugs. Therefore, 
various types of clinical pharmacological studies are incorporated in this thesis.
Most of the studies presented in this thesis were conducted in the Kilimanjaro Region of 
Tanzania. Tanzania is ranked 18 among 22 countries with the highest burden of TB worldwide. In 
Tanzania, TB cases are about 65,000 per annum. Thirty-seven percent of TB patients in Tanzania 
are co-infected with HIV, accounting for 60-70% of the increase in the number of TB patients. 
In chapter 1 of this thesis, the introduction of TB disease, its transmission and major symptoms 
are described. The introduction also explores the magnitude of TB disease globally, how TB/
HIV influences each other and detail of tuberculosis treatment. This part of the thesis ends 
by addressing the pharmacological problems in the treatment of tuberculosis patients. The 
emphasis is on the pharmacokinetic and pharmacodynamics problems affecting tuberculosis 
therapy, combined treatment of TB and HIV, PK of TB drugs, PK sampling for rifampicin, how 
type II diabetic mellitus affects pharmacokinetics of TB drugs, issues of hepatotoxicity and 
fluoroquinolones use in TB treatment.
In chapter 2a, the problem of concurrent treatment of HIV infection and tuberculosis 
is explored from a comprehensive review of the pharmacological interactions between 
rifampicin (a cornerstone in the TB treatment) and antiretroviral drugs. The emphasis was given 
to the antiretrovirals used in the resource-limited setting which include nucleoside reverse 
transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors and protease inhibitors. 
However, new drugs in HIV treatment were also mentioned and the unavailability of second 
line regimen in TB/HIV co-infection treatment was highlighted. This part of the thesis ended by 
giving challenges and research priorities as far as resource-limited settings are concerned. This 
can be done by maximizing the use of already existing programmes and research data, creating 
new data by conducting clinical trials and prospective observational studies and by engaging a 
lobby to make currently unavailable drugs available to those most in need. 
In chapter 2b, a hypothesis that AtriplaR is a focus drug during combined treatment in TB/
HIV co-infected patients was presented. Comprehensive searches in Pubmed with the key 
words enabled us to find relevant information on the three drugs (emtricitabine, tenofovir 
and efavirenz) which are in the fixed dose of AtriplaR. Their interactions with first-line TB drugs 
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were then tested by reading literature as far as safety and efficacy was concerned. This part 
concluded that AtriplaR can be considered an effective and safe antiretroviral drug in TB/HIV 
management for adult and children above 3 years of age.
In chapter 3, the effect of rifampicin based tuberculosis treatment on the pharmacokinetics 
of efavirenz/tenofovir/emtricitabine was evaluated in Tanzanian TB/HIV co-infected patients. 
Approximately one-third of the 40 million people living with HIV/AIDS worldwide are co-
infected with TB. The most powerful component of the first-line TB treatment is rifampicin 
which is also a strong inducer of the cytochrome P450 enzymes. We conducted a phase II 
clinical trial to evaluate its effect on the efavirenz/tenofovir/emtricitabine pharmacokinetic 
parameters. An inducing effect of rifampicin was not found in this study as the area under the 
curve AUC
0-24h
 (exposure) of efavirenz, tenofovir and emtricitabine were slightly higher when 
these drugs were co-administered with TB drugs. On TB drugs the concentrations were slightly 
low, however equivalence was suggested based on geometric mean ratios. Both TB and HIV 
drugs were well tolerated as adverse effects observed were mild and no serious adverse event 
was reported.
In chapter 4, an observational study to describe the pharmacokinetic parameters of first-
line tuberculosis drugs in Northern Tanzania was conducted. In this study, the geometric mean 
AUC
0-24 h
 values of isoniazid, rifampicin, pyrazinamide and ethambutol were 11(3.7-22.7), 39.9 (27.4-
68.3), 344 (209-610) and 20.2(13.4-32.0)h*mg/L respectively. Geometric mean C
max
 of isoniazid 
was 2.8 mg/L, rifampicin 8.9 mg/L, pyrazinamide 38.2 mg/L and ethambutol 3.3 mg/L. C
max
 was 
below the reference range for both rifampicin and isoniazid in 7 and 10 patients respectively. 
More than 30% (7/20) of the patients had a low rifampicin C
max
, which is a concern because low 
rifampicin levels may be associated with worse treatment outcome. A clinical trial with a higher 
sample size and which can assess concentration effect relationships is recommended. 
In chapter 5, comparison of rifampicin pharmacokinetic in plasma and saliva was performed. 
The aim was to assess whether saliva could be an alternative matrix for PK studies and TDM with 
rifampicin. It was observed that geometric mean AUC
0-24h
 of rifampicin in saliva (3.1 h*mg/L) was 
slightly but significantly lower than the protein-unbound AUC
0-24h
 in plasma (5.3 h*mg/L) and 
these were much lower than the plasma AUC
0-24h
 based on total concentrations (32.7 h*mg/L). 
On performance prediction, the value obtained showed that salivary rifampicin is not able 
to predict total or protein-unbound plasma concentrations. The study concluded that 
there is no possibility of using saliva instead of plasma for therapeutic drug monitoring and 
pharmacokinetic studies with rifampicin.
In chapter 6, the effect of type 2 diabetes mellitus on the pharmacokinetics of TB drugs 
was evaluated. Diabetes compromises the response to TB treatment and we conducted a 
pharmacokinetic study to evaluate its effect in the plasma concentrations of the first-line TB 
drugs. Forty Tanzanian adult TB patients (20 TB only, 20 TB and Diabetes) who were in the 
intensive phase of TB treatment for at least two weeks were recruited. Blood sampling took 
place at pre dose, 1, 2, 3, 4, 6, 8, 10, 24 hours after observed drug intake. Exposure to isoniazid 
and rifampicin was reduced in this study. C
max, 
clearance and volume of distribution of isoniazid 
were also adversely affected. The study concluded that these effects are most likely explained 
by the diabetes disease. The recommendation was given to increase the doses of these drugs in 
treating TB-DM patients as it results in improved exposure. 
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Chapter 7 of this thesis is focussing on antituberculosis drug-induced hepatotoxicity. There 
is a high prevalence of risk factors for developing liver toxicity in this era of HIV and hepatitis 
B diseases. However, our study showed that the proportion of patients that developed liver 
toxicity (1/112) during the intensive phase of TB treatment was low when compared to other 
studies done in Malawi and Iran. The study ended by saying that liver toxicity is uncommon in 
the Northern Tanzania region. However, it remains important that TB patients receive clear 
instructions on possible signs and symptoms of hepatotoxicity and they should be instructed 
to visit their doctor in case such symptoms occur. 
In chapter 8a, the issue of fluoroquinolone use was addressed. The survey, which was 
conducted, revealed that fluoroquinolones were used extensively in the registered pharmacies 
and accounted for 12% of the total antibiotic sales. This gave an alarming note as some of the 
fluoroquinolones (e.g. moxifloxacin) are in the second line TB regimen and are being explored 
as first-line TB drugs. 
In chapter 8b, the occurrence of fluoroquinolone resistance was assessed. This chapter 
was aiming to find out whether the resistance is related to previous use of fluoroquinolones 
(chapter 8a). The result was not as expected since we found very low (<1%) fluoroquinolone 
resistance. This finding is encouraging; hence, fluoroquinolone-containing TB regimens can be 
developed to shorten TB treatment duration. 
In conclusion, improved tuberculosis management is urgently required. Strategies that 
improve the quality of drug use and efficacy are crucial to fight TB successfully. Therefore, in 
chapter 9, all the findings reported in the chapters 2-8 are discussed. Pharmacokinetic and 
pharmacodynamic problems affecting tuberculosis therapy were therefore addressed in 
perspective. Furthermore, priorities for future research are explored.
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Tuberculose blijft wereldwijd een groot gezondheidsprobleem, terwijl effectieve behandeling 
al tientallen jaren beschikbaar is. Het wordt wereldwijd gezien als de infectieziekte met de op 
één-na-hoogste mortaliteit na het humaan immunodeficiëntie virus (hiv). Data laten zien dat 
er wereldwijd jaarlijks negen miljoen nieuwe gevallen zijn en 1.4 miljoen gevallen overlijden. 
Tuberculose en hiv zijn overlappende epidemieën. Beiden zijn wereldwijd verklaard als 
ziekten waarvoor wereldwijde aandacht nodig is omdat hiv de grootste risicofactor is voor het 
ontwikkelen van tuberculose. Naast hiv ontwikkelt ook diabetes mellitus zich als een epidemie 
welkeoverlapt met tuberculose, vooral waar het gaat om behandelingsuitkomsten. 
Klinisch farmacologisch onderzoek is altijd translationeel geweest omdat deze discipline 
als doel heeft nieuwe wetenschappelijke data te vertalen in rationale patiëntenzorg. Daarom 
omvat onderzoek in klinisch farmacologische studies onderzoek naar medicijn-interacties, 
medicijntoxiciteit, farmacokinetische data en medicijngebruik. Omdat de behandeling 
van tuberculose een fixed-dose combinatie betreft, is het begrip van farmacokinetische 
eigenschappen en interacties tijdens comedicatie voor co-infectie de sleutel voor rationeel 
gebruik van antituberculose medicatie. Daarom zijn verschillende typen onderzoek opgenomen 
in dit proefschrift. 
De meeste studies in dit proefschrift zijn uitgevoerd in de regio Kilimanjaro in Tanzania. 
Tanzania is wereldwijd het achttiende land van de22 landen met de hoogste druk van 
tuberculose. Er zijn ongeveer 65.000 tuberculose-gevallen in Tanzania. Zevenendertig procent 
van de tuberculose-gevallen in Tanzania zijn co-geïnfecteerd met hiv, wat ongeveer 60-70% is 
van de toename in het aantal gevallen van tuberculose. 
In hoofdstuk 1 van dit proefschrift worden tuberculose, de transmissie ervan en de voornaamste 
symptomen geïntroduceerd. De introductie exploreert ook het probleem van tuberculose 
wereldwijd, hoe tuberculose en hiv elkaar beïnvloeden en de details van tuberculose-
behandeling. Dit deel van het proefschrift eindigt met het formuleren van de farmacologische 
problemen in de behandeling van tuberculose patiënten. De nadruk ligt op de farmacokinetische 
en farmacodynamische problemen die tuberculosebehandeling beïnvloeden, de combinatie 
therapie voor tuberculose en hiv, farmacokinetiek (PK) van TB drugs, PK monsterafname van 
rifampicine, hoe diabetes mellitus II de farmacokinetiek van tuberculose medicatie beïnvloedt, 
vragen over hepatotoxiciteit en fluoroquinolonen gebruik in de behandeling van tuberculose.
In hoofdstuk 2a worden de problemen van gelijktijdige behandeling van hiv infectie en 
tuberculose geëxploreerd in een uitgebreide review over de farmacologische interacties 
tussen rifampicin (de hoeksteen van tuberculose behandeling) en antiretrovirale medicatie. 
De nadruk lag vooral op antiretrovirale medicatie die in ontwikkelingslanden worden gebruikt 
zoals nucleoside reverse transcriptase remmers, non-nucleoside reverse transcriptase remmers 
en proteaseremmers. Echter, nieuwe middelen in hiv behandeling worden ook genoemd en 
de tweedelijns medicatie voor tuberculose/hiv infectie behandeling die niet beschikbaar is 
wordt belicht. Dit deel van het proefschrift eindigt met het beschrijven van uitdagingen en 
onderzoeksprioriteiten voor ontwikkelingslanden. Dit kan gedaan worden door maximaal 
gebruik van bestaande programma’s en onderzoeksdata, door nieuwe data te creëren door 
klinische trials en prospectief observationeel onderzoek uit te voeren en door te lobbyen voor 
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het beschikbaar maken van medicatie die momenteel nog niet beschikbaar is voor hen die dat 
het meeste nodig hebben.
In hoofdstuk 2b wordt de hypothese gepresenteerd dat AtriplaR de focus medicatie is voor 
de combinatie-behandeling voor tuberculose-hiv co-geïnfecteerde patiënten. Een uitgebreide 
zoekactie in pubmed en google met sleutelwoorden gaf ons de mogelijkheid om relevante 
informatie te vinden over de drie medicijnen (emtricitabine, tenofovir en efavirenz) die de 
fixed-dose combinatie vormen van AtriplaR. Deinteractie met eerstelijns tuberculose medicatie 
werd getest door het bestuderenvan literatuur waar het ging om veiligheid en effectiviteit. 
Dit onderdeel concludeerde dat AtriplaR overwogen kan worden als een effectieve en veilige 
medicatie in de behandeling van tuberculose en hiv voor volwassenen en kinderen ouder dan 
3 jaar. 
In hoofdstuk 3 werd het effect van een op rifampicine gebaseerde behandeling van 
tuberculose op de farmacokinetiek van efavirenz/tenofovir/emtricitabine geëvalueerd in 
Tanzaniaanse tuberculose-hiv co-geïnfecteerde patiënten. Ongeveer een-derde van de 40 
miljoen mensen die wereldwijd met hiv/aids leven is co-geïnfecteerd met tuberculose. De 
krachtigste component van eerstelijns tuberculosebehandeling is rifampicine welke ook een 
sterke inductie heeft op cytochroom P450 enzymen. We voerden een fase-II trial uit om het 
effect te evalueren op de farmacokinetische parameters van efavirenz/tenofovir/emtricitabine. 
Er werd geen inducerend effect van rifampicine gevonden want het gebied onder de curve 
AUC
0-24h
(blootstelling) van efavirenz, tenofovir en emtricitabine was maar iets hoger als 
deze medicatie tegelijkertijd met tuberculose-medicatie werd gegeven. De concentraties 
op tuberculose medicatie waren iets lager, maar equivalentie werd gesuggereerd op basis 
van de geometrische gemiddelden ratio’s. Zowel tuberculose en hiv medicatie werden goed 
getolereerd want bijwerkingen die werden gezien waren mild en er waren geen serieuze 
bijwerkingen. 
In hoofdstuk 4 wordt een observationeel onderzoek beschreven naar de farmacokinetische 
parameters van eerstelijns tuberculose medicatie in Noord Tanzania. In dit onderzoek waren 
de geometrisch gemiddelden van AUC
0-24 h 
voor isoniazide, rifampicine, pyrazinamide en 
ethambutol 11(3.7-22.7), 39.9 (27.4-68.3), 344 (209-610) en 20.2(13.4-32.0)h*mg/L respectievelijk. 
Meer dan 30% (7/20) van de patienten had een lage rifampicine C
max, 
wat zorgelijk is, omdat 
lage rifampicine waarden geassocieerd kunnen zijn met een slechte behandeluitkomst. Een 
klinische trial met een grotere steekproef, welke concentratie-effect-relaties kan aantonen, 
wordt aanbevolen.
In hoofdstuk 5 wordt een vergelijking van farmacokinetiek in plasma en speeksel uitgevoerd. 
Het doel was om na te gaan of speeksel als alternatief kan dienen voor PK onderzoek en 
therapeutic drug monitoring (TDM=therapeutische medicatie monitoring) met rifampicine. Het 
geobserveerde geometrisch gemiddelde van AUC
0-24h
 van rifampicine in speeksel (3.1 h*mg/L) 
was iets, maar significant, lager dan de eiwit-ongebonden AUC
0-24h
 in plasma (5.3 h*mg/L) en 
was veel lager dan de plasma AUC
0-24h
 gebaseerd op totale concentraties (32.7 h*mg/L). Op 
voorspellend niveau liet de verkregen waarde zien dat speeksel rifampicine niet in staat is om 
totale of eiwit-ongebonden plasma concentratie te voorspellen. Het onderzoek concludeerde 
dat er geen mogelijkheid is om speeksel te gebuiken in plaats van plasma voor TDM en voor 
studies met rifampicine.
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In hoofdstuk 6 werd het effect van diabetes mellitus type 2 op de farmacokinetiek van 
tuberculose medicatie geëvalueerd. Diabetes compromitteert de respons op tuberculose-
behandeling en we hebben een klinische trial uitgevoerd om het effect te evalueren op de 
plasmaconcentraties van eerstelijns tuberculose medicatie. Veertig volwassen Tanzaniaanse 
tuberculose patiënten (20 patiënten met alleen tuberculose, 20 patiënten met zowel tuberculose 
en diabetes) die minstens twee weken in de intensieve fase van tuberculosebehandeling 
zaten werden gerekruteerd. Bloed werd afgenomen op pre-dosis, 1, 2, 3, 4, 6, 8, 10, 24 uur na 
waargenomen medicatie-inname. We vonden dat blootstelling aan isoniazide en rifampicine 
werd gereduceerd in deze studie. C
max, 
klaring en volumeverdeling van isoniazide werden 
ook nadelig beïnvloed. Het onderzoek concludeerde dat deze effecten hoogstwaarschijnlijk 
worden verklaard door diabetes. De gegeven aanbeveling is om de dosis van deze medicatie te 
verhogen in tuberculose/diabetes patiënten omdat dat resulteert in verbeterde blootstelling. 
Hoofdstuk 7 richt zich op door antituberculosis medicatie-geïnduceerde hepatotoxiciteit. 
Er is een hoge prevalentie van risicofactoren voor het ontwikkelen van levertoxiciteit in deze 
tijd van hiv en hepatitis B. Echter, onze studie laat zien dat het percentage patiënten dat 
levertoxiciteit ontwikkelde tijdens de intensieve fase van tuberculose behandeling laag is in 
vergelijking met andere studies die werden uitgevoerd in Malawi en Iran. De studie eindigde met 
te zeggen dat levertoxiciteit niet veel voorkomt in Noord Tanzania. Echter, het blijft belangrijk 
dat tuberculosepatiënten duidelijke instructies krijgen over mogelijke tekenen en symptomen 
van hepatotoxiciteit en dat ze hun arts moeten bezoeken wanneer zulke symptomen zich 
voordoen. 
In hoofdstuk 8a wordt het gebruik van fluoroquinolonen aangekaard. De survey die werd 
uitgevoerd liet zien dat fluoroquinolonen veel gebruikt worden in geregistreerde apotheken 
en dat ze 12% van de totale antibiotica verkoop omvatten. Dit was alarmerend omdat sommige 
van de fluoroquinolonen, bijvoorbeeld moxifloxacine, onderdeel zijn van tweedelijns 
tuberculosebehandeling. 
In hoofdstuk 8b werd het voorkomen van fluoroquinolonen resistentie bepaald. Het doel 
was om na te gaan of resistentie gerelateerd is aan eerder gebruik van fluoroquinolonen 
(hoofdstuk 8a). Het resultaat was onverwacht omdat we een heel laag resistentieniveau vonden 
(<1%). Deze bevinding is bemoedigend; tuberculose behandeling met fluoroquinolonen kan 
worden ontwikkeld om de behandeling van tuberculose te verkorten. 
Concluderend, verbetering van tuberculose management is hard nodig. Strategieën om de 
kwaliteit en effectiviteit van medicatie te bevorderen zijn cruciaal in het succesvol aanpakken 
van tuberculose. In hoofdstuk 8 worden daarom alle resultaten van hoofdstuk 2 tot en met 7 
gerapporteerd en bediscussieerd. Farmacokinetische en farmacodynamische problemen die 
tuberculosebehandeling beïnvloeden worden in perspectief behandeld. Bovendien worden 
prioriteiten voor toekomstig onderzoek besproken. 
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Ugonjwa wa Kifua Kikuu umeendelea kuwa tatizo kubwa duniani pamoja na kwamba una tiba 
yenye ufanisi kwa miongo kadhaa sasa. Gonjwa hili linashika nafasi ya pili duniani kwa magonjwa 
ambukizi yanayoongoza kwa vifo duniani baada ya ugonjwa wa ukimwi. Takwimu za Dunia 
zinaonyesha kuwa kuna maambukizi mapya yapatayo milioni 9 na vifo milioni 1.4 kwa mwaka. 
Ugonjwa wa Kifua Kikuu na Ukimwi ni magonjwa yanayoingiliana na yameshatangazwa kuwa 
magonjwa hatari duniani yanayohitaji kupewa kipaumbele huku ugonjwa wa Ukimwi ukiwa 
ndio chanzo kikuu cha kuongezeka kwa maambukizi ya Kifua Kikuu. Mbali na ugonjwa wa 
Kifua Kikuu, Kisukari ni ugonjwa ambao pia unaingiliana na Kifua Kikuu ambapo unapokuwa na 
magonjwa yote mawili (yaani Kifua Kikuu na Kisukari) tiba ya Kifua Kikuu imeonyesha kutofanya 
kazi ipasavyo.
Utafiti huu umekuwa na jukumu la kuangalia takwimu za kisayansi katika matumizi sahihi 
ya dawa za kifua kikuu. Hivyo basi utafiti huu uliangalia matumizi ya dawa yanayowezesha 
kiwango kamili kinachostahili kuuwa wadudu ambukizi, mwingiliano wa dawa za kifua kikuu 
na dawa zingine kama za ukimwi na kisukari, na madhara yanayoweza kutokana na dawa za 
kifua kikuu. Kwa vile tiba ya Kifua Kikuu ni muunganiko maalumu wa dawa nne (rifampicin, 
isoniazid, pyrazinamide na ethambutol), hivyo unahitajika uelewa wa hatua zote za mzunguko 
na mwingiliano wa dawa hizi mwilini wakati mgonjwa anapotumia. Pia ni muhimu kuwa na 
kiwango kamili cha dawa hizi katika damu kwa vile usahihi wa matumizi ya dawa za kifua Kikuu 
ndio msingi mkuu wa matibabu. 
Taarifa za tafiti za kisayansi zilizowasilishwa katika kitabu hiki, nyingi zimefanyika Tanzania 
katika Mkoa wa Kilimanjaro. Tanzania iko katika nafasi ya 18 kati ya nchi 22 zilizobeba mzigo 
wa maambukizi makubwa ya ugonjwa wa Kifua Kikuu Duniani. Katika Tanzania kuna takribani 
maambukizi 65,000 kwa mwaka. Asilimia thelathini na saba ya wagonjwa wa Kifua Kikuu wana 
maambukizi ya ugonjwa wa Ukimwi ambapo kiwango hiki cha asilimia Thelathini na saba ndicho 
kinachoongeza idadi ya wagonjwa wa Kifua Kikuu kwa asilimia 60 – 70.
Katika sehemu ya kwanza ya taarifa hii ya tafiti za kisayansi; utangulizi unaohusiana na ugonjwa 
wa Kifua Kikuu, jinsi unavyoambukiza na dalili zake kuu zimeainishwa. Pia utangulizi huu 
umeainisha kiwango cha ugonjwa huu duniani; vilevile namna ambavyo kifua Kikuu kinavyoweza 
kuongeza makali ya ugonjwa wa Ukimwi na vivyo hivyo Ukimwi unavyoweza kuongeza makali ya 
ugonjwa wa Kifua Kikuu na taarifa zingine zinazohusu tiba ya Kifua Kikuu. Mwisho wa sehemu hii 
ya kitabu hiki mkazo umetiliwa kwenye matatizo mbalimbali ya kutibu wagonjwa wa Kifua Kikuu.
Katika sehemu ya 2a; matatizo ya kutibu maambukizi zaidi ya moja yaliangaliwa katika 
kufanya tathmini ya mwingiliano wa dawa ya rifampicin ambayo hutibu kifua kikuu na dawa 
za kurefusha maisha kwa wenye ukimwi. Vilevile mkazo uliwekwa kwenye dawa za kurefusha 
maisha zinazotumiwa na nchi zinazoendelea. Hata hivyo zimetajwa pia dawa mpya za tiba ya 
ukimwi na swala la kutopatikana kwa kundi la pili la dawa kwa wagonjwa walio na maambukizi 
zaidi ya moja yaani Kifua Kikuu na Ukimwi. Mwisho katika sehemu hii changamoto na vipaumbele 
vinavyoendana na watumiaji wa dawa kwenye nchi zinazoendelea. Ushauri ukatolewa wa 
kutumia kikamilifu programu zilizopo na takwimu za kitafiti.kutengeneza takwimu mpya kwa 
kufanya tafiti za kitatibu, tafiti za kuangalia mwenendo wa ugonjwa na kutafuta njia mbadala 
itakayowezesha dawa zisizopatikana kwa sasa ziweze kupatikana kwa wale wanaozihitaji zaidi.
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Katika sehemu ya 2b matumizi ya dawa ya atriplaR wakati wa tiba ya kifua kikuu na ukimwi 
yaliwasilishwa. Vilevile kupitia mitandao ya kisayansi kama Pubmed na google tumeweza kutoa 
taarifa za dawa aina tatu (emtricitabine, tenofovir na efavirenz) ambazo zipo kwenye kiwango 
maalumu kwenye dawa ya atriplaR. Mwingiliano wa dawa hizi na dawa za tiba ya kifua kikuu 
ulifanyiwa majaribio. Hitimisho lilionyesha kuwa dawa ya atriplaR ni salama na ni chaguo la 
kwanza kutibu mtu mwenye maambukizi ya ukimwi na kifua kikuu kwa watu wazima na watoto 
walio zaidi ya miaka 3. 
Katika sehemu ya 3 wagonjwa wenye maambukizi ya ukimwi na kifua kikuu walitumika 
kufanya tathmini ya adhari ya dawa ya rifampicin wakati ikitumika pamoja na dawa za efavirenz/
tenofovir/emtricitabine. Vilevile tulifanya jaribio la kuangalia athari ya kiwango cha dawa 
kilichopo kwenye dawa za efavirenz/tenofovir/emtricitabine inavyotumika na rifampicin. 
Madhara ya rifampicin hayakuonekana kwenye utafiti huu kwa kuwa kiwango cha dawa ya 
efivarenz/tenofovir/emtricitabine kilikuwa kimeongezeka kidogo tofauti na matarajio yetu. 
Kwenye upande wa dawa za kifua kikuu kiwango kilipungua kidogo lakini hakikuwa na madhara. 
Dawa zote za Kifua Kikuu na za ukimwi zilitumika vyema bila madhara yeyote.
Sehemu ya 4. Tafiti ilifanyika kuangalia kiwango cha dawa kwenye chaguo la kwanza la dawa 
za kutibu Kifua kikuu (rifampicin, isoniazid, pyrazinamide na ethambutol). Hii ni muhimu ambapo 
unaweza kulinganisha matumizi halisi ya dawa na kiwango cha dawa kinacholeta ufanisi wa dawa 
mwilini. Zaidi ya asilimia 30% yaani (7/20) ya wagonjwa walikuwa na kiwango kidogo cha dawa ya 
rifampicin, hali ambayo inatia wasiwasi kwa vile kiwango kidogo cha rifampicin kinaweza kuleta 
usugu na mgonjwa kutokupona. Tunashauri tafiti kubwa zaidi ifanyike itakayopima athari za 
viwango vidogo vya dawa za kifua kikuu.
Sehemu ya 5: Kiwango cha dawa ya rifampicin katika damu na mate vililinganishwa. Lengo 
likiwa ni kujaribu kama mate yanaweza kutumika kupima kiwango cha dawa kama rifampicin 
badala ya damu. Hii ni kwa sababu kutoa mate ni rahisi kuliko kutoa damu, hivyo kama mate 
yatatumika kupima viwango vya dawa hata kwa watoto itakuwa rahisi kupimwa. Kwa ujumla 
matokeo ya tafiti hii yalionyesha kiwango kikubwa kwenye damu ikilinganishwa na mate 
(5.3mg/L kwa 3.2mg/L). Hii ilichangiwa na uchache wa wagonjwa kwenye tafiti (15 tu), hivyo 
tunashauri tafiti kubwa zaidi ifanyike ili kuweza kutoa uamuzi wa uhakika kama mate yanaweza 
kutumika badala ya damu.
Katika sehemu ya 6, tathmini yaathari za ugonjwa wa Kisukari kwenye upatikanaji wa 
kiwango sahihi cha dawa za kifua kikuu ilifanyika. Watu wazima 40 (20 wenye maambukizi ya 
Kifua Kikuu pekee na 20 wenye maambukizi ya Kifua Kikuu na Kisukari) ambao walikuwa kwenye 
matibabu ya awali ya tiba ya Kifua Kikuu kwa wiki mbili waliandikishwa kwenye utafiti. Sampuli 
za damu zilichukuliwa kabla ya kutumia dawa na saa 1,2,3,4,6,8,10,24 baada ya kutumia dawa. 
Katika kundi la wagonjwa wenye kifua kikuu na kisukari, kiwango cha isoniazid na rifampicin 
(dawa muhimu katika kutibu kifua kikuu) kilionyesha kupungua kwenye utafiti huu. Pia kiwango 
cha juu kinachotegemewa kupatikana katika dawa hizi mwilini kiliathiriwa. Madhara haya 
yanafikiriwa kuwa yametokana na ugonjwa wa kisukari. Ushauri unatolewa kwamba wakati wa 
kutibu mgonjwa mwenye Kisukari na kifua kikuu kiwango cha hizi dawa muhimu kiongezwe.
Sehemu ya 7: Tafiti hii ilikuwa ikionyesha uharibifu wa Ini unaotokana na dawa za kutibu kifua 
kikuu. Kuna kiwango kikubwa cha visabababishi vya uharibifu wa Ini unaotokana na Matumizi 
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ya dawa katika zama hizi za ugonjwa wa HIV na Uvimbe kwenye Ini. Hata hivyo utafiti wetu 
umeonyesha kuwa uwiano wa mgonjwa kupata uharibifu wa Ini ni 1/112 katika hatua za mwanzo 
za tiba ya TB. kiwango ambacho ni cha chini ukilinganisha na tafiti nyingine zilizofanyika Malawi 
na Iran. Majumuisho ya tafiti yanaonyesha kuwa uharibifu wa Ini unaotokana na utumiaji wa 
dawa za tiba ya TB ni mara chache sana kutokea Kaskazini mwa Tanzania. Hata hivyo bado ni 
muhimu kwa wagonjwa wa TB kupata maelekezo sahihi ya viashiria na dalili za uharibifu wa Ini 
na wanatakiwa waelekezwe kuwasiliana na Daktari mara tu wanapoona dalili hizo zinajitokeza. 
Sehemu ya 8a, suala la dawa ya fluoroquinolone lilizungumziwa. Utafiti uliofanyika 
umeonyesha kwamba dawa hii inatumika sana katika maduka ya dawa yalio na usajili ambapo 
inachukua asilimia 12% ya dawa zote za magonjwa ya kuambukiza. Hii inatupa tahadhari kwa vile 
baadhi ya fluoroquinolones kama Moxifloxacin ziko katika chagua la pili ya tiba ya TB. Hivyo 
katika sehemu ya 8b, usugu wa dawa ya fluoroquinolone ulifanyiwa Tathmini. Ambapo nia ni 
kuangalia kama usugu huo una uhusiano wowote na matumizi ya awali ya dawa hiyo. Matokeo 
yake ilikuwa kinyume na matarajio kwa vile usugu wa dawa hii ulikuwa chini ya asilimia 1(<1%). 
Hii inatia moyo na sasa dawa za aina ya Fluoroquinoline zinaweza kutumika kutibu kufua kikuu 
bila wasiwasi.
Kwa kujumuisha ni kwamba inahitajika hatua za haraka za kuboresha usimamizi wa tiba ya 
kifua kikuu. Na mikakati ambayo itaboresha kiwango cha dawa na ufanisi wake, vitu ambayo ni 
muhimu katika mafanikio ya vita dhidi ya TB. Hivyo sehemu ya tisa ni muhutasari wa sehemu 
zote (1 hadi 8). Matatizo yatokanayo na ufanyajikazi wa dawa mwilini kwenye tiba ya Kifua Kikuu 
na mapendekezo ya tafiti zaidi yametolewa.
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